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Human genome contains millions of regulatory elements - enhancers - that quantitatively regulate 
gene expression. Multiple experimental and computational approaches have been developed to 
associate enhancers with their gene targets. Despite the tremendous progress in understanding 
how enhancers tune gene expression, the field still lacks an approach that is systematic, 
integrative and accessible for discovering and documenting cis-regulatory relationships across the 
genome. 
To address this challenge, we developed a novel computational approach that models and 
integrates gene expression ~ enhancer activity (reg2gene). reg2gene was built upon extensive data 
modeling and integration, and as such, it consists of three main steps: 1) data quantification, 2) 
data modelling and significance assessment, and 3) data integration. We identified two sets of 
enhancer-gene associations (EGAs): the flexible set of ~230K EGAs (flexibleC), and the stringent 
set of ~60K EGAs (stringentC).  We additionally identified major differences across previously 
published computational models of enhancer-gene associations; mostly in the location, number 
and properties of defined enhancer regions and EGAs. All reg2gene functions were gathered in 
the reg2gene R package.  
We performed detailed benchmarking of seven sets of computationally modelled EGAs, but 
showed that none of the currently available benchmark datasets could be used as a “golden-
standard” benchmark dataset. To account for that observation, we defined an additional 
benchmark set of positive and negative EGAs with which we showed that the stringentC model 
had the highest positive predictive value (PPV) across all analyzed computational models. We 
reviewed the influence of EGA sets on the functional analysis of risk SNPs and demonstrated the 
potential of EGAs to identify gene targets of non-coding SNP-gene associations. Lastly, we 
performed a functional analysis to detect novel gene targets, enhancer pleiotropy, and 
mechanisms of enhancer activity. Altogether, this work advances our understanding of enhancer-
mediated gene expression regulation in health and disease.  








Das menschliche Genom enthält Millionen von regulatorischen Elementen - Enhancer -, die die 
Genexpression quantitativ regulieren. Es wurden zahlreiche experimentelle und rechnerische 
Ansätze entwickelt, um Enhancer mit ihren Gen-Targets in Verbindung zu bringen. Trotz der 
enormen Fortschritte im Verständnis, wie Enhancer die Genexpression regulieren, fehlt jedoch 
immer noch ein systematischer, integrativer und zugänglicher Ansatz zur Entdeckung und 
Dokumentation von cis-regulierenden Beziehungen im gesamten Genom. 
Um dieser Herausforderung zu begegnen, haben wir einen neuartigen rechnergestützten Ansatz 
entwickelt, der die Genexpression ~ Enhancer-Aktivität (reg2gene) modelliert und integriert. 
reg2gene wurde auf der Grundlage umfangreicher Datenmodellierung und -integration entwickelt 
und besteht als solches aus drei Hauptschritten: 1) Datenquantifizierung, 2) Datenmodellierung 
und Signifikanzbewertung und 3) Datenintegration. Wir identifizierten zwei Sätze von Enhancer-
Gene-Assoziationen (EGAs): den flexiblen Satz von ~230K EGAs und den stringenten Satz von ~60K 
EGAs (über den in drei oder mehr Publikationen berichtet wurde). reg2gene Funktionen wurden 
im reg2gene R-Paket gesammelt. 
Darüber hinaus charakterisierten wir die Unterschiede zwischen zuvor veröffentlichten 
Berechnungsmodellen von Enhancer-Gen-Assoziationen und zeigten, dass sie sich enorm 
unterscheiden; in der Lage, Anzahl und Eigenschaften von definierten Enhancer-Regionen und 
EGAs. Schließlich führten wir ein gründliches Benchmarking von sieben rechnerisch modellierten 
Sätzen von EGAs durch und überprüften ihren Einfluss auf die funktionelle Analyse von Risiko-
SNPs. Wir zeigen, dass keiner der verwendeten Benchmark-Datensätze als die "goldene" 
Standardmethode zum Testen der Leistung von Berechnungsmodellen angesehen werden kann. 
Um dieser Beobachtung Rechnung zu tragen, definierten wir einen zusätzlichen Benchmark-Satz 
positiver und negativer EGAs und zeigten, dass das stringentC-Modell über alle analysierten 
Rechenmodelle hinweg den höchsten positiven Vorhersagewert (PPV) aufwies. Schließlich 
demonstrierten wir das Potenzial von EGAs zur Identifizierung von Gen-Targets nicht-kodierender 
SNP-Gen-Assoziationen und führten eine funktionelle bioinformatische Analyse der zugrunde 
liegenden Enhancer-Regionen durch, um neue Gen-Targets, Enhancer-Pleiotropie und 
Mechanismen der Enhancer-Aktivität zu erkennen. Insgesamt fördert diese Arbeit unser 
Verständnis der Enhancer-vermittelten Genexpressionsregulation bei Gesundheit und Krankheit.  
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eQTL expression quantitative trait loci  
GWAS genome-wide association study 
HTS high-throughput sequencing 
NGS next generation sequencing 
RNA-Seq RNA sequencing 
SNP  single nucleotide polymorphism 























Complex organisms are constituted of a multitude of specialized cell types. With few exceptions, 
all cells contain the same genetic material; however, genes are expressed at different levels and 
in different combinations across different cell types. Multicellular organisms use a variety of 
mechanisms to regulate the amount of gene products in the cell such as gene expression 
regulation (Levine and Tjian, 2003), alternative splicing (Berget et al., 1977; Chow et al., 1977), 
post-translational modifications of proteins (Walsh, 2006), chromatin modification and reordering 
(Whalen et al., 2016). Nonetheless, most regulation is believed to occur at the level of 
transcription initiation (Levine and Tjian, 2003). 
 
Transcription is regulated by cis-regulatory sequences in the genome that recruit a distinct set of 
trans factors. By promoting or inhibiting the production of mRNAs in each cell, trans factors 
finetune the gene expression of a correct subset of genes. Promoters and enhancers are currently 
the best-characterized cis-regulatory sequences (Andersson et al., 2015). Promoters are located 
nearby the transcription start sites of genes and integrate a total regulatory input into the rate of 
transcriptional initiation (Lenhard et al., 2012), whereas enhancers are distal elements that can 
further refine gene expression across cell types and developmental stages (Banerji et al., 1981; 
Gerster et al., 1986; Blackwood and Kadonaga, 1998). In most eukaryotes, transcription depends 
on distal enhancers and their physical separation from promoters is thought to provide an 
additional level of regulation of gene expression (Levine et al., 2014).  
 
Certain aspects of enhancer-mediated gene expression regulation are known, however, to fully 
understand and appreciate its complexity it is necessary to systematically identify and characterize 
all regulatory elements in a genome-wide manner and discern their cell-type specific patterns 
(Hariprakash and Ferrari, 2019). Especially now, when a daunting amount of high-quality genomic 
data became available. Multiple approaches have been utilized to study enhancer-mediated long-
range gene regulation in a genome-wide manner: predictions using information from the eQTL 
studies (Rockman and Kruglyak, 2006; Gaffney et al., 2012; GTEx Consortium et al., 2017), (3C)-
derived techniques (Dekker et al., 2002; Dostie et al., 2006; Fullwood et al., 2009; Lieberman-
Aiden et al., 2009; Simonis et al., 2006), and reporter assays or cellular screens (Arnold et al., 2013; 
Kheradpour et al., 2013; Kwasnieski et al., 2012; Kvon, 2015; Fulco et al., 2019; Gasperini et al., 
2019). The fourth approach, computational modelling of gene expression ~ enhancer activity, is 




Hereby, I present my work towards documenting cis-regulatory relationships across the genome 
by means of computational modeling. I frame our current understanding of enhancer-gene 
associations (EGAs) into the knowledge of genetic susceptibility. I review and characterize 
differences between published sets of EGAs and perform a thorough benchmarking analysis. 
 
I start by summarizing our current ideas and knowledge about enhancer-mediated gene 
expression regulation. In particular, I discuss general principles of enhancer functions and 
mechanisms of their specificity and modularity. In addition, I briefly describe the rise of the high-
throughput sequencing technologies (HTS) and how they improved our understanding of 
enhancer biology. I present techniques, computational tools and algorithms used in this thesis. 
Lastly, I introduce the current ideas of human (disease) genetics, and how the knowledge about 
enhancer-gene associations can be used to improve our understanding of genetic susceptibility to 
human diseases. 
 
1.2. Enhancer-mediated regulation of gene expression  
 
Gene expression has been an important topic of scientific research for a long time. It started as a 
quest to identify distributor elements of the hereditary information and continued by performing 
an extensive research on how genetic information is communicated, processed and used to 
maintain functions and behaviors of the cell. The first considerable challenge was to identify and 
delineate the structure of genes and other functional elements (Kellis et al., 2014). That is exactly 
what I set off to describe here. 
 
 
1.2.1. Defining functional DNA elements in the human genome 
 
A distributor element of the hereditary information was not known until Gregor Mendel, in 1866, 
postulated the notion of the gene (Mendel, 1866). Throughout the twentieth century, genes were 
attributed to the chromosomes (Waldeyer, 1888; Boveri, 1904; Sutton, 1902, 1903) in the genome 





The initial definition of a gene, simply an element of heredity (Mendel, 1866), evolved as the 
knowledge about its physical nature expanded. Physical nature of it (which dictates phenotypic 
traits of an organism) was attributed to deoxyribonucleic acid (DNA) - a double helical two-chain 
molecule composed of covalently bound nucleotides (Figure 1.1., Avery et al., 1944; Hershey and 
Chase, 1952, Franklin and Gosling, 1953; Watson and Crick, 1953). Each nucleotide was identified 
to be composed of a nucleobase (four possible nucleobases are cytosine [C], guanine [G], adenine 
[A], thymine [T]) and sugar-phosphate backbone (Kossel, 1911) that pair according to Chargaff’s 
rules within a DNA molecule (Chargaff et al., 1952). Along with DNA, RNA molecules were 












Figure 1.1. The structure for deoxyribose nucleic acid (DNA) suggested by Watson and Crick in 
1953. The two ribbons symbolize the two phosphate-sugar chains, and the horizontal rods the 
pairs of bases holding the chains together. The vertical line marks the fiber axis. Figure reprinted 
from (Watson and Crick, 1953). 
 
 
Recently, in April 2020, I decided to search the web by googling the term “gene” aiming to identify 
the most recent definition. Among many definitions, I found the following: 
 
“Gene is a specific sequence of nucleotides in DNA or RNA that is located usually on a chromosome 
and that is the functional unit of inheritance controlling the transmission and expression of one or 
more traits by specifying the structure of a particular polypeptide and especially a protein or 




Genes are not the only functional elements coded in DNA. The era of annotating genome(s) - 
attaching biological information to sequences - started with the development of DNA sequencing 
methods (Maxam and Gilbert, 1977; Sanger et al., 1977). The first sequenced gene was the gene 




for Bacteriophage MS2 coat protein (Min Jou et al., 1972). Later, the same group of scientists 
determined the first two genomes - the complete sequence of bacteriophage MS2-RNA (Fiers et 
al., 1976) and Simian virus 40 (Fiers et al., 1978). In the second half of the twentieth century, many 
teams focused on sequencing the entire genomes. However, the ultimate goal was always to 
sequence the human genome. Nonetheless, in eukaryotes, genes sequences were found to be 
interrupted by the elements that do not directly code for proteins: introns or intervening 
sequences; whereas coding or expressed nucleotide sequences were named exons (Berget et al., 
1977; Chow et al., 1977).  
 
Soon, the vast majority of the genome (98%) was identified not to code for genes. Initially, non-
coding regions were considered to represent a sequence of DNA without any biological function - 
the “junk” DNA (Gregory, 2011). Only relatively recently, the “junk DNA” regions were found to 
harbor various functional sequences including regulatory elements such as enhancers, promoters 
or silencers. In addition, sequences that code for long non-coding RNAs were discovered 
(Kapranov et al., 2007). Today, approximately 20,000 protein coding, 10,000 long non-coding RNA 
genes and millions of regulatory regions have been identified in the (human) genome (ENCODE 
Project Consortium, 2004; Harrow et al.).  
 
Gene-proximal promoters and distant enhancers are among the most studied regulatory elements 
in the human genome (Andersson et al., 2015). Their interactions allow tight spatio-temporal 
regulation of gene expression in a cell type-specific manner. Although enhancers and promoters 
share similar characteristics, they are, in general, considered to represent separate classes of 
regulatory elements (Andersson et al., 2015; Core et al., 2014). Promoters overlap with, or are 
located close to the transcription start sites of genes (TSS) thereby integrating total regulatory 
input into the rate of transcriptional initiation. The structure of human gene promoters can be 
quite complex, typically consisting of a core promoter and nearby (proximal) transcriptional 
regulatory elements (Lenhard et al., 2012). Promoters, work together with other regulatory 
regions, like enhancers, to regulate all stages of RNAPII transcription from RNAPII recruitment to 
transcriptional elongation (Smale and Kadonaga, 2003).  
 
Enhancers are the first regulatory DNA elements shown to be involved in differential gene 
transcription (Gerster et al., 1986). They are generally located up to 1Mb from the transcription 
start sites of genes (Lettice et al., 2003), and increase gene expression regardless of their position, 
orientation and distance to the promoter (Banerji et al., 1981). They do not occur at a defined 
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distance from a TSS (Blackwood and Kadonaga, 1998); do not necessarily regulate the closest gene 
(Mifsud et al., 2015; Schoenfelder et al., 2015; Javierre et al., 2016), can regulate more than one 
gene (Gao et al. 2016; Cao et al. 2017), do not have a specific sequence motif or structure for their 
univocal genome-wide identification (Visel et al., 2009; Roadmap Epigenomics Consortium et al., 
2015) and are very cell-type specific (Joshi, 2014).   
1.2.2. Identifying non-genetic, sequence-independent elements of gene regulation 
 
In addition to information coded in the sequence of our DNA, many sequence-independent 
processes can modulate gene expression patterns in a cell (Rivera and Ren, 2013). Proteins, their 
(chemical) modifications and the 3D genome structure were recognized to have an important role 
in organization, maintenance and communication of genetic information. Although its definition 
changed during the years (Holliday, 1990; Waddington, 1959), the word “epigenome” has been 
generally used to describe sequence-independent processes that modulate gene expression 
patterns in a cell-type-specific manner thereby “extending” information stored in the genomic 
sequence (Rivera and Ren, 2013).  
 
Proteins interact regularly with DNA and RNA. At the frontline of DNA-protein interactions is the 
chromatin - a DNA-histone complex that enables packaging of the mammalian two meters long 
genome (when in its unfolded, linearized form) within the nucleus (Luger et al., 1997). In the 
process of gene expression, DNA and RNA molecules frequently interact with protein complexes. 
For example, the process of transcription in humans is mainly performed by RNA polymerase II 
(Pol II; Roeder and Rutter, 1969). Pol II binds DNA and interacts with one or more general 
transcription factors (protein complexes): TFIIA, TFIIB , TFIID, TFIIE, TFIIF, and TFIIH (Tang et al., 
1996). Many other transcription factors, coactivators (histone acetyltransferases p300 and CBP; 
Ogryzko et al., 1996), modifying enzymes such as DNA and histone methyltransferases (DNMT; 
Viré et al., 2006; Iyer et al., 2016;),  histone deacetylase (Taunton et al., 1996), and chromatin 
remodelers (Stern et al., 1984; Pazin and Kadonaga, 1997) were found to be implicated in 
transcription (regulation). In addition, protein complexes such as DNA helicases (Manosas et al., 
2010), topoisomerases (Champoux, 2001), etc. were found to interact with DNA/RNA.  
 
The genome and chromatin structures were shown to support gene expression and its regulation. 
DNA interacts directly with histone proteins to form nucleosome structures ordered in 10-nm 
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fibers (repetitive nucleosome motifs of ∼200 bp) and organized into 30-nanometer chromatin 
fibres (Olins and Olins 1974; Kornberg 1974; Woodcock et al. 1976; Finch and Klug 1976; Davey et 
al. 2002). Early experiments on eukaryotic chromatin compaction identified differences in the 
degree of compaction between genomic regions containing expressed genes with 
transcriptionally silent regions (Axel et al., 1973). Meanwhile, chromatin was identified to be a 
dynamic structure that allows and restricts transcription factor binding (Bell et al., 2011), whereas 
DNA accessible regions (that correspond to the regions depleted of nucleosomes) were 
associated with transcriptional activity and active enhancers and promoters (Gross and Garrard, 
1988). 
 
Recently, spatial arrangements of the chromatin and nucleus, such as active chromatin hubs 
(Tolhuis et al., 2002), lamina-associated domains - LADs (Guelen et al., 2008), topologically 
associating domains - TADs (Dixon et al., 2012; Nora et al., 2012; Sexton et al., 2012), chromosome 
compartments and territories (Naumova et al., 2013), were identified. Chromatin interactions 
with elements of cohesin complex (Sofueva et al., 2013), CTCF proteins (Zuin et al., 2014), and 
some additional factors (de Wit et al., 2013; Beagan et al., 2017) were suggested to underlie a 
higher-ordered spatial arrangement of the chromatin and nucleus. Importantly, topologically 
associating domains (TADs) are generally defined as regions in the genome characterized by a high 
level of chromatin interactions occurring within them, some of which can be enhancer-gene 
interactions (Dixon et al., 2012; Nora et al., 2012; Sexton et al., 2012; Lupiáñez et al., 2015). They 
correspond to the 3D genome organization structures that are approximately 100 kb to 1 Mbp in 
size, are identified in a wide range of metazoans and show striking conservation across species 
and cell types (Dixon et al., 2012). Although, it was generally accepted that the structural 
organization of the genome into TADs was maintained across different cell types, recent studies 
suggested that the genome exhibits significant cell-cell variability in its 3D organization and 
dynamic chromatin topology (Finn et al., 2019).  
..... 
 
Half a century ago, scientists initiated studies of the possible role of chromatin in the regulation 
of gene expression because they suspected that histones might be repressing transcription 
(Verdin and Ott, 2015). Soon, acetylation of histones was shown to lower their ability to inhibit 
RNA synthesis, and the hypothesis that the reversible post-translational histone acetylation is a 
“dynamic and reversible mechanism for activation and repression of RNA synthesis” was born 
(Allfrey et al., 1964). Although the first studied epigenomic modification was C5-methylcytosine 
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(5mC) - a methylated form of cytosine (Hotchkiss, 1948), it was later associated with promoter 
regions and predicting cell type-specific enhancer activity (Wiench et al., 2011). Meanwhile, 
reversible chemical modifications of proteins, DNA and RNA were identified (Figure 1.2.) and 
multiple chromatin modifications were shown to be implicated in gene regulation, maintenance 







Figure 1.2. A diversity of chemical modifications of DNA, RNA, histone proteins and the genome structure. Figure 
reprinted from (Stricker et al., 2017) 
 
Along with the genome structure, chromatin modifications are considered to represent a group 
of non-genetic factors that influence traits and phenotypes, ageing (Benayoun et al., 2015) and 
cancer (Berdasco and Esteller, 2010). Specifically, modifications of DNA and histone proteins are 
thought to convey and retain regulatory information through DNA replication, when most 
transcription factors dissociate from their binding sites (Jenuwein and Allis, 2001).  
 
Until recently, six different known epigenomic modifications were recognized at the DNA level; 12 
currently known chemical modifications at the histone level (at more than 130 post-translational 
modifications sites on five canonical and some 30 histone variants), and more than 100 different 
known RNA modifications (Stricker et al., 2017). However, the number and complexity of newly 
discovered chromatin marks increases every day as the high-throughput sequencing (HTS) 
techniques of epigenomic profiling improve. However, only some of them were later shown to 






In summary, I introduced you to the most important elements of the human genome and its main 
players (subjects and objects of gene expression regulation): DNA, genes, histones and other 
proteins, chromatin, chemical modifications, the genome structure, etc.  





1.2.3. Early research of gene expression regulation  
 
Gene expression refers to the multi-step processes of transcription, translation, protein 
localization, and post-transcriptional modifications  (Alberts et al. n.d.). As early as the nineteen-
seventies, the conceptual paradigm for understanding transcriptional regulation was established: 
transcription factors bind promoter sequences to promote (or inhibit) binding of the necessary 




The first leap in our understanding mechanisms of gene expression was achieved when the notion 
of a gene was associated with production of a single enzyme that, in turn, affects a single step in 
a metabolic pathway - the famously titled “one gene – one enzyme” hypothesis (Beadle and Tatum, 
1941). The following experiments confirmed the flow of information from DNA to protein through 
the RNA molecule (Brenner et al., 1961; Crick et al., 1961; Leder and Nirenberg, 1964; Nirenberg 
and Matthaei, 1961). This was later reformulated as the Central Dogma of biology:  
 
“Genetic information is transcribed from DNA to RNA and then translated from RNA into protein.”  
(Crick, 1958, 1970).  
 
Around the same time, the first experiment on gene regulation was done in bacteria (Jacob and 
Monod, 1961; Pardee et al., 1959). It identified stretches of DNA that act as regulator genes, 
repressors, co-repressors and revealed certain molecular mechanisms of gene expression. Later, 
the two-signal regulation system of operons was discovered in E.coli (Ptashne et al., 1976). It was 
exemplified with the lac operon where the same regulatory protein acts either as a repressor or 
an activator depending on the position near or within the promoter (Malan and McClure, 1984). 
Since in prokaryotes, gene control serves mainly to enable them to adapt to changes in the 
environment and optimize growth and cell divisions, their regulation was proven to be too simple 
for eukaryotes. In eukaryotes processes of cell differentiation, morphogenesis, and accurate 
response to environmental stimuli require precise regulation.  
 
Many additional mechanisms of gene regulation were identified in eukaryotic gene expression 
such as alternative splicing (Berget et al., 1977; Chow et al., 1977), post-translational modifications 
of proteins (Walsh, 2006), chromatin modification and reordering (Whalen et al., 2016), gene 
expression regulation (Levine and Tjian, 2003 ), etc. However, most regulation in eukaryotes is 
believed to occur at the level of transcription initiation (Levine and Tjian, 2003). This is later 
supported by the observation that the RNA content differs greatly for different cell types and it 
correlates with protein abundance (Schwanhäusser et al., 2011). In addition, transcriptional mis-
regulation is associated with diseases such as cancer (Dawson and Kouzarides, 2012).  
 
Transcription is initiated at core-promoters that recruit RNA polymerase II and together with 
general transcription factors (TFIIA, TFIIB, TFIID, TFIIE, TFIIF, and TFIIH) assemble the pre-initiation 
complex (PIC) to finetune the accurate position of initiation and direction of transcription (Roeder, 
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1996). However, core-promoters cannot support efficient transcription on their own and they 
commonly exhibit only low basal activities (Lenhard et al., 2012). Thus, cell-type-specific activation 




1.2.4. General principles of enhancer function 
 
“Exactly how do enhancers modulate gene expression?” represents one of the central questions 
of genomics.  
 
Decades of studies revealed that in order to activate (or repress) transcription in time and cell-
type specific manner enhancers recruit specific TFs and mobilize cofactors such as p300 (Visel et 
al., 2009) or Mediator (Kagey et al., 2010; Zuin et al., 2014), bind Pol II and general transcription 
factors and assemble the pre-initiation complex (PIC; Figure 1.3., Roeder, 1996) via binding to 
short recognition sequences: transcription factor (TF) binding sites. Cofactors do not typically bind 
DNA directly whereas they are bound by different TFs via protein-protein interactions. They 
execute various biochemical activities - predominately modifying and remodeling the chromatin  
(Visel et al., 2009b; Kagey et al., 2010; Zuin et al., 2014) which ultimately leads to precise activation 
or repression of transcription (Shlyueva et al., 2014). Thus,  enhancers are considered to be the 







Figure 1.3. Schematic representation of enhancer activation. In the first stage, (A) enhancer is inactive, packaged into 
chromatin and poorly accessible to the DNA-binding transcription factors. (B)  Schematic view of chromatin being 
opened by a ‘pioneer factor’ - a DNA-binding protein that is able to occupy inaccessible regions and attract chromatin 
remodeling proteins and histone modifying enzymes that (C) deposit enhancer-typical histone modifications such as 
H3K4me1 and H3K27ac and make enhancer accessible to other TFs.  (D) Representation of enhancer-promoter 
interaction via DNA looping: enhancer-binding and promoter-binding proteins and complexes are indicated; such as 
specific and general transcription factors (TFIIA, TFIIB , TFIID, TFIIE, TFIIF, and TFIIH; here denotes as GTFs), cohesin 
and the Mediator - a multiprotein complex that can stabilize enhancer-promoter interaction, coactivators such as 
p300 (an enzyme that has histone acetylase activity) and  RNA Pol II.  
 
On the other hand, it was considered that enhancers act by increasing the RNA polymerase density 
(number of RNA polymerase II molecules) within the linked gene (Weber and Schaffner, 1985; 
Weber and Schaffner, 1985;  Gerster et al., 1986) or facilitate the recruitment of the pre-initiation 
complex (PIC) to the target promoter and thereby activate transcription (Szutorisz et al., 2005). 
Since neither, the recruitment of polymerase to promoters is necessarily sufficient to activate 
transcription (Dorris and Struhl, 2000), nor the polymerase binding was shown to represent a key 
control point in transcription in mammals (Bartman et al., 2019) the current view is that enhancers 
sometimes act through regulating the release of polymerase from promoter-proximal pausing 
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after it transcribed approximately 40 nucleotides (Muse et al., 2007; Zeitlinger et al., 2007; Core 
et al., 2008). Nevertheless, this is still a subject of extensive research. 
 
Importantly, enhancers were found to function when in physical proximity to a target promoter 
(Müeller-Storm et al., 1989). It has been suspected that an underlying physical interaction is 
facilitated by DNA looping -  a mechanism by which enhancers and promoters are brought 
together in the 3D space of a nucleus (Su et al., 1991; Schleif, 1992). Later, DNA looping was shown 
to, at least partially, facilitate precise regulation of gene expression (Tolhuis et al. 2002; 
Vernimmen et al. 2007; Deng et al. 2012; Jin et al. 2013) and recent single molecule imaging 
approaches confirmed that enhancer-promoter contact is necessary for transcriptional activation 
(Chen et al., 2018a). It is important to note that looping interactions between enhancers and 
promoters are not necessarily stable interactions, rather form and dissociate dynamically (Chen 




1.2.5. Hierarchical mechanisms of enhancer specificity 
 
“How activating regulatory information is communicated from enhancers to their correct 
promoters?” is another important question of modern biology. 
 
Historically, many examples of gene expression regulation came from researching Drosophila 
melanogaster and suggested that the precise enhancer–core-promoter targeting is orchestrated 
at several different levels. For example, one of the first studies of Drosophila melanogaster gene 
expression regulations identified three neighboring genes: decapentaplegic (dpp), SLY1 
homologous (Slh) and out at first (oaf), and showed that they were not necessarily regulated by 
the nearest regulatory regions. Specifically, several dpp enhancers were positioned closer to Slh 
and oaf, but those two genes were remarkably unaffected by the dpp elements (Merli et al., 1996). 
These observations were confirmed in vertebrates; tight spatiotemporal regulation of Hox genes 
was shown to be essential for correct patterning of target tissues and regulated by a hierarchy of 
molecular controls (van der Hoeven et al., 1996; Sharpe et al., 1998). In addition, Tolhuis et al. 
(2002) showed that the locus control region (LCR) of the mouse beta-globin locus in the fetal liver 
was in more frequent contact with the beta-globin promoter than with intervening sequences in 
liver cells where beta-globin is expressed. However, in brain tissue, which does not express beta-
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globin, the contact was absent. Subsequent research identified additional regulation at the level 
of regulatory domains, chromatin modifications, DNA accessibility, and sequence-encoded 
specificities that engage different regulatory proteins (Zabidi and Stark, 2016).  
 
For example, the disruption of topologically associating domains - TADs - was shown to lead to de 
novo interactions of enhancers and promoters, gene misexpression and/or occurence of diseases 
( Spielmann et al., 2012; Spielmann and Mundlos, 2013; Ibn-Salem et al., 2014; Lupiáñez et al., 
2015), which suggested that the spatial organization of the genome represents one level of gene 
expression regulation. Enhancers and their target genes have been frequently found to co-localize 
in the same TAD  region (Symmons et al., 2014) and a role of TADs in directing (or restricting) 
enhancer function in transcriptional regulation is supported by the fact that TAD boundaries are 
depleted between enhancer-promoter interactions (Kvon et al., 2014). Many evidence supports a 
role of TADs in restricting or directing enhancer function during transcriptional regulation 
including the fact that TAD borders hinder the spreading of chromatin marks associated with 
transcriptional activity (Narendra et al., 2015; Tsujimura et al., 2015). Nevertheless, TADs do not 
represent the only level of regulation of enhancer function - many genes co-localized in the same 
TAD region are not co-expressed and enhancers can be selective for certain promoters (Calhoun 
et al., 2002).  
 
The regulation of DNA accessibility and enhancer-promoter tethering are likely to be involved in 
controlling enhancer – core-promoter targeting as well (Calhoun et al., 2002; Fakhouri et al., 
2010). Nucleosomes were shown to represent a barrier for the access of TFs to their target sites 
in vivo and the activation of transcription is correlated with the reorganization of nucleosomes at 
enhancer elements, e.g.  active enhancers are devoid of nucleosomes (Schones et al., 2008, He et 
al., 2010). Nucleosome positioning and DNA accessibility are modified by a dynamic, enzyme-
assisted process of chromatin remodelling that ultimately allows access of regulatory transcription 
machinery proteins to the condensed genomic DNA  (Stern et al., 1984; Pazin and Kadonaga, 
1997). 
 
Although active enhancers enhancers are commonly “nucleosome-free” regions, the histones in 
the flanking nucleosomes often carry specific post-translational modifications that likely affect 
their function and gene expression. Histone modifications are considered to act mainly in two 
ways: either by altering the biophysical properties of chromatin and influencing chromatin 
compaction or by supporting binding of additional transcriptional cofactors that precisely finetune 
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gene expression (Winter et al., 2017).  Elements with the biochemical signatures of enhancers 
(e.g. high level of H3K27ac) have highly cell-type specific activity and that supports their role as 
enhancers (Calo and Wysocka, 2013). In addition, acetylated histones were shown to form a less 
compact chromatin conformation (Garcia-Ramirez et al., 1995), which can potentially facilitate 
the ability of Pol II or transcription factors to access their binding sites on the DNA (Workman and 
Kingston, 1998). Nevertheless, the mechanistic role of histone modifications in enhancer function 
and gene expression regulation remains unclear. Histone marks such as H3K4me1 or H3K27ac 
were shown not the be sufficient, necessary or even mechanistically involved in transcription, 
whereas H3K4me3 cannot maintain transcription when the activating transcription factor is not 
present (Hödl and Basler, 2012; Pengelly et al., 2013) or is rapidly lost, from a previously active 
promoter region, when the activating transcription factor is removed (Hathaway et al., 2012). 
Thus, the question posed a long time ago: “Are histone modifications causally related to gene 
expression or simply its consequence?” (Calo and Wysocka, 2013) remains valid even today.  
 
The observation that reporter genes under control of different enhancer – core-promoter 
combinations exhibit distinct expression patterns suggested that the both enhancer and core-
promoter sequence-encoded specificities are an important determinant of enhancer-targeting 
(Merli et al., 1996; Ohtsuki et al., 1998; Sharpe et al., 1998). In other words, the core-promoter 
sequences falling into different functional classes are activated by distinct types of enhancers by 
means of different cell-type specific TFs or their combinations (Bender et al., 2001; Landry et al., 
2009). It is assumed that their communication is mediated by locally high concentration of specific 
cofactors that interact dynamically and supported by post-transcriptional modifications (Lemon 
and Tjian, 2000; Kulaeva et al., 2012). Nevertheless, which combinations of TFs and cofactors are 
able to activate transcription or which TFs, cofactors, histones, histone modifications or PIC 
components are involved in the implementation process of their biochemical compatibility 




1.2.6. Towards enhancer modularity 
 
With our greater appreciation of the complexity of genomic organization and improved 
understanding of regulatory mechanisms, it became apparent that cis-regulatory elements do not 
function in isolation. Many genes were shown to be controlled by multiple discrete enhancer 
sequences with different tissue specificities  (Simonet et al. 1991; Schwartz and Olson 1999; 
Bender et al. 2001; Burch 2005; Abbasi et al. 2007; Landry et al. 2009; Visel et al. 2009). For 
example, Schwartz and Olson (1999) showed that seven activating regions and three repressor 
regions surround the Nkx2-5 gene (the earliest known marker for cardiogenesis) and their 
differential activity and directed expression patterns are used for the tight spatio-temporal 
regulation of Nkx2-5: differential expression patterns demarcated distinct subpopulations of 
cardiomyocytes within cardiac compartments, but none of the enhancers could individually 
account for the time-wise homogenous, but precisely spatially localized, Nkx2-5 expression 
patterns. Likewise, GATA genes (GATA1-6) are regulated in a modular fashion by sets of enhancers 
that govern distinct temporal and/or spatial patterns of the overall expression in heart, gut, 
hematopoietic lineage development and other tissues (Burch 2005).  
 
 
Strikingly, 65% of the genes involved in mesoderm development of Drosophila were found not to 
be regulated by only a single enhancer. The majority of these genes are regulated by three to five 
redundant enhancers, of which one or more can be deleted without significant phenotypic effects 
(Cannavò et al., 2016). For example, the functional deletion studies revealed that the loss of one 
of the two redundant enhancers in Drosophila, that regulated the expression of the 
developmental genes shavenbaby and snail, did not result in a loss of function or phenotype under 
standardized laboratory conditions but did revealed their importance when the genetically 
modified embryos were treated with high-temperature stress (Dunipace et al., 2011; Frankel et 
al., 2010). In addition, redundant enhancers have been generally found to be characterized by a 
tendency to cluster together, have overlapping expression patterns in reporter assays and their 
similarities in TF binding sites (Hong et al., 2008). Enhancer redundancy is also a characteristic 
feature of mammalian genomes - Hay et al., 2016 showed that at the α-globin locus individual 
enhancers of a cluster act independently and in an additive manner. However, how complex 
patterns and precision of gene expression during development are achieved and why this involves 
elements with apparently redundant function remains elusive. For some cases, it is considered 
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that the key lineage genes in a given cell type tend to be associated with dense cluster(s) of highly 






In this chapter, I summarized many known (or mentioned unknown) aspects of enhancer-
mediated gene expression regulation. However in order to fully understand the complexity of 
gene expression regulation in the cell, and how it has been changed in respect to the 
developmental and environmental stimuli, it is necessary to identify all enhancer elements in the 
genome, discern their cell-type specific patterns and ultimately associate them with their target 
genes. 
 
To achieve that we needed to witness the rise of the high-throughput sequencing (HTS) 
technologies. Their application in the genome-wide identification and characterization of 









Genome-wide techniques that produce descriptive data about the chromatin landscape of the 
genome are collectively called epigenomic profiling technologies (Stricker et al., 2017). They 
derive epigenome profiles that were shown to provide a proxy information useful to facilitate 
annotations of the human genome and identify functional sequences in a genome-wide, 
comprehensive and potentially unbiased manner.  In general, epigenomic technologies stand 
upon the high-throughput sequencing technologies, that, due to their major shift in assay capacity 
as compared to the low-throughput technologies, allowed questioning of the previous locus-
centered conclusions and allowed researchers to extrapolate the previous findings to other parts 
of the genome (Rivera and Ren, 2013).  
 
In this section, I focus on the recent technological advances and how they are reflected on the 
identification and characterization of enhancer regions.  
 
 
1.3.1.  The historic expansion of HTS technologies 
 
Although the main goal of the Human Genome Project (HGP) was mainly to obtain the sequence 
of the human genome (McPherson et al., 2001; Venter et al., 2001; Collins et al., 2003), this project 
initiated major technological improvements. Sanger sequencing was replaced by the Next-
Generation Sequencing (NGS) and the rise of the high-throughput sequencing (HTS) technologies 
was initiated; the growing array of sequencing assays were developed (Margulies et al., 2005; 
Ronaghi et al., 1996).  
 
 
Today, HTS applications exceed far beyond simply sequencing genomes; sequencing assays were 
developed to characterize the transcriptome, map the regulatory information and three-
dimensional organization of the genome, sequence microbiomes, etc. (Figure 1.4., Reuter et al., 
2015). For example, one of the first high-throughput sequencing assays developed was DNase-Seq 
(Crawford et al., 2006). It maps “open” regions of the genome using DNase I digestion followed by 
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DNA sequencing. Around the same time, ChIP-Seq - a method to map transcription factor (TF) 
binding sites and identify chromatin modification was developed (Johnson et al., 2007), as well as 
the RNA-Seq - a method to characterize transcriptome (Nagalakshmi et al., 2008). The HiC - a 
method that allowed the first unbiased, genome-wide research of chromatin organization was 





Figure 1.4. Some of the sequencing-based technologies for mapping human epigenomes. ChIP-Seq is a high-
throughput method to probe DNA-protein associations (Johnson et al., 2007). It can be used to identify chromatin 
modification of TF binding sites.  DNase-Seq, Mnase-seq, and Hi-C can be used for mapping of chromatin structures. 
HiC facilitates genome-wide research of chromatin organization (Lieberman-Aiden et al., 2009), whereas DNase-Seq 
probes chromatin accessibility  (Crawford et al., 2006) and Mnase-seq nucleosome positioning (Schones et al., 2008). 
DNA methylation at 5mC can be probed genome-wide by MethylC-seq or BS-Seq (Cokus et al., 2008). ChIA-PET 
(Fullwood et al., 2009) is used to profile long-distance DNA interactions mediated by a specific protein. Figure 
reprinted from (Rivera and Ren, 2013) 
 
 
Many of the aforementioned HTS technologies were pioneered by The ENCyclopedia Of DNA 
Elements Project - a follow-up of the HGP aimed to identify all functional elements in the human 
genome sequence (ENCODE Project Consortium, 2004). As other large-scale consortia-based 
projects were initiated in the meantime, a colossal amount of genomic and epigenomic data was 
produced by the HTS technologies and was subsequently used to characterize the human genome 
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(Bernstein et al., 2010; Harrow et al., 2012; Stunnenberg et al., 2016), study human genetic 
variation (1000 Genomes Project Consortium et al., 2010), analyze gene expression (GTEx 
Consortium, 2015), produce three-dimensional maps of mammalian genomes (Dekker et al., 
2017), or discover the molecular foundation of human diseases (Cancer Genome Atlas Research 
Network et al., 2013; Welter et al., 2014), etc.   
 
In this thesis, I analyzed a subset of available high-throughput datasets and data types. I further 
introduce the basics of technologies which results I used in this thesis: ChIP-Seq, BS-Seq, DNase-
Seq, Chromatin conformation capture (3C) and derived techniques, CHiA-PET, RNA-Seq, 
microarrays and CRISPR-Cas system. 
 
 




ChIP sequencing or chromatin immunoprecipitation followed by sequencing (ChIP-Seq), is 
an NGS method developed to study protein-DNA interactions in the nucleus (Gilmour et 
al., 1986). Although, chromatin immunoprecipitation per se has been in use since 1988 
(Solomon et al., 1988), prior pairing with sequencing, it was frequently utilized in 
combination with hybridization microarrays - in a technique called ChIP-chip, and in 
tandem with NGS as previously mentioned (Mikkelsen et al., 2007; Robertson et al., 2007; 
Barski et al., 2007). In short, during the ChIP protocol, DNA and its bound proteins are 
cross-linked. The DNA-protein complexes are sheared, and protein-specific antibodies are 
used to select and pull down the DNA fragments associated with the protein of interest. 
Pulled-down DNA fragments are sequenced and aligned to a reference genome. This 
enables genome-wide mapping of a protein’s activity on the genome at base pair 
resolution. The ChIP-Seq data represents a signal across genomic coordinates, where each 
base is associated with a binding strength quantified as a real-valued signal (normalized 
count of the reads covering each location). Although characterized by a high number of 
false positives and the presence of artifacts, ChIP-seq still represents the golden standard 








Bisulfite sequencing (BS-Seq) is an NGS method developed to study DNA methylation 
genome-wide - the methylome. In BS-Seq, DNA sequencing is preceded by bisulfite 
treatment of the DNA, a reaction which converts cytosine residues to uracil, unless those 
cytosines are methylated and a comparison with the reference sequence results in 
identification of the methylated cytosines (Frommer et al., 1992). Bisulfite-treated DNA 
sequencing is a golden standard for probing the methylome genome-wide (Wreczycka et 
al., 2017). As previously mentioned, C5-methylcytosine (5mC) was the first studied 
epigenomic modification (Hotchkiss, 1948) and was shown to change the activity of a DNA 
segment without changing the sequence especially when located in promoter (enhancer) 





DNase-Seq (DNase I hypersensitive sites sequencing) is an NGS method developed to 
study chromatin accessibility in a sample. It identifies regions sensitive to cleavage by 
DNase I enzyme genome-wide - DHSs or DNase I hypersensitive sites (Crawford et al., 
2006; Madrigal and Krajewski, 2012). The accessibility of a genomic segment containing 
genes is a requirement for polymerase to be able to transcribe any genes from that 
segment, thus chromatin accessibility is an important epigenetic mark that indicates 
active regions in the genome. It was succeeded by the FAIRE-Seq (Giresi et al., 2007); 
however, ATAC-Seq has been more commonly used recently (Buenrostro et al., 2013). 
Briefly, it is performed by first treating DNA with a DNase I enzyme, which cuts loose 
accessible chunks of DNA and then primers are ligated to the resulting DNA fragments. 
Primers are amplified and sequenced, and when mapped to the reference genome, they 
indicate which parts of the genome are accessible (Buenrostro et al., 2013).  
 
Chromatin conformation capture (3C) and derived techniques 
 
Chromatin conformation capture (3C, Dekker et al., 2002) and derived techniques such as 
chromosome conformation capture on chip - 4C (Simonis et al., 2006), carbon-copy 
chromosome conformation capture - 5C (Dostie et al., 2006) and HiC (Lieberman-Aiden et 
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al., 2009) are ligation-based (high-throughput) techniques that have been used to 
measure chromatin contact frequencies in the nucleus and study the spatial organization 
of chromatin in a cell. In general, the 3C-based methods consist of several steps including 
crosslinking with formaldehyde, genome fragmentation using restriction enzymes, 
ligation of interacting regions and their quantification (Pombo and Dillon, 2015). The main 
difference between methods is their scope: for example, 3C methods quantify 
interactions between a single pair of genomic loci (Dekker et al., 2002), whereas HiC is a 
fully high-throughput method (Lieberman-Aiden et al., 2009). 3C-based methods can be 
combined with other technologies to adapt them for specific problems, for example, 
CHiA-PET (chromatin interaction analysis by paired-end-tag sequencing) combines Hi-C 




RNA sequencing  
 
RNA sequencing (RNA-Seq) is an NGS method developed to quantify the level of all RNA 
transcripts in a sample. It is performed by sequencing cDNA reverse-transcribed from RNA 
extracted from a sample. Prior to the development of NGS, hybridization arrays were used 
to measure gene expression, or the relative abundance of different mRNA transcripts in 
cells (DeRisi et al., 1996). NGS was first used to quantify gene expression by sequencing 
reverse-transcribed cDNA in 2008 (Morin et al., 2008). Today, RNA sequencing has mostly 
replaced microarrays for gene expression quantification, thanks to its numerous 
advantages: less susceptible to cross-hybridization mistakes, has a better dynamic range, 
offers better detection of highly and lowly expressed genes, provides superior fidelity and 
it does not require the transcript sequence to be known a-priori (Grabherr et al., 2011; 
Zhao et al., 2014).  In RNA-Seq, reads from the sequencing experiment are aligned to a 
reference sequence, and each is assigned to the gene (or transcript) it has originated from. 




Microarray is the platform for genotyping - assessing known markers in the human 
genome - which enables researchers to identify single nucleotide polymorphisms (SNPs) 
or larger structural changes among millions of markers. Specifically, DNA microarray (DNA 
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chip or biochip) is a collection of microscopic DNA spots attached to a solid surface - 
probes - that are used to hybridize a cDNA or cRNA.  Probe-target hybridization is then 
detected and quantified by detection of fluorophore- or chemiluminescence (Taub et al., 
1983). Many different DNA microarrays have been developed, especially by Illumina, and 
used in various genome-wide association studies or eQTL studies such as the GTEx Project 
(GTEx Consortium, 2015).  
 
 
CRISPR–Cas system  
 
The type II CRISPR/Cas9 system (Cas9) is a versatile technology for genome engineering 
(Doudna and Charpentier, 2014; Hsu et al., 2014).  In a nutshell, CRISPR–Cas system is 
targeted to a precise genomic location by a guide RNA (gRNA) - a synthetic RNA 
complementary with a target DNA sequence (Mali et al., 2013) that is fused to a 
catalytically inactive variant of the bacterial Cas9 nuclease (dCas9). The enzymatic activity 
of the Cas9 nuclease is usually terminated by mutation in the RuvC and HNH domains and 
results in  the nuclease-null deactivated Cas9 - dCas9 (Jinek et al., 2012). To successfully 
modify (add or remove) chromatin marks at the target sites a range of chromatin-
modifying enzymes or general transcriptional activator and repressor proteins such as 
p300 (Hilton et al., 2015), LSD1 (Kearns et al., 2015) , DNMT3A (Rivenbark et al., 2012; 
Siddique et al., 2013), KRAB (Fulco et al. 2016; Fulco et al. 2019; Gasperini et al. 2019) can 
be attached to the DNA-binding domains. The grounding behind using genome editing 
techniques, such as CRISPR–Cas system (Canver et al., 2015), for functional 
characterization of regulatory regions, lies in the fact that the fusion of chromatin-
modifying enzymes (or their catalytic domains) and targetable DNA-binding domain can 
be used to change a single chromatin mark at particular genomic sites thereby repressing 
or activating enhancers. In addition, the CRISPR–Cas system allows easy generation of 
targeting constructs and its potential for multiplexing (Stricker et al., 2017). Recently, cell-
based genetic screens - a high-throughput approaches based on CRISPR interference 
(CRISPRi) - have been recently adapted to evaluate candidate regulatory sequences in 
their native genomic context and globally capture perturbations of gene expression 
(Canver et al. 2015; Wakabayashi et al. 2016; Fulco et al. 2016; Diao et al. 2017; Gasperini 





1.3.3. Annotating cis-regulatory elements from chromatin profiles 
 
Enhancers are marked by characteristic chromatin signatures (Figure 1.5., Heintzman et al., 2007), 
but lack motifs that could be used for their general identification (Lee et al., 2015; Colbran et al., 
2017). Thus, functional data (and an extensive use of epigenome mapping technologies mostly 
through the large epigenomic consortia; ENCODE Project Consortium, 2004, Andersson et al., 





Figure 1.5. A schematic representation of regulatory elements in the genome and their distinctive chromatin 
signatures that have been commonly used to facilitate their genome-wide identification. Enhancers are, in general, 
characterized by the presence of: (A) binding of specific TF and cofactors such as p300, (B) chromatin with higher 
accessibility and are depleted of nucleosomes, (C) high levels of H3K4me1 and H3K27ac and (D) low level of DNA 
methylation. Distinctive chromatin features for promoters and insulators are indicated as well.  
 
In general, several main approaches were used to predict enhancers: predictions using motifs and 
conservation (Berman et al. 2002; Kheradpour et al. 2007), chromatin accessibility (Thurman et al. 
2012), enhancer–promoter interactions or predictions from transcription factors regulator 





For example, some methods search for regions in the genome that are highly conserved across 
species (Del Bene et al., 2007; Kheradpour et al., 2007), while others identified genomic regions 
enriched for transcription factor motif matches (Berman et al., 2002; Kheradpour et al., 2007). 
ChIP-seq method was frequently utilized to target specific enhancer-related histone marks or 
identify in vivo binding sites for various TFs and cofactors (such as p300; Visel et al., 2009). Later 
was driven by the rationale that enhancer activity strictly depends on binding of TFs and cofactors 
(Visel et al. 2009; Kagey et al. 2010; Zuin et al. 2014). On the other hand, regions for which the 
presence of high levels of chromatin marks associated with enhancer activity, such as H3K4me1 
and H3K27ac, were commonly identified as putative enhancers (Heintzman et al., 2009; 
Creyghton et al., 2010; Rada-Iglesias et al., 2011). In addition to H3K4me1 and H3K27ac, DNA 
methylation was found to be a robust predictors of enhancer activity (Varley et al., 2013, Whalen 
et al., 2016) and its presence/absence was frequently used enhancer predictions (Shlyueva et al., 
2014).  
 
As enhancers are generally characterized by chromatin with higher accessibility and are depleted 
of nucleosomes (Felsenfeld et al., 1996; Gross and Garrard, 1988), methods that probe chromatin 
accessibility, such as DNase-seq and ATAC-seq, have been generally used for their genome-wide 
identification (Thurman et al. 2012). Importantly, the majority of surveyed TFs was found to bind 
almost exclusively to open chromatin (ENCODE Project Consortium, 2004) and transcription factor 
binding and DNA accessibility were found to be highly correlated (Kaplan et al., 2011; Pique-Regi 
et al., 2011). 
 
Lastly, ever since enhancer-derived RNAs were observed at regions marked by enhancer-
associated chromatin modifications they have been used for enhancer identification (Kim et al., 
2010). Active enhancers produce bi-directional non-coding RNAs (eRNAs; Wang et al., 2011), 
which expression level correlates with the functional activity of the enhancer (Mikhaylichenko et 
al., 2018) and with the activation of nearby genes (De Santa et al., 2010; Lai et al., 2013). This 
enabled the use of eRNAs  (Andersson et al., 2014) or nascent transcription (Hah et al., 2011) as a 
marker for annotation of active enhancers across cell lines in a genome-wide manner. 
 
Up today, there is no consensus on which chromatin marks should be used to predict enhancers 
(Shlyueva et al., 2014; Stricker et al., 2017). To overcome aforementioned non-specificity of 
individual chromatin marks to predict enhancer regions in the genome, (Ernst et al., 2011) 
proposed computational integration of epigenomic datasets. In a comprehensive epigenomic 
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study of nine human cell lines,  (Ernst et al., 2011) proposed that the human genome could be 
segmented into regions that carry one of 15 different combinations of chromatin modification 
marks and that each chromatin state corresponds to a specific category of genomic features. 
Meanwhile, epigenomics and transcriptomics datasets were integrated computationally using 
approaches such as CSI-ANN (Firpi et al., 2010), Seqway  (Kleftogiannis et al., 2015), ChromHMM  
(Ernst and Kellis, 2012), DEEP (Hoffman et al., 2012), etc.  In addition, separate computational 
methods that use machine-learning approaches to identify characteristic DNA sequence features 
in experimentally determined enhancers were developed to use these chromatin features to 
predict novel enhancers (Kantorovitz et al., 2009; Narlikar et al., 2010).  
 
Nevertheless, only in vivo testing of the reporter or in vivo editing of the enhancer in transgenic 
animals have been considered to be a definitive proof of enhancers and their activity (Visel et al., 
2007; Catarino and Stark, 2018).  
 
 
1.3.4. Genome-wide identification of enhancer-gene interactions  
 
Genome-wide approaches did identify numerous putative enhancers, but the vast majority of 
them have not been functionally tested and we still do not know which genes and in which cell 
types (if any) enhancers regulate (Arnold et al. 2013; Kvon et al. 2014; Catarino and Stark 2018; 
Fulco et al. 2019).  
 
Elucidating the function and targets of enhancers remains elusive for multiple reasons: relative 
location of the enhancer with respect to its target genes can be greatly variable (Lettice et al. 
2003), one gene is commonly regulated by more than one enhancer and one enhancer regulates 
more than one gene (Simonet et al. 1991; Schwartz and Olson 1999; Bender et al. 2001), 
enhancers are very cell-type specific (Burch 2005; Abbasi et al. 2007; Landry et al. 2009; Visel et 
al. 2009) and hard to identify genome-wide per se (Hariprakash and Ferrari 2019), or enhancers 
can “skip” over a proximal to gene to regulate a more distant one (Merli et al. 1996). Remarkably, 
activation of a specific gene may be activated in multiple cell types by distinct enhancers (Visel et 




Multiple approaches have been utilized to study enhancer-mediated long range gene regulation 
and can be broadly categorized into four categories: predictions using information from the eQTL 
studies (Rockman and Kruglyak 2006; Gaffney et al. 2012; GTEx Consortium et al. 2017), 3C-related 
technologies (Dekker et al. 2002; Simonis et al. 2006; Dostie et al. 2006; Lieberman-Aiden et al. 
2009; Fullwood et al. 2009), and reporter assays or cellular screens (Arnold et al. 2013; Kwasnieski 
et al. 2012; Arnold et al. 2013; Kheradpour et al. 2013; Kvon 2015; Gasperini et al. 2019).  Lastly, 
computational modelling has been commonly used to map enhancers to their putative genes 




Figure 1.6. Schematic representation of four main methodological approaches used to annotate regulatory regions 
with their target genes: 1) Information about the 3D genome architecture and chromatin interactions are commonly 
used as a proxy of enhancer-mediated regulation of gene expression; 2) An overlap between expression quantitative 
trait locus (eQTL) and regulatory region can be used to assign eQTL associated gene (eGene) to tested enhancer 
regions. 3) Associations of regulatory regions and their targeted genes have been assessed computationally. 4) A 
direct functional confirmation or quantitative readout of enhancer activity can be tested in reporter assays and 




The fact that enhancers are brought into contact with their target promoters by potentially 
“looping out” large stretches (up to 1Mb) of the intervening DNA has been exploited to predict 
enhancers. The development of the chromosome conformation capture (3C) and derived 
techniques (Dekker et al. 2002; Simonis et al. 2006; Dostie et al. 2006; Lieberman-Aiden et al. 
2009; Fullwood et al. 2009) allowed genome-wide assessment of the interaction frequencies 
between different sites on the  same  or  different  chromosomes, which, in turn, provided 
information  about  the  physical  properties  of  the chromatin fiber and as a proxy for enhancer-
mediated regulation of gene expression (Dekker et al. 2002).  
 
An overlap between expression quantitative trait locus (eQTL) and regulatory region can be used 
to assign eQTL-associated gene (eGene) to tested enhancer regions. eQTLs are a population-based 
measure of the effect of genetic polymorphism on gene expression (GTEx Consortium et al., 2017). 
They are defined as nucleotide variants that correlate with differences in gene expression 
(Rockman and Kruglyak, 2006). Ever since integration of eQTLs with other genomic features was 
shown to provide a good estimate of the regulatory effect on target genes (Gaffney et al., 2012), 
they have been frequently used to annotate risk SNPs to their target genes (Welter et al., 2014). 
On the other hand, if some regulatory region was found to overlap with eQTL this was (could be) 
used as a proof of a genetic link between the regulatory region and its potential target gene (GTEx 
Consortium, 2015).  
 
To provide a direct functional confirmation or quantitative readout of enhancer activity, reporter 
assays (Arnold et al., 2013) and cellular screens were developed (Fulco et al., 2019; Gasperini et 
al., 2019). In vivo based systems enhancer–reporter assays (Kvon, 2015) test regulatory potential 
of thousands of enhancers using one of defining properties of enhancers - activation of gene 
transcription from a minimal promoter (Banerji et al., 1981). Reporter transcription can be 
detected by various methods such as RNA in situ hybridization (O’Kane and Gehring, 1987), live 
imaging of nascent RNA (Bothma et al., 2014), lacZ staining (Kothary et al., 1989) or by activation 
expression of fluorescent proteins such as GFP (Chiocchetti et al., 1997). The genome-wide 
versions of enhancer reporter assays - massively parallel reporter assays; MPRAs, (Patwardhan et 
al., 2009) have been used to test regulatory potential of thousands of enhancers across different 
cells or tissues simultaneously ( Kwasnieski et al., 2012; Arnold et al., 2013; Kheradpour et al., 
2013). They are designed in three conceptually different ways: to randomly probe different parts 
of the genome by creating “enhancer-traps”, to directly test enhancers for in vivo activity in 
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enhancer-reporter vectors, or to test enhancers in the context of a longer DNA sequence using, 
for example, BAC transgenesis (Kvon, 2015). 
 
On the other hand, cell-based genetic screens have been recently adapted to evaluate candidate 
regulatory sequences in their native genomic context by perturbing sequences using the CRISPRi 
(dCas9-KRAB) system (Canver et al. 2015; Wakabayashi et al. 2016; Fulco et al. 2016; Diao et al. 
2017; Gasperini et al. 2017; Fulco et al. 2019; Gasperini et al. 2019). In a nutshell, chromatin-
modifying enzymes or general transcriptional activator and repressor proteins such as p300 
(Hilton et al. 2015), LSD1 (Kearns et al. 2015) , DNMT3A (Rivenbark et al. 2012; Siddique et al. 
2013), KRAB (Fulco et al. 2016; Fulco et al. 2019; Gasperini et al. 2019) are attached to the 
CRISPR/Cas9 system to modify chromatin marks at the target sites. Importantly, by using single-
cell RNA sequencing (scRNA-seq) screens one can globally capture gene expression perturbations 
without strong a priori hypothesis about target genes (Fulco et al. 2019; Jaitin et al. 2016; 












1.4. Functional characterization of enhancers by computational modelling  
 
 
In genomics and bioinformatics, computational algorithms have been used to support biological 
research and answer various questions such as analyzing protein-protein interactions (Marcotte 
et al., 1999; Qi et al., 2006; Papanikolaou et al., 2015), aligning biological sequences (Altschul et 
al., 1990), annotating enhancers and enhancer-gene interactions genome-wide (Mount and 
Mount, 2001). Here, I shortly introduce the rationale behind using algorithms to annotate 




1.4.1. Computational approaches to identify gene-enhancer associations 
 
 
Algorithms that were developed to identify enhancer-gene associations can be broadly 
categorized as: 1) correlation-based; 2) supervised learning-based; 3) regression-based and 4) 
methods based on other scores (Table 1.1., Hariprakash and Ferrari, 2019). The number and type 
of features used by an individual algorithm varies, but most of them take into account a 
combination of gene expression, histone marks, chromatin accessibility and the distance between 
enhancers and genes (Hariprakash and Ferrari, 2019).  
 
 
 Correlation-based modelling 
 
Correlation corresponds to any statistical relationship, causal or not, between two 
random variables or bivariate data. It is usually measured by Pearson and Spearman 
correlation coefficients that range between +1 and −1 (where 1 denotes a total positive 
linear correlation, 0 no linear correlation, and −1 total negative linear correlation).  
 
As long as enhancers have been recognized as regulatory elements in the eukaryotic 
genomes, a direct correlation between their activity and transcription rate was 
recognized (Gerster et al. 1986). However, recently, this property was used to link 
enhancers with their target genes:  for example, the correlation-based enhancer-gene 
association algorithms, such as PreSTIGE (Corradin et al. 2014) and ELMER (Silva et al. 
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2019), originate on the rationale that the activity status of an enhancer and its target gene 
is correlated across multiple cell types  Ernst et al. 2011 correlated gene expression with 
different histone modification marks, including enhancer associated marks H3K27ac and 
H3K4me1, Sheffield et al. 2013 correlated DNase I hypersensitivity and gene expression, 
whereas Varley et al. 2013 focused on DNA methylation. Thurman et al. 2012 as well used 
DNase-seq read coverage at DHS regions and correlated them to DNase-Seq signals at 
promoters, whereas Corradin et al. 2014 used H3K4me1 ChIP-Seq and RNA-Seq signal to 
estimate the activity of enhancers and genes, and assess their relationship. Importantly, 
to identify putative EGAs by correlation methods a certain degree of variance in enhancer 
activity is required.  
 
Supervised learning-based methods  
 
In general, supervised learning is a type of machine learning that aims to identify a 
function which maps an input to an output based on input-output pairs. In the case of 
enhancer-gene associations, supervised learning algorithms leverage a set of EGAs that 
are assumed to represent “known” true positives and negatives, and build a model that, 
given the training set, identifies patterns in functional data. Models typically incorporate 
features derived from epigenomics and transcriptomics data across different cell types in 
the training set. However, as the number and type of possible features are greatly 
variable, predictions tend to be very algorithm-specific (Hariprakash and Ferrari 2019). 
Trained models can be generally used to predict EGAs in other cell types; however, given 
the very cell type-specificity of enhancers, the reliability of models varies greatly for 
different cell types (Cao et al. 2017). The main limitation of supervised learning is that the 
training set requires a set of known positive and negative interactions.  
 
For example, Gao et al. (2016) identified EnhancerAtlas enhancer - promoter associations 
across 48 cell lines and 22 tissues using IM-PET algorithm - a random forest classifier 
developed by He et al. (2014) that integrates four types of models/data sources to predict 
enhancers: TF and promoter activity correlation, correlation of enhancer and promoter 
activity, enhancer and promoter sequence co-evolution and distance between enhancer 
and promoter. On the other hand, enhancer-to-promoter distance, H3K4me1, H3K4me3, 
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Regression-based methods work on the rationale that, since multiple enhancers can 
regulate a single gene, a combinatorial rather than pairwise approach should be used to 
predict enhancer-gene associations (Reuter et al., 2015). Regression-based methods have 
the ability to determine the relative influence of one or more predictor variables and thus 
can assess significant relationships and at the same time assess the strength of impact for 
multiple variables (Hariprakash and Ferrari, 2019). The main limitation of regression 
methods is that they rely on arbitrarily chosen parameters, for example a maximum 
number of enhancers tested around each TSS. In addition, they do prefer larger datasets 
- number of cell types with available functional data used to build the models (Hariprakash 
and Ferrari, 2019).  
 
One of the regression based algorithms that I analyzed in this thesis is FOCS (FDR-
corrected OLS with Cross-validation and Shrinkage). In FOCS, Hait et al. (2018) used 
ordinary least squares regression method and across-cell type epigenomic signals to learn 
predictive models. They modelled activity of promoters based on the activity level of its 
ten closest enhancers (within a window of ±500 kb around the gene’s TSS) using DHS 
signals from the ENCODE (106 cell types), Roadmap DHS (73 different cell types and 
tissues), FANTOM5 CAGE (600 human cell lines and primary cells), and GRO-Seq 
expression data (23 different human cell lines).   
On the other hand, JEME (Cao et al., 2017) is a hybrid method that combines a regression 
step followed by a random forest classifier (supervised learning) trained to predict EGAss 
based on each cell type-specific data. First, they built per-gene regularized regression 
models (LASSO and elastic net) of gene expression and enhancer activity using across-cell-
type signals: RNA-Seq, DHS, H3K4me1, H3K4me3, and H3K27ac ChIP-Seq and FANTOM5 
CAGE datasets. In the second step, they assessed cell-type specific enhancers and 
individually, for each cell-type, they built a Random Forest classifier based on the 
previously inferred information (prediction errors, distance between enhancers and TSS, 
and levels of activity signals for analyzed chromatin marks) and trained it with the 'gold-
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standard' answers: ChIA-PET, Hi-C or eQTL reported interactions. They assessed model 





Table 1.1. Pros and cons of four commonly used computational approaches that model enhancer-gene associations.  
 
 
 Pros Pros Example method 
 
Correlation 
● Identify multiple 
targets of an 
enhancer and can 
directly derive a 
quantitative 




correlation patterns in 
case enhancer regions 
are defined at a 
resolution higher than 
that of the functional 
chromatin mark data 
used to measure their 
activity 
 
● availability of genomic 
data over a large 
panel of cells, with 
comparable quality 
and resolution across 
all conditions 
 
● is not a complete 
consensus about 
which epigenomic or 
transcriptomic data 
assess enhancers 
activity the best 
 
● confounded by 
enhancers active only 
in one or few cell 
types 
 
● do not directly 
consider the fact that 
multiple enhancers 
can act on a gene in a 
cooperative fashion 
 
● Varley et al. 
2013 
 
● Thurman et al, 
2012 
 
● Corradin et al. 
2014 
 
● Ernst et al. 2011 
 





● once the model is 
trained, it can predict 
EGAs in other cell types 
● reliability of the model 
can vary greatly when 
applied to different 
cell types 
● requires a set of 
known positive as well 
as negative 
interactions 
● JEME (Cao et al. 
2017); 
 




● More flexible 
prioritization of 
EGAs by adjusting a 
single threshold on 
the score. 
 














Other methods: score-based and data integrations  
 
In general, algorithms can combine experimental results into a single score that assess the 
modelling success. For example, GeneHancer (Fishilevich et al., 2017) quantifies a single 
quantitative score that defines the strength of association between enhancers and target genes, 
taking into account multiple types of information. GeneHancer, for example, combines eQTLS, TF-
target gene co-expression, eRNAs, capture Hi-C and genomic distance between enhancer and 
target gene by performing various data transformations and weights to combine aforementioned 
heterogeneous datasets into a single quantitative value. The main limitation of such approaches 
is that they rely on a number of assumptions and arbitrarily defined parameters or weights 
(Hariprakash and Ferrari, 2019). 
 
 
As in the case of enhancer definition, to overcome inherent weaknesses of different high-
throughput technologies which results are used to assess links between enhancers and their 
target genes, data integration of different epigenetic datatypes was proposed (Ernst et al. 2011). 
Computational approaches such as PreSTIGE (Corradin et al. 2014), TargetFinder (Whalen et al. 
2016), SPEID (Singh et al. 2019), RIPPLE (Roy et al. 2015), IM-PET (He et al. 2014), DECRES (Li et al. 
2018) were developed to integrate information about the 3D genome architecture, eQTLs, levels 
of epigenetic marks, and/or results of reported assays. For example, with TargetFinder, Whalen 
et al. 2016 integrates chromatin states with Hi-C interaction maps to predict individual and cell 
type-specific enhancer–promoter interactions using. However, aforementioned methods run for 
only a handful of cell lines. Some o the aforementioned methods belong to this category as well: 
EnhancerAtlas (Gao et al., 2016), JEME (Cao et al. 2017), GeneHancer (Fishilevich et al., 2017), 
FOCS (Hait et al., 2018), HANCER (Wang et al. 2019).  However, their predictions were never 






1.5. Statistical background of the reg2gene algorithm 
 
1.5.1. Algorithms implemented in reg2gene 
 
As we, later on, implemented five algorithms in reg2gene to account for different relationships 
between enhancer activity and gene expression: Pearson and Spearman correlation, distance 





We implemented an elastic net algorithm (Zou and Hastie, 2005) - a penalized regression 
method that was shown to work well for high-dimensional data with few examples - "large 
p, small n" cases and in context of association studies (Waldmann et al., 2013). Along with 
lasso (Tibshirani, 1996) and ridge regression (Hoerl and Kennard, 1970; Tikhonov et al., 
1995), elastic net simultaneously assesses the strength of an impact of enhancers (assess 
the errors terms in predicting TSS activity based on the activity of all candidate enhancers) 
on their target genes and identifies significant models (Friedman et al., 2009).  
 
Elastic net is implemented in the glmnet R package (Friedman et al., 2009) that fits a 
generalized linear model via penalized maximum likelihood.  
 




over a grid of values of regularization parameter lambda λ. l(y,η) is the negative log-
likelihood contribution for observation i. The elastic-net penalty is controlled by α and to 
actually execute the elastic net algorithm, we set α to be 0.5 (α=1 corresponds to lasso, 
whereas α=0 corresponds to ridge regression). The ridge penalty shrinks the coefficients 
of correlated predictors towards each other while the lasso tends to pick one of them and 
discard the others. On the other hand, the elastic-net penalty mixes these two methods, 
by linearly combining the L1 and L2 penalties, and if predictors are correlated in groups, it 
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tends to select the groups in or out together. As compared with least square regression, 
elastic net extends the least squares minimization with a term that includes the values of 
the predictor coefficients, β, in the minimization process. Thus, elastic net encourages a 
grouping effect, where strongly correlated predictors tend to be in or out of the model 





Random forest is a machine learning algorithm that uses an ensemble of decision trees 
(Breiman et al., 1984; Friedman et al. 2001) to solve classification, regression or other 
computational problems (Breiman, 2001).  
 
It operates by constructing a multitude of decision trees at training time and returning the 
class that is the mode of the classes (classification) or mean prediction (regression) of the 
individual trees as an output (Ho, 1995). Each of the classification trees is built using a 
bootstrap sample of the data, and at each split the candidate set of variables is a random 
subset of the variables. Thus, random forest uses both bootstrap aggregation (Friedman 
et al. 2001), and random variable selection for tree building. Each tree is unpruned (grown 
fully) and the algorithm seeks an ensemble that can achieve both low bias and low 
variance (from averaging over a large ensemble of low-bias, high-variance but low 
correlation trees). The most important parameters to choose in RF are the number of 
input variables tried at each split, number of trees to grow for each forest and the 
minimum size of the terminal nodes (Liaw and Wiener, 2002).  
 
Due to its characteristics, especially the ability to return the measures of variable 
importance (Bylander 2002), random forest algorithm has been frequently used in 
bioinformatics for variable selection, prediction modelling, pathway analysis, genetic 
association, epistasis detection, etc (Diaz-Uriarte and de Andrés 2005, Chen and Ishwaran 
2012). RF is effective in “large p, small n” problems - situations when there are many more 
variables than observations and it has a good predictive performance even when most 
predictive variables are noisy. In addition, it does not overfit, is invariant to monotone 
transformations of the predictors and can handle a mixture of categorical and continuous 
predictors which interactions it can incorporate in the final model. Lastly, its “grouping 
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property” of trees enables RF to adeptly deal with correlation and interaction among 






The main limitation of the previously introduced Pearson and Spearman correlation 
coefficient is that they are only sensitive to linear relationships. To account for the 
nonlinear regulatory relationships, we implemented the distance correlation coefficient 
as well (Székely et al., 2007). The DC has proven its power and computational 
effectiveness (Gorfine et al., 2012) in detecting nonlinear dependence for two variables 
with arbitrary dimensions because its estimations are quite simple without any 
distribution assumption (Guo et al., 2014). In biology, it was frequently used to; for 
example, infer the gene regulatory networks from expression data. 
 
In general, the key idea of distance correlation is to measure the discrepancy between the 
joint characteristic function and the product of its marginal characteristic functions in a 
special weighted L2 space. Specifically, for random variables (X,Y), denote the joint 





Pearson correlation coefficient is a measure of linear correlation between two variables. 
It has a value between +1 and −1, whereas +1 denotes a total positive linear correlation, 
0 no linear correlation, and −1 a total negative linear correlation (Pearson, 1895). 
 
Given a pair of random variables (X,Y) population Pearson correlation coefficient (ρ) is 
calculated as the covariance between random variable over the product of their standard 
devitations(𝜎𝜎𝑋𝑋is standard deviation of X, and 𝜎𝜎𝑌𝑌is the standard deviation of Y). The sample 
Pearson correlation coefficient (rxy) is obtained by substituting estimates of the 






The Spearman correlation coefficient (ρ) is defined as the Pearson correlation coefficient 
between the rank variables. It is a nonparametric measure of rank correlation - a statistical 
dependence between the rankings of two variables that assesses how well the 
relationship between two variables can be described using a monotonic function. 
Spearman correlation of +1 or −1 occurs when each of the variables is a perfect monotone 
function of the other and when there are no repeated data values.  For a sample of size n 
raw scores Xi , YI are converted to ranks rg Xi , rgYI and Spearman correlation coefficient is 
calculated as the covariance between ranks over the product of standard devitations of 





1.6. Understanding disease variants with epigenomics  
 
Any disease or disorder that is caused by mutations in one or more genes can be referred to as a 
genetic disease (Nyhan and Sakati 1987). For example, putative causal variants in apolipoprotein 
E have been found to be associated with Alzheimer's disease (Sillén et al. 2008), IL23R with Crohn's 
disease (Duerr et al. 2006), whereas a common human translocation involving c-myc is critical to 
the development of most cases of Burkitt lymphoma (Finver et al. 1988). 
 
Since the first disease-associated enhancer was identified in Hirschsprung disease (Grice et al. 
2005), more and more SNPs have been annotated to their putative causal genes based on the 
overlap with regulatory regions of the annotated gene (Styrkarsdottir et al. 2018; Short et al. 2018; 
Zhang et al. 2018; Schork et al. 2019). Soon, it became obvious that identification of regulatory 
elements and linking them to genes, pathways, and cellular processes represents the fundamental 
limitation of the functional characterization of GWAS results (and other association studies; 
Gallagher and Chen-Plotkin 2018), and a major obstacle for improving our understanding of 
diseases etiologies (Whalen et al. 2015).  
 
To study inherited genetic variation in health and disease, traditional genetic approaches such as 
linkage analysis (Lathrop et al. 1984) and genome-wide association studies have been utilized 
(Haines et al. 2005). However, development of the whole-genome and whole-exome sequencing 
enabled researchers to study the role of de novo mutations in an unbiased manner (Veltman and 
Brunner 2012). Nonetheless, the great majority of identified SNPs was found to be non-coding 
and the precise molecular mechanisms by which those polymorphisms exert their effects remains 
mostly unknown (Pickrell 2014). Putative causal genes were commonly annotated to SNPs based 
on their proximity to genes (Welter et al. 2014) and/or overlap with eQTLs (GTEx Consortium et 
al. 2017). However, since the role of enhancers in genetic susceptibility to various human traits 
and diseases became more evident (Smith and Shilatifard 2014; Chen et al. 2018), SNPs started to 
be more frequently annotated to their putative causal genes based on the overlap with regulatory 
region of an annotated gene (Styrkarsdottir et al. 2018; Short et al. 2018; Zhang et al. 2018; Schork 
et al. 2019).  
 
 
In my thesis, I focus on the annotation analysis of the results of genome-wide association studies 
(GWASs), because, during more than a decade-long history of GWAS experiments (Haines et al. 
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2005), thousands of SNPs have been associated with various phenotypes and diseases (Welter et 




1.6.1. Basics of genome-wide association study (GWAS)  
 
Genome-wide association study (GWAS) is an observational type of a study that is performed to 
identify genetic association with phenotypes of interest. GWASs typically focus on associations 
between single-nucleotide polymorphisms (SNPs) and phenotypes like human diseases. In GWASs, 
statistical associations are tested across many individuals in the genome-wide manner. GWASs 
mainly identify risk-associated “common variants” - single-nucleotide polymorphisms (SNPs) 
relatively frequent in the human population. In other words, GWA studies follow the “common 
disease-common variant” (CD/CV) hypothesis that assumes that common diseases are caused by 
common variants, which manifest frequently in the studied population, and lead to susceptibility 
to complex polygenic diseases (Schork et al. 2009).  
 
GWAS SNPs were found to be statistically over-overrepresented in (human) diseases and traits 
(Freedman et al. 2011; Blattler et al. 2014), but the majority (~93%) of risk-associated index SNPs 
(and SNPs that are in high LD to index SNPs) are not precisely located in the protein coding regions 
(Tak and Farnham 2015; ENCODE Project Consortium 2004; Maurano et al. 2012). Nevertheless, 
noncoding variants were shown to cause common diseases more likely than the non-synonymous 
coding variants (Manolio et al. 2008), and they account for the majority of disease heritability 
(Frazer et al. 2009). 
  
It was hypothesized that noncoding GWAS SNPs modulate disease etiology by causing changes in 
gene expression (Gerasimova et al. 2013). Recently, information produced through the 
biochemical surveys of the human genome (e.g., ENCODE (ENCODE Project Consortium 2004), 
Roadmap Epigenomics (Roadmap Epigenomics Consortium et al. 2015), the IHEC (Stunnenberg et 
al. 2016) raised high hopes that many non-coding risk-associated SNPs could be explained through 
their effect on gene expression. GWAS SNPs were found to be equally proportioned between the 
intergenic and intronic compartments (Freedman et al. 2011; Blattler et al. 2014), enriched for 
enhancer-associated regulatory chromatin states in biologically-relevant cell types (Ernst et al. 
2011), evolutionarily conserved elements (Lindblad-Toh et al. 2011), histone marks (Schaub et al. 
57 
 
2012; Trynka et al. 2013; Grubert et al. 2015) and accessible regions (Maurano et al. 2012; Pickrell 
2014).  
 
Several methods that integrate epigenetic and genetic information have been developed: 
RegulomeDB (Boyle et al. 2012), HaploReg (Ward and Kellis 2012), FunciSNP (Coetzee et al. 2012), 
GWAS3D (Li et al. 2013), rSNPBase (Guo et al. 2014), etc. In addition multiple sources of enhancer-
gene associations have been made available: EnhancerAtlas (Gao et al. 2016), JEME (Cao et al. 
2017), GeneHancer (Fishilevich et al. 2017), FOCS (Hait et al. 2018), HANCER (Wang et al. 2019), 
etc. However, we do not know if the initial choice of the annotation tools/data sources have a 
large effect on the interpretation of the results of a downstream GWAS analysis.  
  
 
1.6.2. The GWAS Catalog and DisGeNET  
 
Since the research on the genetic causes of disease has accelerated, as a result of both the 
completion of the human genome (Venter et al. 2001; McPherson et al. 2001; Collins et al. 2003) 
and the development of the NGS techniques (Ronaghi et al. 1996; Margulies et al. 2005), 
systematic integration of fragmented and heterogeneous information about the genetic causes of 
disease - scattered across specialized catalogues focused on specific disease classifications (i.e. 
Mendelian, or rare diseases), different model organisms, or on particular technological 
approaches (such as GWAS) - was crucial to support the development of precision medicine and 
drug discovery  (Piñero et al. 2017).  
 
One of the largest and comprehensive collections of human gene-disease associations (GDAs) 
currently available is DisGeNET (Piñero et al. 2017). Contrary to the GWAS Catalog, which focuses 
only on common polygenic diseases and variants, DisGeNET systematically integrates data from 
animal models, manually curated repositories, and the scientific literature.  For example, The 
DisGeNET release 4.0 includes the following resources: the Comparative Toxicogenomics 
Database (CTD), UniProt, OMIM, ClinVar, Orphanet, The GWAS Catalog, the Rat Genome Database 
(RGD), the Mouse Genome Database (MGD), and the Genetic Association Database (GAD). 
 
On the other hand, the GWAS Catalog is a free online database that compiles data of GWASs and 
summarizes their unstructured data (and data from different literature sources) into easily 
accessible data (Welter et al. 2014). For example, the catalog contains information and locations 
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of risk-associated SNPs supplemented with information about mapped/reported genes, details of 
the GWAS analysis (cohort size, ethnicity, etc.), study groups design, publication history, etc. After 
the first GWA study was performed in 2005 (Haines et al. 2005), thousands of GWASs were 
published and several thousands of genomic polymorphisms have been statistically associated 
with human phenotypes and diseases in the meantime (Hindorff et al. 2009). To organize large 
amounts of information produced by the GWA studies, attempts have been made at creating 












1.7. Contribution of this thesis 
 
 
Despite the tremendous progress in understanding how enhancers tune gene expression and of 
which genes, the field still lacks an approach that is systematic, integrative and accessible for 
discovering and documenting cis-regulatory relationships across the genome. Up today, multiple 
approaches have been utilized to study enhancer-mediated long range gene regulation and they 
can be broadly categorized into four categories: predictions using information from the eQTL 
studies (Rockman and Kruglyak 2006; Gaffney et al. 2012; GTEx Consortium et al. 2017) or 3C-
related technologies (Dekker et al. 2002; Simonis et al. 2006; Dostie et al. 2006; Lieberman-Aiden 
et al. 2009; Fullwood et al. 2009), and direct functional confirmation of enhancer activity by 
reporter assays or cellular screens (Arnold et al. 2013; Kwasnieski et al. 2012; Arnold et al. 2013; 
Kheradpour et al. 2013; Kvon 2015; Gasperini et al. 2019).  
 
The fourth approach, computational modelling of gene expression ~ enhancer activity, was the 
main subject of this thesis. Recently, several data integration approaches aimed to predict 
enhancer-gene associations were developed based on a large number of tissues, cell types and 
cell lines: EnhancerAtlas (Gao et al., 2016),  JEME (Cao et al. 2017), GeneHancer (Fishilevich et al., 
2017), FOCS (Hait et al., 2018), HANCER (Wang et al. 2019). However, their results, e.g. sets of EGA 
predictions, were never systematically analyzed, nor were their differences characterized. We do 
not know whether they predict the same regions in the genome as enhancers. Likewise, we do 
not know if they predict the same set of enhancer-gene associations. Lastly, although enhancer-
gene associations have been used to assign non-coding risk SNPs to their target genes, it is still 
unknown if (and how) various sets of predictions (EGAs) influence the result of risk-SNP functional 
analysis.   
 
I analyzed four main problems of enhancer-gene associations: first, I reviewed and characterized 
differences between published sets of enhancer-gene associations, and then, I set off to develop 
a novel approach that models and integrates gene expression ~ enhancer activity (reg2gene). I 
performed a thorough benchmarking of seven sets of EGAs, and lastly, I reviewed how different 
predictions of enhancer-gene association could influence the results of functional analysis of SNPs. 
Thus, to get a complete overview of the complex problem such as associating genes with their 
regulatory regions, I supplemented the original idea - development of a novel tool to link 
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enhancers with genes they regulate - with many additional information and somewhat 
unexpected analyses.  
 
In Chapter 2, I describe datasets and methods that I used/integrated to map and benchmark 
enhancer-gene associations.   
 
In Chapter 3, I introduce the problem of computational modelling of gene expression ~ enhancer 
activity. I review four computational methods that predict EGAs:  JEME - joint effect of multiple 
enhancers (Cao et al. 2017), GeneHancer (Fishilevich et al. 2017), EnhancerAtlas 2.0 (Gao et al. 
2016), and FOCS - FDR-corrected OLS with Cross-validation and Shrinkage (Hait et al. 2018). I 
showed that individual sets of predictions differ tremendously; especially in the location, number 
and properties of defined enhancer regions and characteristics of enhancer-gene associations.  
 
In Chapter 4, I describe our work to develop a computational method that models and integrates 
enhancer activity ~ gene expression is the genome-wide and systematic manner - reg2gene.  
Although our central question was to computationally model enhancer-gene association, due to 
a prominent role of enhancer definition and its influence on the final modelling performance, I 
dedicated a large section of this chapter towards reviewing, analyzing and identifying the robust 
set of enhancers. I thoroughly explain the process of developing the reg2gene method and 
characterize three sets of EGAs (enhancer-gene associations) that were identified using reg2gene 
data modeling and integration:  stringentC, flexibleC, inhouseM. 
 
The work described in Chapter 5 provided us with additional information about seven sets of 
(analyzed or developed) enhancer-gene associations: EnhancerAtlas (Gao et al. 2016), JEME (Cao 
et al. 2017), GeneHancer (Fishilevich et al. 2017), and FOCS (Hait et al. 2018) and three inhouse 
models: stringentC, flexibleC, inhouseM. Specifically, I ran benchmarking of the reported 
associations by overlapping them with commonly used benchmark datasets: eQTLs (Westra et al. 
2013, GTEx Consortium et al. 2017) and chromatin interactions reported in Xie et al. (2016) and 
Javierre et al. (2016). I further benchmarked EGAs based on results of cellular screens (Gasperini 
et al. 2019) and an inhouse method that identified false positives (FP) and true negatives (TN) in 
the genome. I show that the benchmark datasets suffer from low-reproducibility rate and that the 
stringentC models have the highest PPV (positive predictive values) if cellular screen and inhouse 




In Chapter 6, I present results of SNP-to-gene annotation analysis performed using different 
sources of enhancer-gene associations. Specifically, I annotated risk polymorphisms from the 
GWAS Catalog, colorectal cancer (CRC) SNPs, rs104111210 and showed that sets of annotated 
genes varied in their size. I demonstrate that some well-known gene-CRC associations were 
identified by certain sets of EGAs, while they were found to be missed by other EGAs methods. 
Lastly, I detected examples of enhancer-based pleiotropy and emphasized the potential of EGAs 
to identify it. I reported possible TFs that underlie such regulation and identify a novel gene-
disease association using overlap of SNPs with enhancers.   
 
In Chapter 7, I summarize the main results of this thesis and conclude with my view on the 
remaining perspectives of computational modelling of enhancer-gene associations. I elaborate the 
outlook for applying our growing understanding of transcriptional regulation to dissect the 
contributions of noncoding genetic variation to human disease and to manipulate gene expression 













I performed all computational modelling and downstream analysis supervised by Dr. Vedran 




2.1. Data processing and integration 
As a computational and data integration tool, reg2gene, relies on extensive data integration of 
multiple (epi)genetic datasets. Herby, I shortly introduce those datasets. 
The NIH Epigenomic Roadmap download and preprocessing  
We used epigenomes reported in the NIH Epigenomic Roadmap dataset - at time the 
largest collection of human epigenomes for primary cells and tissues - to define enhancers 
and predict enhancer-gene associations (Bernstein et al., 2010; Roadmap Epigenomics 
Consortium et al., 2015). Its 111 reference human epigenomes were profiled for histone 
modification patterns, DNA accessibility, DNA methylation and RNA expression; and were 
additionally extended with sixteen epigenomes from the ENCODE Project (ENCODE 
Project Consortium, 2004). Specifically, we selected epigenomic datasets - H3K27ac, 
H3K4me1, DNase I hypersensitivity, and DNA methylation. In addition, we used 
ChromHMM-predicted chromatin states for 127 Roadmap epigenomes (15-state 
ChromHMM model; (Ernst and Kellis, 2012). ChromHMM aggregated multi-dimensional 
matrices of chromatin marks into a small number of chromatin states based on a 
multivariate Hidden Markov Model and was previously used to systematically characterize 
chromatin states across 127 Roadmap cell types. 
From the https://egg2.wustl.edu/roadmap/, we downloaded 127 imputed H3K27ac and 
H3K4me1 ChIP-Seq, DNase-Seq, RNA-Seq, and WGBS DNA fractional methylation 
genome-wide signal coverage tracks from the NIH Roadmap Epigenomics Project  
(Roadmap Epigenomics Consortium et al., 2015), as bigWig files. We removed epigenomes 
reported to be of poor quality (three WGBS fractional methylation reference epigenomes: 
E001, E003, and E017). We allowed for only one donor per epigenome tissue or cell type. 
In addition, we downloaded info about spatial context (chromatin states) across 127 
epigenomes from the core 15-state model, that was prediceded using ChromHMM v1.10 





Computational models of enhancer-gene associations: JEME, FOCS, GeneHancer, EnhancerAtlas 
 
GeneHancer preprocessing 
From https://genecards.weizmann.ac.il/geneloc/index.shtml, we downloaded single  .csv 
document (GeneHancer enhancers are not cell-type specific) with 243,281 GeneHancer 
enhancers on the 28.11.17. GeneHancer version was 4.6 and it contained enhancer 
locations and corresponding metadata; including names of associated genes. We wrote 
an inhouse R scripts to: 1) extract locations of enhancers, 2) obtain one-to-one mapping 
between genes and enhancers (necessary since more than one gene was reported to be 
associated with single enhancer region saved as one row of the table), 3) liftover hg38 to 
hg19 enhancer coordinates (rtracklayer R package), 4) obtain gene locations either by 
using GeneHancer-reported HCGN gene names or ENSEMBL IDs and setting them to be 
equal to the extended TSS coordinates (+/-1000 bp) of the GENCODE v24 genes.  Post 
processing, we defined 506,684 unique GeneHancer unique enhancer-promoter 
associations.  
EnhancerAtlas preprocessing 
We downloaded enhancer-target relationships for 70 EnhancerAtlas cell/tissue types 
from http://www.enhanceratlas.org/ on the 28.11.17. We used an in-house script to 
create a union of all enhancer-target relationships reported in different cell types, by 
pooling all reported interactions across cell types into one object. To account for the 
multiple observations of the same E - G association across multiple cell/tissue types, we 
requested that each enhancer-target relationship can occur only once in the final dataset. 
Since only ENSEMBL transcript identifiers were reported, we performed ENST mapping to 
ENSG using EnsDb.Hsapiens.v75 to obtain gene IDs. Based on the overlap in ENSEMBL ID’s 
between GENCODE and reported genes, EnhancerAtlas gene coordinates were set to be 
equal to extended TSS coordinates (+/-1000 bp) of the GENCODE v24 genes. 
FOCS preprocessing 
We accessed FOCS enhancers (on the 15.1.2018.) and enhancer-promoter links (on the 
13.9.2018) from the http://acgt.cs.tau.ac.il/focs/download.html. We downloaded all four 
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reported datasets of enhancer predictions: 1) ENCODE DHS (encode.enh.pos.RData), 2) 
Roadmap DHS (roadmap.enh.pos.RData), 3) FANTOM5 CAGE (fantom.enh.pos.RData), 
and 4) GRO-Seq enhancer regions (groseq.enh.pos.RData).  
Additionally, we downloaded four reported sets of enhancer - gene FOCS associations: 1) 
ENCODE DHS (encode_interactions.txt), 2) the Roadmap Epigenomics project DHS 
(roadmap_interactions.txt), 3) FANTOM5 CAGE (fantom_interactions.txt), and 4) GRO-
Seq (groseq_interactions.txt), and pooled reported interactions together. We wrote an in-
house script to assign coordinates to the FOCS gene names by overlapping reported gene 
names with GENCODE v24 genes and taking over GENCODE extended (+/-1000 bp) TSS 
coordinates.  After excluding interactions on the chromosome Y, we obtained 117,355 
unique FOCS EP links. 
JEME preprocessing 
We downloaded four JEME datasets on the 11 October 2017 from 
http://yiplab.cse.cuhk.edu.hk/jeme/: elastic net and LASSO predictions (enhancer - gene 
links) for FANTOM5 and ENCODE/Roadmap cell types and tissues.  To define JEME 
enhancers, we pooled results of LASSO and elastic net predictions across all Roadmap cell 
types and tissues, and extracted reported enhancer regions and kept unique entries. In 
addition, for analysis of enhancer-gene interactions, we pooled all predictions across all 
four JEME datasets and identified 929,682 unique enhancer-gene associations. Gene 
coordinates were set to be equal to the extended TSS coordinates (+/-1000 bp) for genes 




Benchmark datasets: eQTL and studies of chromatin interactions  
PC-HiC dataset preprocessing 
(Javierre et al., 2016) reported a genome-wide dataset that is strongly enriched for 
genomic interactions with promoter regions across 17 human primary blood cell types. It 
was experimentally created by PC-HiC methods. Active promoter enhancer links from PC-
HiC dataset were accessed as a PCHiC_peak_matrix_cutoff5.tsv object on 17.1.2017. from 
http://www.sciencedirect.com/science/article/pii/S0092867416313228.  We pooled 
interactions across cell types and kept only unique interactions. We identified a total of 
728,838 unique interactions (31,253 annotated promoters and on average 175,000 
interactions per cell type).  
CCSI preprocessing 
We accessed the CCSI (Chromatin Chromatin Space Interaction) database on the 11th 
January 2017 from http://120.79.23.67/ccsi/download.php and downloaded all hg38 4C, 
5C, HiC, ChIA-PET datasets (N=44). We pooled interactions from all reported datasets into 
one object, and lifteovered (to the human genome version hg19) coordinates of both 
anchors of all interacting pairs using CrossMap program. We removed all interacting pairs: 
1) which had the start and end coordinate of the anchor switched (start was downstream 
of end); 2) at least one anchor of the interacting pair was longer than 10 kb, or 3) two 
anchors within the same interacting pair overlapped together. In the original publication, 
a total of 3 017 962 pairwise interactions across 91 chromatin interaction datasets was 
reported. Since eQTLs occupy a single position in the genome, whereas anchors of 
interactions can vary in size, we tested the size of interacting regions reported in CCSI 
database and PC-HiC interactions. We identified large differences in the size of reported 
interacting regions (Supplementary Figure 1.). The CCSI database reported interactions 
among 1Mb long regions in the genome. Since long regions more likely overlap one or 
more enhancers (that themselves generally span several hundred base pairs), we decided 
to set a limit on the size of interacting regions - 10Kb and identified 1 587 002 such 
interaction pairs.  
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TAD regions  
We downloaded coordinates of TADs regions for 37 hg19 cell types/tissues on the 25th of 
April 2019 from the http://promoter.bx.psu.edu/hi-c/publications.html. TADs 
coordinates originated from five publications (Lieberman-Aiden et al. 2009, Rao et al. 
2014, Dixon et al. 2015, Leung et al. 2015, Schmitt et al. 2016) and as a part of ENCODE 
Consortium (ENCODE Project Consortium 2012). 
GTEx database preprocessing 
We accessed 44 GTEx datasets V6 (corresponding to 44 analyzed cell types) on 5.10.2016. 
from the http://gtexportal.org/home/datasets. We pooled together info about eQTLs and 
associated gene names (.v6p.signif_snpgene_pairs.txt) across all 44 tissues into one 
object, and separately pooled info about genes (.v6p.egenes.txt) into another object. We 
merged these two datasets together by gene’s id and identified a total of 6,654,931 
entries, or 2,498,498 unique  eQTL-gene pairs. Gene coordinates were set to be equal to 
extended TSS coordinates (+/- 1000bp) identified in the GENCODE dataset for genes which 
ENSEMBL IDs overlapped.  We pooled together EGAs across all cell types and identified 1 
million cis eQTLs-gene associations (N=1 034 370) of which 388,160 was unique 
(Supplementary Figure 2.). 
Westra et al. (2013) eQTLs preprocessing 
We downloaded trans- and cis- eQTLs reported in Westra et al., (2013) on 9.3.2017.  from 
www.genenetwork.nl/bloodeqtlbrowser/ (2012-12-21-
CisAssociationsProbeLevelFDR0.5,  2012-12-21-TransAssociationsProbeLevelFDR0.5). We 
liftovered hg18 to hg19 eQTL coordinates using rtracklayer R package and we set gene 
coordinates to be equal to extended TSS coordinates (+/-1000 bp) of the GENCODE v24 
genes based on the overlap in ENSEMBL ID’s between GENCODE and reported genes.  In 
Westra et al., (2013), 1,962,237 cis and 4,542 trans eQTLs from peripheral blood samples 




“CRISPR/Cas9 positives” (Fulco et al., 2019; Gasperini et al., 2019) preprocessing 
We downloaded table of the 664 enhancer-gene pairs on the 15 January 2019 
(https://www.cell.com/cms/10.1016/j.cell.2018.11.029/attachment/d650f1e9-c627-
4073-a6db-6fe44d4e2149/mmc2.xlsx). We used an in-house script to pair enhancers and 
genes that reported in separate tabs of the same object. Since gene coordinates were not 
reported, based on reported ENSEMBL ID, we identified and set genes coordinates to be 
equal to extended TSS coordinates (+/- 1000bp) reported for genes in the GENCODE 
dataset. This resulted in 449 “high-confidence” enhancer-gene interactions. 
GENCODE preprocessing 
GTF files were downloaded from http://www.gencodegenes.org/releases/24lift37.html 
(01.06.2016.), and liftovered from GRCh38 to GRCh37 using in-house script. GTF files for 
basic annotation and non-coding RNAs were merged together. Genes located on the Y 
chromosome were removed from further analysis due to the lack of chrY coverage in 
some of the reported Roadmap epigenomes. Exon locations (GTF entries with type 
"exon") with confidence levels 1 and 2, and exon length longer than 10bp were used in 
the further analysis. In addition, exon regions were reduced (for each gene we individually 
reduced its exons), such that, per individual gene, each location in the genome could be 
covered with only one exon. For each gene, we assessed the corresponding transcriptional 
start site, and extended it +/-1000bp (promoters function from GenomicRanges R 
package).  
TF download and preprocessing 
We downloaded human TF binding sites in narrowPeak format and corresponding 
metadata from the UCSC Uniform track 
http://hgdownload.cse.ucsc.edu/goldenPath/hg19/encodeDCC/wgEncodeAwgTfbsUnifo





GWAS Catalog preprocessing 
We accessed and downloaded GWAS Catalog on the 5th of February 2019, using 
makeCurrentGwascat()  function from the gwascat R package. We liftovered SNP 
coordinates from the hg38 to hg19 using liftOver() function from rtracklayer. Since we 
were particularly interested in the non-coding polymorphisms we screened the 
“CONTEXT” reported in the GWAS Catalog and extracted only SNPs in one of the following 
categories: intergenic variant, intron variant, 3 prime UTR variant, 5 prime UTR variant, 
regulatory region variant, upstream gene variant, TF binding site variant, TF binding site 
variant x intron variant. In addition, we removed all entries that overlapped exons of 
protein coding genes (exon regions from GENCODE, used in the previous analyses). 
DISGENET download and preprocessing  
We downloaded all variant-disease associations from the DIGENET database on 
25.7.2019. from http://www.disgenet.org, and filtered out associations reported in the 
GWAS Catalog or GWASDB. This resulted in 310,502 DISGENET entries. To cross-reference 
phenotype terms from DISGENET and GWAS Catalog we downloaded the Experimental 
Factor Ontology (EFO) file in the OBO format (https://www.ebi.ac.uk/efo/efo.obo; 
25.7.2019.). 
 
2.2. Characterization of published enhancers and enhancer-gene 
associations 
2.2.1. Extracting and characterizing enhancer regions  
Locations of enhancer regions were individually extracted from the processed sets of enhancer-
gene associations for each analyzed method: EnhancerAtlas (Gao et al. 2016), JEME (Cao et al. 
2017), GeneHancer (Fishilevich et al. 2017), and FOCS (Hait et al. 2018). Unique enhancer regions 
were used for downstream comparisons. In the case of FOCS enhancers, we separately extracted 
four different enhancer definitions: GRO-Seq, ENCODE, Roadmap, FANTOM5. Nevertheless, when 
compared to other sets of enhancers, we used only enhancer regions that were reported in the 
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final FOCS models. For each enhancer definition, we quantified their number, size distribution, 
genome coverage, etc.  
 
2.2.2. Identifying an overlap between enhancers and other functional elements 
We assessed overlaps between enhancer regions and exons, introns, intergenic regions and 
promoters in the human genome.  
First, for each gene, we identified exon locations in the GENCODE database (Harrow et al., 2012) 
and infer other genomic features. We defined promoters as regions 2000bp upstream and 200bp 
downstream from the TSS of a gene. All gaps between exons but within genes were assessed as 
introns, whereas intergenic regions were assessed as gaps between genes. We quantified the 
number of overlaps between enhancers and all four categories of genomic features.     
2.2.3. Juxtaposing sets of enhancers  
To assess an overlap between four different sets of enhancers we first calculated the Jaccard index 
(as the pair-wise measure of similarity between sets) in an inhouse script that, for each 
combination of enhancers, identified an overlap between enhancers (binary output), and divided 
the size of their intersection by the size of their union. An overlap between enhancers was 
assessed using the GenomicRanges package in R.  
In addition, we created a union of all enhancer definitions together and identified all base pairs in 
the genome that are “covered” by at least one enhancer definition. Next, we quantified the 
enhancer coverage for those positions. In other words, we identified groups of overlapping 
enhancer elements and reduced them to one enhancer region whose start and end positions were 
based on the lowest start and highest end positions within its group of overlapping enhancer 
elements. For each unified enhancer, we identified publications which reported enhancer(s) that 
overlap(s) with a unified enhancer definition. Each unified enhancer definition can have an 
overlapping enhancer in one (publication-specific enhancers) or up to four publications.  
2.2.4. Analyzing enhancer activity signals for sets of enhancers  
To analyze differences in enhancer activity for different enhancer definitions we quantified their 
activity based on the signal from the genome-wide H3K27ac, H3K4me1 ChIP-Seq and DNase-Seq 
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and WGBS coverage tracks from the Roadmap dataset (Bernstein et al., 2010). Individually for 
each dataset, we extracted enhancer regions on the chromosome 1 and calculated the mean 
coverage value of the input signal in each Roadmap cell types (for example a ChIP-Seq signal for 
certain histone modification) using regActivity() function from the reg2gene R package. For each 
cell type and chromatin mark, we reported a single number - an averaged quantified enhancer 
signal for chromosome 1.   
2.2.5. Comparing predicted enhancers and ChromHMM-predicted chromatin states 
For each enhancer definition, we used enhancers on the chromosome 1 as windows and screened 
the ChromHMM-predicted (Ernst and Kellis, 2012) 15-state chromatin models across 127 
Roadmap epigenomes (Ernst and Kellis, 2012). For each identified chromatin state, we quantified 
the percentage of per-base coverage with enhancers. We did that individually for each cell type 
and then averaged the signal across cell types. Later, the same analysis was repeated for the “in-
house” and “consensus” enhancers. 
2.2.6. Identifying an overlap between sets of enhancer-gene associations 
To identify intersections between two sets of enhancer - gene associations reported in different 
publications, we used benchmarkInteractions() function from the reg2gene package. This function 
compares two datasets at the time, and identifies if locations of both elements of the pair, 
enhancers and genes, from those two analyzed datasets overlap together. If they do, they were 
considered to be overlapping counterparts. We requested that the result of this analysis is binary. 
Importantly, two enhancer regions (from the two tested enhancer-gene prediction methods) had 
to have an overlap in at least one 1bp, whereas the overlap of the two associated genes was 
measured on the level of TSS and TSSes were requested to be equal. To adjust for the fact that 
gene locations were not uniform across different publications (for example, JEME gene locations 
were reported as TSSes, whereas we identified the GeneHancer gene locations using reported 
names and the biomaRt functions; Durinck et al., 2009),  we equalized gene locations based on 
their ENSEMBL IDs. Specifically, we used gene names reported in each publication (ENSEMBL IDs), 
matched them with the GENCODE genes, and used the matched GENCODE TSS locations as 
enhancer-associated gene locations. We resized TSSes +/- 1000 bp.  
For each set of enhancer-gene associations, we identified an overlap with all other datasets, and  
summed up the number of identified overlaps across all five publications. Since we requested that 
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overlap information is binary (whether or not there is at least one overlapping E-G association), 
for a single enhancer - gene association we could report from 1 to 4 counts. For example if one  
enhancer - gene association from FOCS, has at least one counterpart in JEME and EnhancerAtlas, 
it will receive a count of three (or EGA overlapped with FOCS, EnhancerAtlas and JEME). Later, the 
same procedure was repeated for  the “in-house” and “consensus” EGAs. 
 
2.3. reg2gene 
2.3.1. reg2gene algorithm 
reg2gene method is mostly explained in Chapter 4.  
2.3.2. reg2gene R package 
reg2gene is available as an R package at the Github: https://github.com/BIMSBbioinfo/reg2gene 
2.3.3. Defining “in-house” enhancers 
We defined 184,005 “in-house” enhancers based on the cross-cell-type information from the core 
15-state ChromHMM model v1.10 (Ernst and Kellis, 2012). Briefly, ChromHMM aggregated multi-
dimensional matrices of chromatin marks into a small number of chromatin states and 
systematically characterized those states across 127 Roadmap cell types. Specifically, we 
calculated per base coverage of ChromHMM EnhG_6 and Enh_7 chromatin states across 127 
Roadmap epigenomes (Kundaje et al., 2015). Stretches of the genome predicted as EnhG_6 and 
Enh_7 in at least 20% of the Roadmap epigenomes, e.g. minimum per base coverage of 24, were 
identified as enhancers.  
2.3.4. Unifying enhancer definitions into “consensus” enhancers 
First, a “consensus” enhancer definition was obtained by calculating an overlap between our own 
ChromHMM-based “in-house” definition and previously proposed enhancer definitions from 
EnhancerAtlas (Gao et al. 2016), JEME (Cao et al. 2017), GeneHancer (Fishilevich et al. 2017), and 
FOCS (Hait et al. 2018). Importantly, we did not use one enhancer definition from FOCS whereas 
we separately included: four groups of FOCS enhancers: DHS Roadmap, DHS ENCODE, GRO-seq, 
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and CAGE FOCS enhancers. In addition, we subsetted enhancers from EnhancerAtlas and included 
only those that were smaller than 5kb and JEME enhancers reported in the elastic net models. As 
explained in Chapter 2.1., within each publication, we merged/reduced together all overlapping 
enhancers, e.g. groups of enhancers that overlapped together were defined as one enhancer 
region which start and end positions were based on the lowest start and highest end positions of 
original enhancers).  
As a result, we calculated the per base genome coverage using eight individual enhancer 
definitions (“in-house”, JEME, GeneHancer, EnhancerAtlas and four FOCS enhancer definitions: 
DHS Roadmap, DHS ENCODE, GRO-seq, and CAGE FOCS). We defined “consensus” enhancers as 
stretches of the genome covered by at least three enhancer definitions.  
Second, we additionally processed “consensus” enhancers as follows: first, we overlapped 
enhancers with the binding sites of 161 transcription factors (TFBS) designated by ENCODE ChIP-
seq peaks (POLR2A and POLR3G were excluded). If enhancers overlapped TFBS, and boundaries 
of corresponding ChIP-seq peaks were longer than the enhancer region boundaries, we extended 
enhancer boundaries to match those of TFBS. We additionally extended enhancers for +/- 100bp, 
merged them, and then reduced them back to their original width.  
We removed enhancer regions smaller than 20bp, and processed large (> 2kb) enhancer regions 
in the three steps procedure in which we used borders between high and low TF occupancy in the 
genome to segment large enhancers into smaller functional subunits. TF occupancy borders were 
identified based on the processed ENCODE ChIP-seq peak tracks.  
We calculated genome-wide per base TF coverage for 161 transcription factors (ENCODE ChIP-seq 
narrow peaks excluding POLR2A and POLR3G). We used the calculated median of base-pair 
coverage as a cutoff to segment coverage track into two types of regions - regions with high and 
low TF occupancy (median of 23 was calculated exclusively using large enhancers). We partitioned 
large enhancers into smaller functional subunits (<2kb) using inferred borders between high and 
low TF occupancy and functional segments with above median ChIP-seq peak coverage were 




Small enhancer regions (<50bp), created during the segmentation step, were merged with the first 
upstream enhancer region (alternatively to the first downstream enhancer). Enhancers were 
extended +/-100bp, merged, and reduced to the previous size.  
Large enhancers that did not overlap with borders of high and low TF occupancy were tiled to 2kb 
segments. Smaller identified functional segments with above median ChIP-seq peak coverage 
were retained for further analysis.  
In the end, we re-checked distribution of the width of enhancers, and all short enhancers were 
removed. In addition, we removed all enhancers located 2 kb upstream and 1kb downstream of 
the genome-wide locations of TSSes when such enhancers did not overlap the first intron. We 
further characterized enhancers as described in Section 2.2.5.    
 
2.3.5. Testing gene expression quantification protocol 
To test a precision of the reg2gene signal quantification protocol, we compared the previously 
reported scores and reg2gene calculated values. Specifically, we focused on the gene expression 
scores calculated based on the RNA-Seq signals. We downloaded RPKMs calculated by the 
Roadmap consortium for all 127 cell types and compared them with levels of gene expression 
quantified using the bwToGeneExp function from the reg2gene R package. For each cell type 
individually, we quantified gene expression and calculated the Pearson correlation coefficient 
between identified gene expression levels and reported RPKMs. We reported correlation statistics 
across all cell types. 
2.3.6. Analyzing an overlap with TADs 
 
We extracted coordinates of TADs regions for 37 hg19 cell types/tissues and originated from five 
publications (Lieberman-Aiden et al., 2009, Rao et al., 2014; Dixon et al., 2015; Leung et al., 2015; 
Schmitt et al., 2016) and as a part of ENCODE Consortium (ENCODE Project Consortium, 2012). 
We identified whether a given enhancer-gene association (EGA) is located within any of the 
defined TAD regions. For each cell type, we calculated the percentage of EGAs that were found 




2.4. “Benchmarking” enhancer-gene associations  
2.4.1. Analyzing an overlap with eQTLs 
In detail explained in Chapter 5. 
2.4.2. Analyzing an overlap with chromatin interactions 
In detail explained in Chapter 5. 
 
2.5. Benchmarking with “positive” and defining “negative” EGAs 
2.5.1. Defining “negative” EGAs 
In detail explained in Chapter 5. 
2.5.2. Defining “positive” EGAs 
In detail explained in Chapter 5. 
 
 
2.6. Functional analysis of GWAS Catalog SNPs, CRC SNPs and rs10411210  
2.6.1. Annotating the GWAS Catalog 
We annotated each GWAS Catalog polymorphism to the target gene based on the hierarchical 
overlapping procedure. First, genomic regions of interest were annotated as promoters and 
associated with corresponding genes if they were located within +/-1000bp from the TSS. Such 
SNPs were filtered out. The remaining genomic regions were overlapped with enhancer regions, 
and genes associated with those enhancer regions were assigned to polymorphism.  
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2.6.2. Identifying the nearest gene for each SNP in the GWAS Catalog 
Using the GENCODE-reported TSS, we wrote an inhouse R script that calculates the distance 
between TSS and SNP, and assigns closest gene to the analyzed SNP.  
2.6.3. Identifying an overlap between enhancers and other functional elements 
We identified an overlap between SNPs and other functional elements in the human genome as 
described in Section 2.2.2. 
2.6.4. Visualizing results  
To visualize results of SNP-to-gene annotation analysis with different sets of enhancer-gene 
associations (EGAs), we developed a specific R function - plotInteractions(). 
2.6.5. Identifying SNPs in LD with the index SNP 
To identify all SNPs that are in linkage disequilibrium (LD) with the index SNP we used the 
proxysnps R package (https://rdrr.io/github/slowkow/proxysnps/) and get_proxies() function. 
First, using the SNP identifier we queried the Biomart database (grch37.ensembl.org) using the 
biomaRt R package (Smedley et al., 2009) and identified the genome location of a tested SNP. 
Then, we searched for all SNPs that are in LD with the index SNP in the CEU population and 
R.squared=0.6 using get_proxies() .                
2.6.6. Performing enrichment analysis 
For each identified set of CRC-associated genes we performed gene enrichment analysis for: 
molecular function, cellular component, biological process, human phenotype ontology, OMIM 
disease, and KEGG, Reactome, and PANTHER pathways using enrichR R package (Kuleshov et al., 
2016) and identified TOP10 enrichment results. 
2.6.7. Identifying transcription factor binding sites 
To identify transcription factor binding sites, we wrote an inhouse function that queries genome 
(enhancers) sequences and identifies motifs for transcription factors that are available in the 
JASPAR2014 database (Mathelier et al., 2014). Our function first identifies genomic sequences for 
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enhancer regions using getSeq() from BSgenome.Hsapiens.UCSC.hg19 R packages, and then 
searches for TF binding motifs using searchSeq() functions from TFBSTools R package (Tan and 
Lenhard, 2016), min.score="90%", strand="*"). 
2.6.8. Identifying TF motifs  
In addition, we wrote an inhouse function that searches through the ChIP-Seq UCSC datasets and 
identifies an overlap between TF binding peaks and genomic regions of interest (enhancers). A 
total of 690 narrow peak profiles was analyzed (it corresponded to 161 TFs). Data processing and 
download was explained in Section 2.1.  
2.6.9. Benchmarking with the DisGeNET sets of genes 
To identify colorectal cancer associated genes we queried the DisGeNET database for the 
EFO:0005842 term. In addition, we identified ancestral terms for colorectal cancer: intestinal 
cancer, carcinoma, cancer, neoplasm and queried the DisGeNET database for those terms. For 
that we used the ontoCAT R package (Adamusiak et al., 2011) and getTermSynonyms() and 
getTermById() functions.  
2.6.10. Literature search 














Results I: Review of the computational methods 




In this section, I review computational genome-wide methods that were developed to map cis-
regulatory interactions in the human genome. Based on conversations with Dr. Altuna Akalin and 
Dr. Vedran Franke, I defined the scope of this analysis.  
Abstract 
Multiple computational methods that model enhancer activity ~ gene expression have been 
developed to map cis-regulatory interactions in the human genome. However, different sets of EGA 
predictions were never systematically analyzed, nor were their differences characterized.  
Here, we analyzed four methods that computationally model EGAs:  JEME - joint effect of multiple 
enhancers (Cao et al. 2017), GeneHancer (Fishilevich et al. 2017), EnhancerAtlas 2.0 (Gao et al. 
2016), and FOCS - FDR-corrected OLS with Cross-validation and Shrinkage (Hait et al. 2018). We 
showed that individual sets of predictions differ tremendously; first in the location, number and 
properties of defined enhancer regions, and then, we demonstrated that methods generally predict 
discern sets of enhancer-gene associations. This analysis allowed us, for the first time, to 
systematically compare computational predictions of enhancer-gene associations and identify 
their differences. 
We postulated that the observed changes are likely a consequence of the fact that different 







Thousands of regulatory DNA sequences (especially enhancers) have been identified in the human 
genome, however, elucidating their function and target genes remains elusive (ENCODE Project 
Consortium 2004; ENCODE Project Consortium 2012). The field lacks an approach that is 
systematic, integrative and accessible for discovering and documenting cis-regulatory 
relationships across the genome. Different experimental and computational techniques, as well 
as data integration approaches were proposed to improve our understanding of enhancer-
mediated gene expression regulation (Hariprakash and Ferrari 2019).  
In this research, we specifically focused on studying enhancer-mediated gene expression 
regulation by means of computational modelling of enhancer activity ~ gene expression. Multiple 
computational methods that study enhancer-gene associations have been developed (He et al. 
2014; Corradin et al. 2014; Roy et al. 2015;  Gao et al. 2016; Whalen et al. 2016;  Cao et al. 2017; 
Fishilevich et al. 2017; O’Connor et al. 2017; Hait et al. 2018; Li et al. 2018; Libbrecht et al. 2018; 
Wang et al. 2019, Singh et al. 2019), but their results were never systematically reviewed. Up until 
today, two crucial questions remained unanswered: 
a) Do computationally predicted enhancer-gene associations (EGAs) predict the same 
enhancer regions in the genome, or not?  
b) If and how much computationally predicted enhancer-gene associations (EGAs) 
predictions are similar or different to each other.  
 
To answer those questions, we analyzed four computationally models of EGAs:  JEME(Cao et al. 







3.2.1. An overview of used datasets - reg2gene 
I reviewed several computational methods developed to predict enhancer-gene associations: 
JEME  (Cao et al. 2017), EnhancerAtlas (Gao et al. 2016), GeneHancer (Hait et al. 2018), FOCS 
(Fishilevich et al. 2017), and later, in the next Chapter, I used it to define locations of enhancers 
and improve enhancer-gene associations (Table 3.1.). 
 
Table 3.1. Characteristics and statistics behind datasets used in this chapter 
 
Data source Technology/Data type Processing 
algorithm 
Used as/for: N[EGAs or 
interaction] 
JEME (Cao et al. 
2017) 
Roadmap (H3K4me1, 
H3K27ac, DHS, H3K27me3) 
and FANTOM CAGE,  ChIA-
PET, Hi-C, eQTL 








(Fishilevich et al. 
2017) 
ENCODE (DHSs, H3K27ac), 
Ensembl, Roadmap, 
FANTOM5, VISTA, eQTLs , 
eRNA co-expression , TF co-
expression, capture Hi-C 
(CHi-C) and gene target 









(Gao et al. 2016) 
ChIP-Seq, DNase-Seq, CAGE, 
FAIRE-Seq, transcription 
factor binding and DHS, 
FAIRE, eRNA, P300 binding 











FOCS (Hait et al. 
2018) 
GRO-Seq, FANTOM5 CAGE, 















3.3.1. Identification of computational approaches to study enhancer-gene associations 
(EGAs) 
In order to identify previously published enhancer-gene associations and analyze their pros and 
cons, prior to developing the reg2gene algorithm, we set off to review all previous publications 
that computationally model enhancer-gene associations. We identified multiple such publications 
(Table 3.2.). 
Table 3.2. Summary of computational methods used to study enhancers and enhancer-gene associations (EGAs) 
 
Exclusion reason Method Author Paper 
NA FOCS Hait et al., 2018 
FOCS: a novel method for analyzing enhancer 
and gene activity patterns infers an extensive 
enhancer–promoter map 
NA JEME Cao et al. 2017 
Reconstruction of enhancer–target networks in 
935 samples of human primary cells, tissues and 
cell lines 
NA GeneHancer 
Fishilevich et al. 
2017 
GeneHancer: genome-wide integration of 
enhancers and target genes in GeneCards 
NA EnhancerAtlas Gao et al., 2016 
EnhancerAtlas: a resource for enhancer 
annotation and analysis in 105 human 
cell/tissue types. 
Data integration only 
to   define enhancers  HACER Wang et al. 2019 
HACER: an atlas of human active enhancers to 
interpret regulatory variants 
12 cell lines IM-PET He et al. 2014 
Global view of enhancer–promoter interactome 
in human cells 
5 cell lines RIPPLE Roy et al. 2015 
A predictive modeling approach for cell line-
specific long-range regulatory interactions 
12 PreSTIGE cell lines PreSTIGE 
Corradin et al. 
2014 
Combinatorial effects of multiple enhancer 
variants in linkage disequilibrium dictate levels 
of gene expression to confer susceptibility to 
common traits 
6 ENCODE cell lines  TargetFinder 
Whalen et al. 
2016 
Enhancer–promoter interactions are encoded 




8 cell types DECRES Li et al. 2018 
Genome-wide prediction of cis-regulatory 




Ashoor et al. 
2015 




Libbrecht et al. 
2018 
A unified encyclopedia of human functional 
DNA elements through fully automated 
annotation of 164 human cell types 
8 cell lines CISMAPPER 
O'Connor et al. 
2016 
CISMAPPER: predicting regulatory interactions 
from transcription factor ChIP-seq data 
6 cell lines  SPEID Singh et al. 2016 
Predicting Enhancer-Promoter Interaction from 
Genomic Sequence with Deep Neural Networks 
 
We decided not to thoroughly review publications that had no computational component such as 
Segway (Libbrecht et al. 2018) and HANCER (Wang et al. 2019) and methods which models were 
built upon on a small number of cell lines: RIPPLE (Roy et al. 2015), TargetFinder (Whalen et al. 
2016), SPEID (Singh et al. 2019), CISMAPPER (O’Connor et al. 2017), DECRES  (Li et al. 2018), IM-
PET (He et al. 2014) or PRESTIGE Corradin et al. 2014). For example, RIPPLE modelled five cell lines, 
TargetFinder and SPEID six, CISMAPPER and DECRES eight,  and IM-PET or PRESTIGE modelled 12 
cell lines. 
In the end, we analyzed only four methods that computationally model EGAs:  JEME - joint effect 
of multiple enhancers (Cao et al. 2017), GeneHancer (Fishilevich et al. 2017), EnhancerAtlas 2.0 
(Gao et al. 2016), and FOCS - FDR-corrected OLS with Cross-validation and Shrinkage (Hait et al. 
2018). As expected, each of them individually differed in the selection of data sets that were used 
to define enhancers or model enhancer-gene interactions, as well as in their choice of algorithms 
(Table 3.3.). For example, in GeneHancer, Fishilevich et al. 2017 pooled previously reported 
enhancers from the Ensembl database  (Cunningham et al. 2015) together with FANTOM5 and 
VISTA (Visel et al. 2007) enhancers, whereas Hait et al. 2018 (FOCS) used DHS peak positions, raw 
sequence data of 245 GRO-Seq samples and CAGE tag peaks. In terms of algorithm selection, 
JEME, as compared to FOCS that represents the only full regression method, is a combination of 
regression and supervised learning methods, whereas GeneHancer reported “elite” enhancers 
and enhancer-gene associations based on calculated threshold score (SGE) that integrated various 
levels of information. In addition, the number of cell types and tissues that were used for 
modelling differed as well across methods. Gao et al. (2016) reported associations across 48 cell 
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lines and 22 tissues, JEME predictions are available for two datasets: 127 Roadmap cell types and 
tissues and 808 FANTOM5 samples. FOCS modelled promoters and its ten closest enhancers using 
DHS signals from 106 ENCODE cell types, 73 Roadmap DHS cell types and tissues, 600 FANTOM5 
human cell lines and primary cells, and GRO-Seq expression data from 23 different human cell 
lines.  
 
Table 3.3. Details about four computational methods analyzed in this thesis that model enhancer-gene interactions  
Method Datasets used to 
define enhancers 




N of cell 
types 
FOCS (Hait et 
al. 2018) 






FANTOM5) and DHSs 
level (Roadmap, 



















JEME  (Cao et 
al. 2017) 
Two sets: a) Roadmap 
ChromHMM 
predictions pooled 
across cell-types, b) 























Enhancers reported in: 
a) Ensembl (based in 
DHSs and H3K27ac 
from Roadmap and 
ENCODE), b) 





and gene target 
distance (nearest 
neighbor) combined 















(Gao et al. 
2016) 
Enhancer defined 
based on 8 tracks: 
DHS, eRNA, P300 and 
POL2 binding sites, 
nucleosome- 
depletion, H3K4me1 
and H3K27ac, TFBS 
and CHIA-PET signals 
H3K4me1, H3K27ac,  
H3K4me3, RNA-Seq, 
gene-target distance  
IM-PET VISTA database 
(Visel et al., 2007) 





3.3.2. Enhancer definitions from different sets of EGAs vary tremendously in their 
properties 
After we downloaded and processed enhancer-gene associations reported in JEME (Cao et al. 
2017), GeneHancer (Fishilevich et al. 2017), EnhancerAtlas 2.0 (Gao et al. 2016), and FOCS (Hait et 
al. 2018) and extracted their enhancers, we spotted the large differences in the number of 
reported enhancers:  1,008,243 EnhancerAtlas enhancers (out of 2 534 123 originally reported in 
the publication), 189,301 GeneHancer enhancers (284,834 reported), and 291,992 JEME 
enhancers (we pooled FANTOM5 CAGE and Roadmap enhancer regions) and 103,979 “pooled” 
FOCS enhancers was identified (Supplementary Table 1.). We additionally identified four groups 
of FOCS enhancers consisting of 65,423 FANTOM5, 255,925 GRO-Seq, 408,802 ENCODE and 
470,546 Roadmap enhancers. However, since we additionally processed original enhancer 
definitions (to simplify comparisons between enhancer definitions; Methods) we consequently 
reduced the number of original enhancers reported in each publication; for example, 1M 
EnhancerAtlas enhancers was reduced to less than 200,000 enhancers. Except in their number, 
reported enhancers differed in the percentage of the genome they cover and their length (Figure 
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Figure 3.1. General characteristics of enhancers reported in four publications: JEME (Cao et al., 2017), GeneHancer 
(Fishilevich et al., 2017), EnhancerAtlas (Gao et al., 2016), and FOCS (Hait et al., 2018). A. Percentage of the genome 
covered by each enhancer definition in respect with the number of enhancer regions (all overlapping enhancers were 
reduced to one enhancer region). The size of each point corresponds to the number of enhancers reported in the 
corresponding publication. B. Distribution of enhancer sizes (plotted on the log10 scale). C. Percentage of the per-
base overlap between promoter, intron, exon, and intergenic regions and published enhancer regions. D. Percentage 
of the genome covered by enhancers (30% of the genome is covered by at least one enhancer definition); category 1 
spans a number of bp that are covered by only one enhancer definition (publication-specific enhancers), whereas 
category 4 spans genome locations that are covered by all four enhancer definitions from different publications. E.  
Heatmap of calculated Jaccard index; a measure of similarity between enhancer definitions calculated as the 
intersection over the union. F. Distributions of the averaged enhancer activity quantified separately for each 
enhancer definition across all four chromatin marks (DNase, H3K27ac, H3K4me1 and DNA methylation). In short, 
within each cell type, the mean value of enhancer activity across all enhancers on the chromosome 1 was calculated, 
and then averaged across cell types. G. Averaged percentage of ChromHMM chromatin states covered by different 
enhancer definitions. Across each cell type, a per-base enhancer overlap was calculated for each individual chromatin 
state; and then it was averaged across cell types; and divided by the total length of the genome covered by an 
analyzed mark. H. Histogram of the number of enhancers that show full per-base overlap with regions predicted by 
ChromHMM as heterochromatin, repressed Polycomb, weak repressed Polycomb and quies. 
Enhancer length ranged from 1 bp (GeneHancer) up to 3.2 million bp  reported in EnhancerAtlas, 
with an average between 408.5 bp (FOCS) and 2852.4 (EnhancerAtlas; Supplementary Table 1.). 
For each publication, enhancers mostly overlap with introns and intergenic regions, and show 
small overlap with exons and promoters (Figure 3.1.C). We identified that one third of the genome 
is covered by at least one enhancer definition and more than two-thirds of the enhancer regions 
in the genome is covered by a publication specific enhancers, e.g. enhancers reported in only one 
publication (Figure 3.1.D). We calculated the Jaccard index (intersection between datasets divided 
by the size of the union) to measure the similarity between enhancer definitions. The highest 
similarity between two definitions of enhancers was observed for GeneHancer vs EnhancerAtlas 




For each published enhancer definition, we examined differences in the level of quantified 
enhancer activities. We show that enhancer activity varies across chromatin marks, cell types and 
enhancer definitions. Nevertheless, the rank of publication of averaged enhancer activity was 
preserved across chromatin marks (Figure 3.1.F): JEME enhancers show the lowest averaged 
enhancer activity signal, whereas FOCS enhancers show the highest averaged signal for three 
chromatin marks (H3K4me1, H3K27ac, DHS) and the lowest for DNAme.  
We calculated per-base overlap between enhancers and ChromHMM-predicted chromatin states 
for 127 Roadmap epigenome (15-state ChromHMM model, Figure 3.1.G) to test whether 
ChromHMM predicted enhancer-like chromatin states (6_EnhG, 7_Enh, 12_EnhBiv) have a higher 
percentage of enhancer coverage than other states. In short, ChromHMM software learns and 
characterizes chromatin states by integrating multiple chromatin datasets and the resulting model 
can then be used to systematically annotate a genome in one or more cell types (Ernst and Kellis, 
2012). Only for EnhancerAtlas enhancers we observed that the overlap between enhancer-like 
ChromHMM states and enhancer definitions was higher than for other chromatin states (63% 
overlap of 6_EnhG and 70% overlap of 7_Enh with EnhancerAtlas enhancers). However, all other 
ChromHMM chromatin states showed as well a high percentage of coverage by EnhancerAtlas 
enhancers; for example, 49% of predicted Polycomb repressed regions - 13_ReprPC and 
14_ReprPCWK - were covered by EnhancerAtlas enhancers. In the case of GeneHancer, 91% of the 
actively transcribed regions predicted by ChromHMM (1_TssA) were covered by enhancer regions, 
whereas 57% and 53% of the ChromHmm predicted enhancer regions (6_EnhG and 7_Enh) were 
covered by the same definition of enhancers. Although all enhancer definitions should represent 
active enhancers in the genome, we tested whether some publication-defined enhancer regions 
show full per-base overlap with ChromHMM-predicted heterochromatin, repressed Polycomb, 
weak repressed Polycomb and quies regions. We identified 272, 274, 1,121, and 13,672 such 
enhancers for JEME, FOCS, GeneHancer and EnhancerAtlas.  
3.3.3. Comparing enhancer-gene associations (EGAs) across computational datasets 
We additionally compared enhancer-gene associations across different methods. We identified 
117 355, 506 471, 929 682, and 2 327 946 enhancer - gene associations in FOCS, GeneHancer, 
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Figure 3.2. General characteristics of enhancer-gene associations (EGA) reported in four publications:  JEME (Cao et 
al., 2017), GeneHancer (Fishilevich et al., 2017), EnhancerAtlas (Gao et al., 2016), and FOCS (Hait et al., 2018). A. 
Number of enhancer-gene associations, enhancer and genes reported in each study. B. Per publication distribution 
of the number of genes associated with each enhancer region. C. Per publication distribution of the number of 
enhancers reported for each gene.  
FOCS had, on average, less associated genes per enhancer and enhancers per gene (median 
ranged between 6 for FOCS up to 24 for EnhancerAtlas (Figure 3.2.B). A maximum of 608 
enhancers for one gene was reported in the EnhancerAtlas (Supplementary Table 1.). One 
enhancer region was associated with a maximum of 52 genes in GeneHancer and EnhancerAtlas 
reported EGAs.   
To investigate the publication-specificity of reported enhancer-gene associations, we overlapped 
enhancer - gene associations reported in different publications as described in Methods. The 
highest number of overlaps between two sets of EGAs was identified for GeneHancer-FOCS EGAs; 
59% of GeneHancer EGAs was confirmed by FOCS EGAs (59%, Figure 3.3.), whereas 8% of FOCS 
EGAs is confirmed by GeneHancer EGAs. In addition, only 3% of FOCS EGAs were confirmed by 




Figure 3.3. The heatmap of the percentage of overlaps between sets of enhancer-gene associations (EGAs). 
Percentage was calculated for each set individually, and it corresponds to the number of identified overlaps divided 
by the total number of EGAs in analyzed publication. Columns correspond to the queried datasets: for example, 59% 







We identified multiple computational methods that study enhancer-gene associations (He et al. 
2014; Corradin et al. 2014; Roy et al. 2015;  Gao et al. 2016; Whalen et al. 2016;  Cao et al. 2017; 
Fishilevich et al. 2017; O’Connor et al. 2017; Hait et al. 2018; Li et al. 2018; Libbrecht et al. 2018; 
Wang et al. 2019, Singh et al. 2019). However, we thoroughly reviewed four methods:  JEME - joint 
effect of multiple enhancers (Cao et al. 2017), GeneHancer (Fishilevich et al. 2017), EnhancerAtlas 
2.0 (Gao et al. 2016), and FOCS - FDR-corrected OLS with Cross-validation and Shrinkage (Hait et 
al. 2018), because we were primarily interested in analyzing publications that had a computational 
component, which models were built upon a large number of cell lines and that predicted several 
thousands interactions. This is the first time that results and protocols of different computational 
methods were systematically compared and we corroborated previous observations that the 
initial choice of epigenomic marks used to map enhancers has a large impact on the final number 
and characteristics of defined enhancers (Zentner and Scacheri 2012), and consequently, on the 
number and properties of defined EGAs (Hariprakash and Ferrari 2019).  
In terms of enhancers, publications differed more than a ten-fold in their number: from hundred 
thousand enhancers reported in FOCS to up to one million unique enhancers in EnhancerAtlas 2.0. 
Importantly, some publications (JEME and EnhancerAtlas) predicted enhancers and EGAs 
individually, for each analyzed cell type/tissue, whereas others (GeneHancer and FOCS) reported 
no cell-type specific predictions, and thus, to enable comparison of enhancer regions, we pooled 
enhancers predicted in JEME and EnhancerAtlas across all cell types and processed them 
additionally. This caused the reduction in the total number of enhancers: 1M EnhancerAtlas 
enhancers was reduced to less than 200,000 enhancers. Nevertheless, the difference in the 
number of enhancers reported across methods remained. 
A discrepancy in the number of predicted enhancers in the human genome has been previously 
reported in the literature: an initial estimation of 1 million enhancer regions (Heintzman et al. 
2009, ENCODE Project Consortium 2012), was exceeded when by Thurman et al. (2012) predicted 
2.9 predicted million DHSs many of which are likely enhancer regions, or downsampled to 43,011 
enhancer candidates based on FANTOM5 CAGE datasets (Andersson et al. 2014). However, even 
today, we still do not know the true number of enhancers and we lack a genome-wide exhaustive 
reference list of all non-coding regions that can act as enhancers (Hariprakash and Ferrari 2019). 
Especially, since none of the currently discovered chromatin marks was found to be perfectly 
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predictive of an enhancer activity (Shlyueva et al. 2014) and the number of newly discovered 
marks associated with an enhancer activity is still growing  (Stricker et al. 2017; Mathelier et al. 
2015). This is further complicated by their dynamic and cell type-specific nature of enhancers 
(Joshi 2014, Chen et al. 2018) and the fact that enhancer relative location, with respect to its target 
genes, can be greatly variable (Lettice et al. 2003).  
Thus, different publications used different protocols to define enhancers. In general, FOCS and 
JEME enhancer regions were defined as an aggregate of enhancer definitions across different data 
types and/or sources, whereas GeneHancer and EnhancerAtlas represent a weighted consensus 
of different enhancer definitions. Specifically, FOCS used peaks from various GRO-Seq, FANTOM5 
CAGE, Roadmap DHSs, ENCODE DHSs tracks to define enhancers, whereas EnhancerAtlas 
integrated eight different data types such as information about P300 and POL2 binding sites, CHIA-
PET signals, levels of histone modifications, etc. On the other hand, Fishilevich et al. simply pooled 
previously reported enhancers from the four data sources: ENCODE (ENCODE Project Consortium 
2012), the Ensembl regulatory build (Cunningham et al. 2015), FANTOM5 (Andersson et al. 2014) 
and the VISTA Enhancer Browser (Visel et al. 2007) to define GeneHancer enhancers. In JEME, Cao 
et al. (2017) used ChromHMM-based 15-state (Ernst and Kellis 2012) systematic annotations of 
127 Roadmap cell types and pooled and processed the identified regions to define a final set of 
enhancers. 
Upon identifying differences in their number, we set off to investigate other properties of defined 
enhancers. We showed that reported enhancers differed in the percentage of the genome they 
cover, their length, and coverage of other functional elements in the genome such as promoters, 
intronic and exonic regions. For example, JEME enhancers had lowest overlap with promoter 
regions, whereas FOCS had the highest overlap with introns. Although regulatory elements may 
have both enhancer and promoter functions (Andersson et al. 2015; Andersson and Sandelin 
2020), the percentage of promotes that have a strong enhancer activity in the genome was shown 
to not be large (3% out of 20,719 tested gene promoters in human K562 cells had strong enhancer 
activity in vitro, Dao et al. 2017),  and we expected to observe that the highest number of enhancer 
regions overlap the non-coding introns of genes or intergenic regions. Especially since intronic 
enhancers were commonly found to be engaged in the long-range gene interactions with distant 
genes (Pomerantz et al. 2009; Harismendy et al. 2011; Maurano et al. 2012; Smemo et al. 2014). 
Indeed, this was the case for all methods. 
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On the other hand, sets of enhancers did not necessarily show the highest overlap with 
ChromHMM predicted enhancer-like chromatin states (6_EnhG, 7_Enh, 12_EnhBiv, Ernst and 
Kellis 2012) across 127 Roadmap cell types and tissues (Roadmap Epigenomics Consortium et al. 
2015). In short, ChromHMM software was used to learn chromatin states by integrating multiple 
chromatin datasets and systematically annotate 127 Roadmap genomes into 15 chromatin states 
such as: enhancers, active transcribed regions, Polycomb repressed regions, etc., and we expected 
to observe that computational predicted enhancers show the highest coverage with three 
ChromHMM-predicted enhancer-like chromatin states. However, we observed this hold true only 
for EnhancerAtlas enhancers, which however, showed high overlap with other, non-enhancer 
ChromHMM-predicted chromatin states. Unfortunately, this is likely a consequence of the fact 
that EnhancerAtlas reported enhancer regions that are, on average, longer than enhancer regions 
defined in other publications and not mutually exclusive. Strikingly, some of defined enhancers 
are even located in “inactive” chromatin states (as predicted by ChromHMM as heterochromatin, 
repressed Polycomb, weak repressed Polycomb and quies regions), across all 127 Roadmap cell 
types (Roadmap Epigenomics Consortium et al. 2015). Strikingly, because we would assume that 
such regions should not be predicted to be enhancer regions, especially since most of the methods 
used Roadmap datasets as an input for their algorithms.  
Quantified enhancer activity varied across enhancer definition as well; this further indicated that 
enhancers cover distinct regions in the genome. To corroborate this observation, we performed 
an additional analysis that demonstrated that two-thirds of the enhancer regions in the genome 
were covered by a publication specific enhancers, e.g. enhancers reported in only one publication, 
whereas, the two methods that, on average, reported the largest enhancers (GeneHancer and 
EnhancerAtlas) exhibited the biggest overlap between enhancer definitions. It is important to 
emphasize that one third of the genome was actually reported to be an enhancer by at least one 
of the analyzed methods, as compared to the previous report by (Li et al. 2018) that labelled 6.8% 
of the genome as enhancers and 0.6% as promoters in one or more of six well-characterized cells.  
Since we were further interested in pursuing computational modelling of enhancer activity ~ gene 
expression, this analysis posed a grim question, which, if any, of enhancer definitions should we 
use in our future research or functional analyses of risk associated SNPs. This will be answered in 
the future chapters of this thesis. 
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We showed that the diversity of enhancer definitions had a large influence on the final predictions 
of enhancer-gene associations (EGAs). By identifying a large discrepancy in the number and 
properties of identified sets of EGAs, we corroborated the previous observations by Hariprakash 
and Ferrari 2019 that the first practical problem of computational methods that study cis 
regulatory interactions is actually an identification of enhancer regions themselves. However, to 
be able to compare results coming from different methods, we had to perform an extensive data 
integration. As compared to predictions of enhancer regions, the complexity of EGA predictions is 
even more puzzling; it is complicated by the fact that enhancers tend to “skip” over a proximal to 
gene to regulate a more distant one (Merli et al. 1996), regulate more than one gene (Simonet et 
al. 1991; Schwartz and Olson 1999; Bender et al. 2001), and activation of a specific gene may be 
activated in multiple cell types by distinct enhancers (Burch 2005; Abbasi et al. 2007; Landry et al. 
2009; Visel et al. 2009). Likewise, since the selection of computational algorithms and data sources 
to assess E-G associations differed across methods, which should, as well, have a great impact on 
the final enhancer-gene predictions. Especially since each method (either experimental or 
computational) suffers from specific or general technical and biological limitations of HTS 
technologies and can additionally hinder the creation of an exhaustive reference list of enhancers.  
3.5. Conclusions 
 
In general, enhancer-gene associations coming from different methods are hardly directly 
comparable. Due to the differences in the way multiple parameters and information are used to 
define enhancers and promoters itself, algorithmic details, but also, how true positive ETG pairs 
are defined, final sets of assessed enhancer-gene associations differ. With this in mind, we set off 
to develop and benchmark a computational method that maps cis-regulatory interactions in the 









Results II: reg2gene - a novel computational method 





In this section, I set off to develop a novel computational method that associates regulatory regions 
with genes they regulate in a genome-wide manner - the reg2gene algorithm. Method was 
designed together with Dr. Altuna Akalin and Dr. Vedran Franke. 
Abstract 
We develop a novel computational method that associates regulatory regions with genes they 
regulate in a genome-wide manner - the reg2gene algorithm. 
reg2gene was built upon extensive data modeling and integration, and as such, it consists of three 
main steps: 1) data quantification, 2) data modelling and significance assessment, and 3) data 
integration. reg2gene relies on the largest collection of epigenomics or transcriptomic data in 
humans at time - the Roadmap datasets and its five epigenomics subsets: H3K4me1, H3K27ac, 
DNAme, DHS and RNA-Seq; and implements three correlation-based methods: Pearson, Spearman 
and distance correlation and executes elastic net regression and random forest. Models were 
integrated by the majority voting approach and further improved by an ensemble voting with 
enhancer-gene associations (EGAs) reported in: EnhancerAtlas (Gao et al. 2016), JEME (Cao et al. 
2017), GeneHancer (Fishilevich et al. 2017), and FOCS (Hait et al. 2018). As a result, we report two 
sets of enhancer-gene associations: a flexible set of ~230K EGAs reported in at least 2 publications) 
and a stringent set of  ~60 EGAs reported in three or more publications. Predicted sets of EGAs 
generally colocalized within the same topologically associating domain. 
reg2gene functions were gathered in the reg2gene R package. This package can enable solving of 




Most regulation of gene expression is believed to occur at the level of transcription initiation 
regulated by cis-regulatory sequences in the genome, such as enhancers and promoters, that 
recruit a distinct set of trans factors (Levine and Tjian, 2003). Although certain aspects of gene 
regulation are understood, the precise methodology for its research is missing and the field lacks 
an approach that is systematic, integrative and accessible for discovering and documenting cis-
regulatory relationships across the genome. 
 
Different experimental and computational techniques have been in use to study enhancer-
mediated gene expression regulation in a genome-wide manner and they can be broadly 
categorized into four categories: computational modelling of gene expression~enhancer activity 
(Hariprakash and Ferrari, 2019), eQTL studies (GTEx Consortium et al., 2017), HiC technologies 
(Lieberman-Aiden et al., 2009), and direct functional confirmation of enhancer activity by reporter 
assays or cellular screens (Arnold et al., 2013; Kheradpour et al., 2013; Kvon, 2015; Fulco et al., 
2019; Gasperini et al., 2019).  
 
Since we previously showed that individual sets of predictions differ tremendously, especially in 
the location, number and properties of defined enhancer regions and enhancer-gene associations, 
we set off to develop a novel computational method that associates regulatory regions with their 
gene targets in a genome-wide manner, but that, at the same time, overcomes shortcomings of 







4.2.1. The intuition behind the voting procedure  
Majority voting is a simple binary decision rule that opts for an alternative that has a majority, 
that is, more than half the votes. By creating an ensemble classifier one can combine the 
classification rules of multiple classifiers and potentially narrow down the hypothesis space 
(Figure 4.1.). Such an ensemble, created by averaging or majority voting often appears to be more 
accurate than individual predictions (Yang et al., 2010). 
 
 
Figure 4.1. A schematic illustration of partitioning and narrowing a hypothesis space by using an ensemble classifier. 
(A) Hypothesis space of a single classifier, (B) Hypothesis space of an ensemble classifier.   
 
Nonetheless, in order to improve predictions, the base classifiers need to be accurate (better than 
chance) and diverse from each other (Tsymbal et al., 2005). This need for diversity originates from 
the assumption that if a classifier makes a misclassification there should be another classifier that 
complements the first classifier by correctly classifying the misclassified sample. Ideally, each 






4.2.2. An overview of used datasets  
I used several publicly available datasets and original publications to define locations of enhancers 
and genes, predict enhancer-gene associations, and improve and benchmark predictions of EGAs 
(Table 4.1.). To achieve that I performed data integration on various levels by combining 
information from:  
1) epigenomes profiles (histone modification patterns, DNA accessibility, and DNA 
methylation from the Roadmap dataset; (Bernstein et al., 2010; Roadmap Epigenomics 
Consortium et al., 2015),  
2) computational algorithms that model gene expression ~ enhancer activity,   
3) computational methods developed to predict enhancer-gene associations: JEME, 
EnhancerAtlas, GeneHancers, FOCS (Cao et al., 2017; Fishilevich et al., 2017; Gao et al., 
2016; Hait et al., 2018). 
Since I already reviewed enhancer-gene associations reported in JEME, EnhancerAtlas, 
GeneHancers, FOCS, here, I will only review datasets that I used to define enhancers and genes 
and model their activity. Nonetheless,those datasets are thoroughly described in Chapter 2 - 
Methods. 
Table 4.1. Characteristics and statistics behind used datasets in this chapter 
 
Data source Technology/Data type Processing 
algorithm 
Used as/for:  N of 
EGAs/intera
ctions 
NIH Roadmap ChIP-Seq for H3K27ac, 
H3K4me1, BS Seq for DNA 
methylation and DHS Seq  




















(Harrow et al., 
2012) 








4.3.1. The reg2gene algorithm 
reg2gene consists of the three main steps that are executed in the following order:  
1) data quantification,  
2) data modelling and assessment, and  
3) filtering and voting (Figure 4.2.). 
 
 Step 1. Data quantification: 
    Quantifying enhancer activity with regActivity function from the reg2gene R package 
For each enhancer region, reg2gene individually quantifies its activity using .bigwig files 
as an input. For example, bigwig files for ChIP-Seq, DNase-Seq or WGBS signals. It 
calculates the mean coverage value of the input signal (for example H3K4me1 ChIP-Seq 
signal) over each enhancer location and quantile normalizes quantified signals. This 
procedure is implemented as a regActivity() function and for example, we ran it four 
times to quantify enhancer activity based on four chromatin marks. 
Quantifying gene expression with bwToGeneExp function from the reg2gene R 
package 
For each gene, gene expression levels are quantified based on the signal from the 
genome-wide RNA-Seq coverage tracks. First, for each exon region, the mean coverage 
value of the input signal is calculated and quantile normalized as the log(gene 
expression scores + 1). Then, a sum of the mean exon expressions (mean exon 




Figure 4.2. A workflow of reg2gene modelling procedure. A three-step design is described in detail in this Chapter. 
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Step 2. Modelling and assessment 
 
Modelling 
For each gene, enhancers that are located within +/-1Mb from the transcription start 
site (TSS) are identified (using the regActivityAroundTSS function) and gene 
expression~enhancer activity models are built using five algorithms: Pearson and 
Spearman correlation coefficient, distance correlation, elastic net and random forests. 
Before modelling, enhancer activity and gene expression scores were scaled and 
centralized. Elastic net modelling is used together with five-fold cross-validation 
(cv.glmnet() and lambda that gives minimum mean cross-validated error (lambda.min) 
was selected. Random forest was run with 500 trees with the Gini index as a measure 
of variable importance. For each model, associateReg2Gene function reports 
association statistics - it estimates p-values for reported coefficients by randomly 
resampling response variables (gene expression) 1000 times, and from the resampling 
statistics it assesses P-value based on the Gamma distribution. In addition, the algorithm 
implements data scaling and centalizes data.  
Assessment of statistical significance 
For each combination of algorithms and chromatin marks, reg2gene individually 
performs an assessment of the model significance across the full set of modelled 
enhancer-gene pairs: it simultaneously threshold models by its q-value and modelling 
statistics using predefined threshold level.  
The rationale behind calculating the model-specific threshold (Figure 4.3.) is that, 
contrary to the q-value which can be uniformly used as a threshold across all 
combinations of algorithms and chromatin marks, such a single value threshold could 
not be applied for modelling statistics which was individually calculated by five different 
algorithms. For example, Pearson and Spearman correlation coefficient has a value 
between +1 and −1, where 1 is total positive linear correlation, 0 is no linear correlation, 
and −1 is total negative linear correlation. Distance correlation coefficient is 0 if and only 




On the other hand, elastic net and random forest work on the rationale that multiple 
enhancers can regulate a single gene, and thus, they identify significant relationships 
between multiple enhancers and target genes simultaneously as they assess the 
strength of impact of those enhancers on their target. Random forest variable 
importance is measured by the variance of responses and is only limited by the 
minimum lower value of zero. For example, the maximum value across all reg2gene 
random forest models for the variable importance was 74. Elastic net coefficients 
calculated for each enhancer-gene pair have no predefined upper and lower limit since 
they were calculated using five-fold cross-validation procedure and assessed for lambda 
that minimizes mean cross-validated error. Thus, since each of the five algorithms 
calculated enhancer-gene association differently, we decided to establish a procedure 
that will uniformly identify model-specific thresholds.  
Statistical significance assessment protocol 
Due to its limited upper and lower value, Pearson and Spearman correlation coefficient 
is the most intuitive measure of statistics: +/-0.3 is usually considered to imply a weak 
positive/negative correlation; +/-0.5 moderate positive/negative correlation; whereas 
+/-0.7 implies strong positive/negative correlation. Thus, we decided to develop a 
uniform thresholding procedure based on results of Pearson and Spearman correlation 
models.  
First, all models that report Pearson and Spearman correlation coefficient are analyzed.  
We sorted model statistics within each model type and identified a value that 
corresponds to the third quartile of model statistics (Figure 4.2.). We assess this split 
based on the observation that roughly one-quarter three-quarter split in each of 
analyzed Pearson or Spearman-based model series had an absolute correlation 
coefficient above 0.3.  
The inferred value of the third quartile was used to assess model significance - statistics 
above the assessed value corresponds to the significant results, whereas all values 




Figure 4.3. Schematic representation of the model significance assessment. For each out of twenty models (for 
example, one model corresponds to Spearman correlation coefficients for 8.9M enhancer-gene pairs  that were 
assessed based on the enhancer activity quantified using H3K4me1 signals) assessment was performed individually 
as described in text. In short, model statistics that were found to be above the certain value - the measure of the 
third quartile - was considered significant, whereas all values below that threshold were considered not to be 
significant.  
 
Step 3. Filtering and hierarchical majority voting  
pre-voting filtering 
Since reg2gene modelling procedure will inevitably fail to model certain associations, 
simply because it relies on a scarce dataset(s), we developed a filtering protocol that 
filters out such genes and enhancer regions. Thus models with:  
a) zero standard deviation of gene expression or enhancer activity across 
different cell types,  
b) more than 90% of the cell types with the expression level or enhancer activity 
equal to zero;  
c) at least one across-cell-type overrepresented value (maximum of 10 cell 
types can share the same value); 
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d)  characterized by a small number of gene expression or enhancer activity 
clusters which is an indicator of a bad imputation protocol (a minimum 30 
unique values, across different cell types, was requested to be quantified for 
each gene). 
 
In addition, a stepwise procedure was implemented to test and remove missing data:  
1) cell types that had missing information for more than 75% of tested 
enhancers; 
2) enhancers/genes with missing activity level in more than 75% of cell types,  
3) the remaining missing values. 
 
Hierarchical majority voting 
reg2gene performs hierarchical majority voting to integrate information from different 
algorithms and epigenomic marks and assess the final modelling success. As mentioned 
in the introduction, majority voting is a simple binary decision rule that opts for an 
alternative that has a majority, or in other words, more than half the votes. Thus, for 
each analyzed enhancer-gene link reg2gene integrates twenty binary scores obtained 
by modelling and assessing the statistical significance via 2-step voting procedure 
(Figure 4.4.).  
Step 1: For each enhancer-gene pair, we counted the number of significant associations 
assessed within each algorithm or across chromatin marks. In our case, there were a 
total of four models (corresponding to four epigenomic marks used to quantify 
enhancer activity) ran  using one computational algorithm, and thus by statistical 
significance assessment each EG pair could achieve a score from zero to four for the 
voted algorithms. For example, voting was performed based on results of modelling 
using distance correlation models for H3K4me1, H3K27ac, DNA methylation and DHS 
datasets. If more than two votes were identified (e.g. this EG pair was assessed to be 
significant by more than one chromatin mark) such enhance-gene pair was considered 
to be voted (by an algorithm) using the majority voting approach. We repeated this 
voting analysis individually for each of the five algorithms.  
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Step 2: The majority voting approach is repeated, but across step 1 voting results (voting 
across algorithms). In this case, each enhancer-gene pair could achieve five votes for 
five algorithms. Enhancer-gene pairs that achieved more than three votes in the second 
step of the voting procedure were considered to be hierarchically majority voted. 
 
Figure 4.4. Schematic representation of the hierarchical voting procedure, We first voted models assessed with one 
algorithm and then voted them across assessed algorithmic votes. There were a total of four models (H3K4me1, 
H3K27ac, DNA methylation and DHS epigenomic datasets used to quantify enhancer activity) for each computational 
algorithm, and thus, by statistical significance assessment each EG pair could achieve a score from zero to four when 
vote within algorithms, and 0-5 when voted across step 2 voting results.   
 
Step 3 (optional):  voting with previous methods by defining a union of all associations 
across EGA methods.  
 
 
4.3.2. reg2gene R package 
 
reg2gene is available as an R package at the Github: https://github.com/BIMSBbioinfo/reg2gene 
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4.3.3. More than 280 thousands enhancer regions are predicted by three or more 
enhancer definitions 
Since we showed that the majority of previously reported enhancers are publication-specific, we 
decided to define “consensus” enhancer regions and use them for computational modelling. We 
“recycle” the idea that the majority voting approach can improve the accuracy of computational 
models (Yang et al., 2010) and treated sets of enhancers (H1 - EnhancerAtlas, H2 - GeneHancer, 
H3 - JEME , H4 - FOCS, H5 - in-house enhancers) as classifiers that define individual hypothesis 
spaces and which integration narrows down the hypothesis space and return more accurate 
predictions. We first defined in-house enhancers as explained in Methods (Figure 4.5.A), and then, 
we voted them together with other enhancer definitions (Figure 4.5.B). We identified a total of 
184,005 “in-house” enhancer regions and 286,723 “consensus” enhancers (consensusE).  
 
 
A.                                                                                                            B. 
Figure 4.5. Schematic representation of defining in-house (IHEs) and “consensus” enhancers - consensusE. A. We 
defined IHE as follows: we screened 127 Roadmap cell-types for ChromHMM-predicted chromatin states and 
identified regions in the genome that were predicted as EnhG_6 and Enh_7 in more than 25 cell types. We processed 
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identified enhancer regions as described in Methods. B. We screened across 8 enhancer definitions and identified 
regions that were reported as enhancers in at least three datasets. Enhancer overlap was identified on the level of a 
base pair.  
 
 
We showed that consensusE have constrained sizes, less likely to overlap gene promoters and 
more likely reside in introns and intergenic regions as compared to other publication-reported 
enhancers (Figure 4.6.). For example, less than 5% of in-house enhancers overlap promoters, as 
compared to 19.7% GeneHancer enhancers. Across all methods, the highest overlap of enhancers 





A.       B. 
 
Figure 4.6. General characteristics of the two sets of defined enhancers: in-house enhancers (IHE) and consensusE. A. 
Distribution of enhancer lengths (plotted on the log10 scale). B. Percentage of the per-base overlap between 
promoter, intron, exon, and intergenic regions and defined enhancer regions. C. Histogram of the percentage of 
ChromHMM chromatin states covered by different enhancer definitions averaged across cell types. For each cell type, 
a per-base enhancer overlap was calculated for each individual chromatin state; averaged across cell types; and 




4.3.4. reg2gene modelling and voting identified sets of “consensus” E-G associations 
After we identified “consensus” enhancer regions, we used those regions as an input for the 
reg2gene algorithm. First, their activity was quantified four times - based on the four imputed 
Roadmap datasets for different chromatin marks: H3K4me1, H3K27ac, DNA methylation and DHS. 
Next, gene expression was quantified for each of 34,359 GENCODE genes (Harrow et al., 2012). 
To test the precision of the reg2gene quantification protocol by comparing previously reported 
RPKM scores and reg2gene quantified values across 127 Roadmap cell types (in details described 
in Method section). We observed that the Pearson correlation coefficient between reported 
RPKMs and quantified values was consistently high across cell types (range: 0.82-0.98, 
median=0.95, mean=0.943). 
 
We paired enhancers and genes that were located within +/- 1Mb window together and identified 
nearly 8.9 million enhancer - gene pairs (Chapter 2). We used those pairs and their quantified 
signals as an input for the modelling step of the reg2gene algorithm - we modelled gene 
expression~enhancer activity using Pearson and Spearman correlation coefficient, distance 
correlation, elastic net and random forest. On average, we modelled 267 enhancers per individual 
gene (range: 1-574, Supplementary Table 1.), and 25 genes per enhancer (range: 1-150).  
 
For each enhancer-gene pair a total of 20 modelling statistics was produced (enhancer activity 
was quantified based on levels of four chromatin marks, and each of them was modelled using 
five algorithms) that were thresholded to assess the statistical significance (as explained 
previously). In a nutshell, each of the models (for example enhancer activity (H3K4me1)~gene 
expression modelled using elastic net) was thresholded by requesting: 1) q-value to be lower than 
0.1 and 2) the absolute value of model statistics to be higher than model-specific threshold 
inferred (as explained above). The identified binary score reported whether a given enhancer-
gene pair is statistically associated or not. By integrating multiple types of information across all 
twenty models via previously explained hierarchical majority voting procedure (in the step1 we 
performed voting across chromatin marks and then we voted across step1 results), for each 
enhancer-gene pair we identified one final binary score that reported whether or not that pair 
was statistically associated. We identified 1,007,448 such enhancer-gene associations and 
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referred to them as an “in-house” model (inhouseM). For this set of EGAs, a median of three genes 
per enhancer element was identified (mean=5.5, max=96), and 25 enhancers per gene (max=172, 
Supplementary Table 1.). 
 
To improve the robustness of our predictions, we further voted inhouseM together with  enhancer 
- gene associations predicted by JEME, GeneHancer, EnhancerAtlas and FOCS methods (Cao et al. 
2017, Gao et al. 2016, Fishilevich et al. 2017, Hait et al. 2018).  We identified associations which 
overlapped with other EGAs at least twice (flexibleC) or three times (stringentC consensus 
enhancer - gene associations). Both datasets, the stringentC and flexibleC, span several thousands 
enhancers-gene associations: 227,271 and 61,240, respectively (Figure 4.7.A). flexibleC dataset 
spans 21,124 genes and 107,489 enhancers, has a mean of 1.94 genes per enhancer and a median 
of 9 for enhancers per gene (mean=12.4). On average, stringentC models count 14,225 genes and 
44,559 enhancers (mean of genes per enhancer=1.25; median [enhancers per gene]=3, mean=4.2, 
Figure 4.7.C-B, Supplementary Table 1.). 
 
 
A.       B.    C. 
 
Figure 4.7. General characteristics of in-house (in-house) and consensus enhancer-gene associations (EGA): flexibleC 
and stringentC. A. Number of enhancer-gene associations, enhancers and genes reported in flexibleC and stringentC 
predictions.  B. Per method distribution of the number of genes associated with each enhancer region. C. Per method 
distribution of the number of enhancers reported for each gene.  
4.3.5. The majority of EGAs co-localize within the same TAD 
Since enhancers and their target genes have been frequently found to co-localize in the same TAD 
(Symmons et al. 2014) and spatial organization of the genome represents another level of gene 
expression regulation (Spielmann et al. 2012; Spielmann and Mundlos 2013; Ibn-Salem et al. 2014; 
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Lupiáñez et al. 2015), we hypothesized that the colocalization profile of EGAs within TADs can be 
used to assess the performance of EGA predictions.  
To test that, we calculated and averaged the percentage of enhancer-gene associations that were 
located within the same TAD in 37 cell types/tissues from Lieberman-Aiden et al. 2009,  ENCODE 
Project Consortium 2012,Rao et al. 2014, Dixon et al. 2015, Leung et al. 2015, Schmitt et al. 2016. 
Specifically, for each cell type and set of enhancer-gene associations, we counted the number of 
EGAs that are located within the same TAD regions and calculated the summary statistics (Figure 
4.8.).  
 
Figure 4.8. Distribution of the percentage of enhancer-gene associations (EGAs) that were found to be located within 
the same TAD domain tested across 37 cell types from Lieberman-Aiden et al. 2009,  ENCODE Project Consortium 
2012,Rao et al. 2014, Dixon et al. 2015, Leung et al. 2015, Schmitt et al. 2016. 
Sets of the FOCS and stringentC reported EGAs showed the best summary statistics - percentage 
of EGAs located within the same TAD across cell types (median=83.5% [range: 58.2-90.1%] and 
median=81.6% [56.8-86.6%]). On the other hand, inhouseM EGAs had on average the lowest 




reg2gene associated genes with their regulatory regions based on assessment of correlation 
between enhancer activity status and its target gene expression across multiple cell types. This 
approach was based on the observation that regulatory information can be particularly revealing 
when compared across many cells or tissues within a single genome (Ernst et al. 2011, Sheffield 
et al. 2013, Varley et al. 2013, Reuter et al. 2015). Previously, Ernst et al. (2011) correlated 
normalized signal intensities of H3K27ac, H3K4me1 and H3K4me2 with gene expression across 
nine cell types, whereas Sheffield et al. (2013) discovered distinct associations between more than 
500K DHSs and promoters, CpG islands, conserved elements, and transcription factor motif 
enrichment using correlation between matched DNase-seq and gene expression data from more 
than 70 cell-types. Varley et al. (2013) used a diverse collection of 82 human cell lines and tissues 
to correlate CpG methylation and gene expression. However, those methods were limited by the 
availability of genomic data - a large panel of cells, with comparable quality and resolution across 
all conditions is required to build an accurate model of enhancer activity ~ gene expression. 
However, the optimal number of cell types to be considered in the enhancer-gene pairs 
annotation is yet to be determined (Hariprakash and Ferrari 2019), and thus, the reg2gene relies 
on the largest collection of epigenomics or transcriptomic data in humans at time - the Roadmap 
datasets  (Bernstein et al. 2010, Roadmap Epigenomics Consortium et al. 2015). 
The main advantage of correlation approaches is that they can identify multiple targets of an 
enhancer and directly derive a quantitative measure of the strength of association (Hariprakash 
and Ferrari 2019), On the other hand, the most frequently used measures of correlation, the 
Pearson and Spearman correlation coefficients, can only detect linear relationships. They are not 
sensitive to the nonlinear regulatory relationship that tends to be very common in biology (Brunel 
et al. 2010) and especially prevalent among gene regulatory networks (Guo et al. 2014). However, 
to detect nonlinear dependence for two variables with arbitrary dimensions one can use distance 
correlation (Székely et al. 2007). DC has proven its power and computational effectiveness to 
capture both linear and non-linear relationships (Gorfine et al. 2012). In addition, distance 
correlation estimates are quite simple without any distribution assumption (Guo et al. 2014). Thus, 
along with Pearson and Spearman correlation, we additionally implemented distance correlation 
in the reg2gene pipeline. 
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However, correlation does not directly consider the fact that multiple enhancers can act on a gene 
in a cooperative fashion (Reuter et al. 2015). To account for that, we implemented the elastic net 
- a regularized regression approach (Zou and Hastie 2005) - and random forest (Breiman 2001). 
Random forest has recently become a popular machine learning technique in bioinformatics 
(Zhang and Ma 2012), due to its ability to give a measure of feature importance (Bylander 2002), 
run efficiently on large datasets without over-fitting, and its inherently non-parametric structure 
(Friedman et al. 2001). It has been frequently used for variable selection, prediction modelling, 
pathway analysis, genetic association, epistasis detection, etc. (Diaz-Uriarte and de Andrés 2005, 
Chen and Ishwaran 2012). For example, in the case of enhancer predictions, Rajagopal et al. (2013) 
identified sets of chromatin marks that appeared to be the most informative and robust across 
cell-types and replicates using random forest. We mainly implemented the random forest 
algorithm due to the “grouping property” of RF trees (Ishwaran et al. 2010) that enabled us to 
adeptly deal with correlation and interaction between enhancer activity and gene expression.  
Likewise, elastic net has been used to solve biological problems that require modelling of high-
dimensional data with few examples and strongly correlated predictors (Zou and Hastie 2005) - 
such as epigenomic data. For example, EMERGE used elastic net algorithm to predict genomic 
regulatory elements (enhancers) from multiple genomic signatures (van Duijvenboden et al. 
2016), whereas results of genome-wide association studies were analyzed with elastic net to  
prioritize risk-associated SNPs (Wu et al. 2009) or identify gene-gene interactions (Park and Hastie 
2008).  Since, it simultaneously assesses the strength of an impact of enhancers (assess the errors 
terms in predicting TSS activity based on the activity of all candidate enhancers) on their target 
genes and identifies significant models we implemented elastic net algorithm to account for the 
cooperative activity mode of multiple enhancers. 
To assess the statistical significance for each model, reg2gene calculated the binary score that 
defined whether the association between enhancers and target genes was statistically significant 
or not. Thus, similar to GeneHancer (Fishilevich et al. 2017), we allowed more flexible prioritization 
of EGAs by adjusting a single threshold on the score. Then, binary scores were integrated using 
the majority voting approach. With this additional data integration step, we aimed to overcome 
the non-specificity of individual chromatin marks to predict enhancer regions in the genome (as 
suggested in Ernst et al. 2011).  
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Similar to reg2gene, JEME combined regression-based (lasso and elastic net) and supervised ML 
modelling (random forest, Cao et al. 2017), however, none of the previous methods reached the 
scope of reg2gene modelling. Especially since, we modelled each putative enhancer-gene 
interaction a total of twenty times: we quantified four enhancer activity scores (H3K4me1, 
H3K27ac, DNAme and DHS) and performed modelling using five algorithms. Since a consensus 
about which epigenomic or transcriptomic data assess enhancer activity the best does not exist 
(Shlyueva et al. 2014), we selected chromatin marks that were previously suggested to be more 
robust (although not perfect) predictors of enhancer activity than other marks (Whalen et al. 
2016) and reported within the Roadmap datasets (Roadmap Epigenomics Consortium et al. 2015). 
Although, we did not directly model other predictors of enhancer activity, such as eRNAs - bi-
directional non-coding RNAs produced at the location of enhancers which expression level 
correlates well with the functional activity of the enhancer (Mikhaylichenko et al. 2018), other 
methods, which predictions we integrated as the last step of our analysis, did.  
Specifically, we voted our predictions together with predictions from other four computational 
method that map cis-regualtory interactions:  JEME - joint effect of multiple enhancers (Cao et al. 
2017), GeneHancer (Fishilevich et al. 2017), EnhancerAtlas 2.0 (Gao et al. 2016), and FOCS - FDR-
corrected OLS with Cross-validation and Shrinkage (Hait et al. 2018) aiming to improve the 
reproducibility of our results and account for the fact that we might have had missed some of the 
associations that were previously identified across multiple publications (that used different 
epigenomes as an input than we did). We again relied on the approach from Yang et al. 2010 and 
treated EGAs as multiple classifiers that were combined by majority voting to narrow down the 
hypothesis space and to report more accurate models than individual predictions. Thereby, by 
integrating reg2gene predictions together with GeneHancer or EnhancerAtlas, we indirectly used 
information from the FANTOM5 (Andersson et al. 2014), and GTEx consortium (GTEx Consortium 
et al. 2017), GRO-Seq, etc.  
All reg2gene functions were gathered in the reg2gene R package that, additionally to the 
enhancer-gene associations modelling, enables solving of similar biological problems such as 
modelling across cell types, tissues or time course series (for example, the time course of 





Prior to implementing the reg2gene algorithm, we made three important choices: a) identify the 
relevant gene annotations, b) define enhancer regions for which we will quantify activity signal 
and run modelling, c) define chromatin marks which signal will be used to quantify enhancer 
activity. First, for each gene, we identified exon locations in the GENCODE database (Harrow et al. 
2012), one of the most comprehensive databases of protein-coding genes and their features. 
Second, since the initial choice of epigenomic marks used to map enhancers has a large impact on 
the final number and characteristics of defined enhancers (Zentner and Scacheri 2012), and 
consequently, on the number and properties of defined EGAs (Hariprakash and Ferrari 2019), we 
improved the robustness of our predictions by identifying a consensus of enhancers. We first used 
the Roadmap datasets as the largest collection of epigenomics or transcriptomic data in humans 
at time to identify enhancer regions predicted across its 127 cell types/tissues (Roadmap 
Epigenomics Consortium et al. 2015). Similar to JEME that used the same dataset to predict 
enhancers, we relied on ChromHMM predictions of chromatin states (Ernst and Kellis 2012) and 
identified 184,005 genomic locations that were commonly predicted as enhancer-like across many 
different cell types. We next considered sets of enhancers from EnhancerAtlas (Gao et al. 2016), 
JEME (Cao et al. 2017), GeneHancer (Fishilevich et al. 2017), and FOCS (Hait et al. 2018), and our 
in-house definition to represent different classifiers (that define individual hypothesis spaces) and 
their integration was proposed to narrow the hypothesis space and return more accurate 
predictions (Yang et al. 2010). In other words, we defined 286,723 “consensus” enhancers as 
regions in the genome that were covered by at least three enhancer definitions. This number 
represents a relatively small subset of initially estimated 1 million enhancer regions (Heintzman 
et al. 2009, ENCODE Project Consortium 2012) or 2.9 million DHSs (DNase I hypersensitive sites; 
Thurman et al. 2012), but nevertheless outperforms 43,011 enhancer candidates from the 
FANTOM5 consortium (Andersson et al. 2014). On the other hand, as a consensus of enhancer 
definitions, this number is smaller than the number of individual JEME enhancers (~300K), but 
larger than the number of GeneHancer and EnhancerAtlas enhancers (~200K). However, an 
exhaustive reference list of enhancers is missing and their true number is still unknown (Shlyueva 
et al. 2014, Hariprakash and Ferrari 2019). 
Although regulatory elements may have both enhancer and promoter functions (Andersson et al. 
2015; Andersson and Sandelin 2020), the percentage of promotes that have a strong enhancer 
activity in the genome was shown to not be large (3% of tested gene promoters in human K562 
cells, Dao et al. 2017), and we hypothesized that “better” enhancer predictions should have a 
smaller overlap with promoters. As compared to previously defined enhancers, our enhancer 
117 
 
regions rarely overlapped with promoter regions (>5% of in-house enhancers as compared to 20% 
GeneHancer enhancers). As expected, ChromHMM-predicted enhancer-like states (6_EnhG and 
7_Enh) showed a greater per-base overlap with in-house enhances (45-51%), as compared to 0% 
of covered heterochromatin regions or 2% of quies. 
..... 
 
Prior to reg2gene modelling, we paired the “consensus” enhancers with genes to define 8.9 
million enhancer - gene pairs of which ~1M was statistically significant and further voted together 
with JEME, GeneHancer, EnhancerAtlas and FOCS EGAs. We defined two datasets of voted EGAs: 
~230K EGAs in the flexibleC set (EGAs voted by two methods), and ~60K stringentC EGAs (EGAs 
voted by three methods). Datasets were built on top of ~110K and ~45K enhancer regions that 
altogether indicated that predictions are genome-wide. As compared to the previous 
computationally assessed EGAs, we report the most stringent dataset in every aspect: number of 
genes, enhancers, EGAs, an average of genes reported per enhancer region or vice versa 
enhancers per gene. For example, we calculated that EnhanceAtlas enhancers were paired with a 
median of 24 genes. This large number of interactions could be a consequence of the fact that 
EnhancerAtlas-defined enhancers were on average longer than enhancers defined in other 
publications (up to 3Mb), but as well we might have inflated the statistics with our protocol that 
pooled (and reduced) all enhancer-gene associations across 105 analyzed cell types. Indeed, Gao 
et al. 2016 reported that one EnhancerAtlas enhancer was associated with 2.4 target genes, and 
each gene was associated with 4.1 enhancers when an average was calculated in individual cell 
types. Likewise, we calculated that GeneHancer enhancers participate, on average, in 14 
interactions per gene (median), but Fishilevich et al. 2017 reported 1.44 genes per enhancer and 
7.47 enhancers per gene. In FOCS, each promoter was reported to be linked to 2.4 enhancers or 
specifically, in optimally reduced models, each promoter was linked, on average, to 3.2, 2.8, and 
3.6 enhancers in the Roadmap, FANTOM5, and GRO-seq datasets  (Cao et al. 2017). Those 
numbers are similar to a mean of 1.94 genes per enhancer and a median of 9 for enhancers per 
gene for flexibleC and mean of 1,25 genes per enhancer for stringentC models. Nevertheless, as 
we still do not have a precise knowledge about the total number of enhancer regions in the human 
genome (Shlyueva et al. 2014), nor the number of their interactions  (Hariprakash and Ferrari 
2019). Thus, we do not know which reported statistics represent the correct population average. 
However, since in vivo testing of the reporter or in vivo editing of the enhancer in transgenic 
animals has been considered to be a definitive proof of enhancers (Visel et al. 2007; Catarino and 
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Stark 2018), we considered the estimation of Fulco et al. (2019) -  individual enhancers regulate 
up to 5 genes, whereas individual genes can be regulated by up to 12 distal elements - to be the 
“most” precise estimations at time.    
Due to the fact that boundaries between topologically associating domains have specific insulating 
properties, TADs are generally defined as regions in the genome characterized by a high level of 
chromatin interactions occurring within them, many of which can be enhancer-gene interactions 
(Nora et al. 2012; Lupiáñez et al. 2015). Thus, we hypothesized that the higher percentage of EGAs 
within topologically associating domains denotes better predictions of regulatory associations and 
we calculated the percentage of colocalizing events. Since TADs show a general conservation in 
relative position across different cell types and/or organisms (Dixon et al. 2012; Vietri Rudan et al. 
2015), we expected to observe that the number of interactions reported in different cell types 
should not vary much, and encouraged us to calculate an average colocalization percentage across 
different cell types. Except in the case of inhouseM EGAs, we confirmed our expectation that EGAs 
are mostly colocalized in the same TAD region, and showed that, on average, more than 80% of 




We developed and implemented the reg2gene algorithm - a computational method that maps cis-
regulatory interactions in the human genome. Although reg2gene itself performs computational 
modelling, we integrated its results (predicted enhancer-gene associations) together with four 
other sets of enhancer-gene associations: EnhancerAtlas (Gao et al. 2016), JEME (Cao et al. 2017), 
GeneHancer (Fishilevich et al. 2017), and FOCS (Hait et al. 2018). With this approach, we aimed to 
produce results that are more robust. To analyze whether or not that holds truth, in the following 
















In this section, I benchmark results of five computational methods that map cis-regulatory 
interactions in the genome-wide manner. I defined the scope of this analysis mainly together with 
Dr. Vedran Franke, and supported by Dr. Altuna Akalin.  
Abstract 
Multiple approaches have been utilized to study enhancer-mediated long-range gene regulation 
in a genome-wide manner: predictions using information from the eQTL studies (GTEx Consortium 
et al. 2017), (3C)-derived techniques (Lieberman-Aiden et al. 2009; Fullwood et al. 2009), reporter 
assays or cellular screens (Arnold et al. 2013; Gasperini et al. 2019); and their results have been 
frequently used to benchmark computational models of gene expression ~ enhancer activity.  
 
In this chapter, I benchmark enhancer-gene associations assessed by reg2gene and other 
computational methods: JEME (Cao et al. 2017), GeneHancer (Fishilevich et al. 2017), 
EnhancerAtlas 2.0 (Gao et al. 2016), and FOCS (Hait et al. 2018) using eQTLs from two studies 
(GTEx Consortium et al. 2017, Westra et al. 2013), and chromatin interactions from two data 
sources (Xie et al. 2016, Javierre et al. 2016).  
First, I show that none of the used benchmark datasets can be considered to represent a “golden” 
standard that can ultimately exhibit differences in the performance between computationally 
methods that assess enhancer-gene associations. Thus, we additionally defined a set of positive 
and negative EGAs by combining results of cellular screens (Gasperini et al. 2019) and defining an 
“in-house” EGA negatives using an extensive data integration approach (Ernst and Kellis 2012). 
With such defined benchmark dataset, we showed that stringentC models indeed have the highest 





Multiple computational methods have been developed to assess cis-regulatory interactions in the 
human genome. Previously, we systematically analyzed several of them: JEME (Cao et al. 2017), 
GeneHancer (Fishilevich et al. 2017), EnhancerAtlas 2.0 (Gao et al. 2016), and FOCS (Hait et al. 
2018) and showed that their protocols and predictions vary tremendously: especially in the 
location, number and properties of defined enhancer regions and enhancer-gene associations. 
Next, we developed a novel method - the reg2gene algorithm - that, in addition to the 
computational modelling of gene expression ~ enhancer activity, integrates its results (enhancer-
gene associations) with results of the aforementioned methods. Finally, here, we compare their 
results and a potential to be benchmarked (or benchmark). 
Up until today, multiple test datasets have been frequently used to benchmark computationally 
predicted EGAs (Gao et al. 2016, Cao et al. 2017, Hait et al. 2018). They can be broadly categorized 
into predictions of EGAs using information from: the eQTL studies (GTEx Consortium et al. 2017), 
chromosome conformation capture (3C)-derived techniques (Lieberman-Aiden et al. 2009; 
Fullwood et al. 2009), or direct functional confirmation of enhancer activity by reporter assays 
(Arnold et al. 2013) and cellular screens (Arnold et al. 2013). In other words, eQTL-eGene 
associations or reported chromatin interactions have been considered to represent a good proxy 
(but not a direct proof!) of enhancer-mediated regulation of gene expression; especially since 
each of the aforementioned high-throughput technologies/datasets is characterized by specific or 
common limitations marked by noisy data and high number of false negatives or positives 
(Hariprakash and Ferrari 2019).  
This opens a question, which, if any, of the aforementioned datasets should be used for 
benchmarking and what would be results. To answer those questions, in this chapter, I benchmark 
seven sets of enhancer-gene associations using six different experimental datasets and 




5.2.1. The intuition behind the benchmarking protocol  
 
We used two eQTL studies as benchmark datasets (GTEx Consortium et al., 2017, Westra et al., 
2013). To benchmark with eQTL-eGene associations, we firstly identified eQTLs that overlap with 
enhancers and then, for each overlapping eQTL-enhancer pair, we compared whether the eQTL-
associated eGene (gene associated with the given eQTL) equals enhancer-annotated gene (Figure 
5.1.). If yes, that pair was considered to be part of the benchmark dataset.  
 
Figure 5.1. Schematic representation of benchmarking EGAs with pairs of eQTL-eGene associations. First, we would 
identify eQTLs that overlap with enhancers and then, for each overlapping eQTL-enhancer pair, we compared 
whether the eQTL-associated eGene (gene associated with the given eQTL) equals enhancer-annotated gene. If yes, 
that pair was considered to be benchmarked.  
We benchmarked sets of EGAs with chromatin interactions from the PC-HiC experiment (Javierre 
et al., 2016) and CCSI database (Xie et al., 2016). Since, both anchors of chromatin interactions 
(locations of the interacting pair are commonly referred to as an anchor one and anchor two) 
could potentially overlap the TSS or enhancer location, we tested an overlap twice, in both 
orientations. We first identified an overlap between the enhancer regions and anchor one of the 
interacting pair, and confirmed it by locating the TSS within the anchor two region. Then, we 
tested if there was an overlap between the enhancer region and anchor two of the interacting 
pair, and anchor one and gene location. If we identified an overlap in any of these two overlapping 
steps, we considered the analyzed enhancer-gene association to be benchmarked with the given 





Figure 5.2. Schematic representation of benchmarking EGAs with pairs of chromatin interactions. We tested an 
overlap between both anchors of chromatin interactions and the TSS-enhancer pair twice; anchors in both 
orientations are compared to the tested enhancer-gene pair.  
Importantly, prior to benchmarking, we accounted for the fact that many EGAs do not have a 
potential to be benchmarked at all - they are located outside of any region that is present in the 




5.2.2. An overview of used datasets  
 
I used multiple datasets to benchmark assessed interactions (Table 5.1.): eQTL studies (Westra et 
al., 2013, GTEx Consortium et al., 2017), the 3C-technology based studies (the PC-HiC study by 
Javierre et al., 2016) and the CCSI database (Xie et al., 2016), result of a single-cell cellular screen 
(Gasperini et al., 2019). 
 
 
Table 5.1. Characteristics and statistics behind datasets used in this chapter 
 
Data source Technology/Data type Processing 
algorithm 





et al., 2017) 
Microarrays/eQTLs NA Benchmarking 388,160 
(Westra et al., 
2013) 
Microarrays/eQTLs NA Benchmarking 672,717 
(Javierre et al., 
2016) 
PC-HiC NA Benchmarking 728,838 
CCSI database  
(Xie et al., 2016) 
3C, 4C, 5C, ChIA-PET and 
Hi-C 
NA Benchmarking 1 587 002 
 
(Gasperini et al., 
2019) 
dCas9-KRAB  NA Benchmarking 449  
Lieberman-Aiden 
et al. 2009, Rao et 
al. 2014, Dixon et 
al. 2015, Leung et 
al. 2015, Schmitt 
et al. 2016, 
ENCODE Project 
Consortium 2012 







5.3. Results  
5.3.1. Validation of our benchmarking procedure  
 
Authors of the previous computational EG association methods used eQTLs and chromatin 
interactions as a “golden benchmark” datasets to benchmark their predictions and assess the 
performance of their algorithms (Cao et al. 2017, Hait et al. 2018). To get a better understanding 
of the benchmarking problematics, we, as well, benchmarked our predictions using those two 
datasets. 
However, contrary to the previous publications that mostly benchmarked using one dataset, we 
set off to systematically benchmark cis-regulatory interactions using two eQTL studies (GTEx 
Consortium et al. 2017, Westra et al. 2013), and two sources of chromatin interactions (Xie et al. 
2016, Javierre et al. 2016) which largely varied in their sizes (Supplementary Figure 2.). We 
specifically opted to use benchmark datasets that were reported to provide a good proxy 
information of enhancer-mediated gene regulation (Hariprakash and Ferrari 2019) and/or that 
were utilized by the previous publications to benchmark their results (Cao et al. 2017, Hait et al. 
2018). 
As the primary source of eQTLs, we used the GTEx database - a largest repository of tissue-specific 
eQTLs (GTEx Consortium et al. 2017). We additionally included the second source of eQTLs as a 
control - Westra et al. 2013 - that we specifically selected because it reported eQTLs across a large 
number of cell types, as well as trans eQTLs. Contrary to cis eQTLs, trans eQTLs alter the structure, 
function or expression of a diffusible factor (Ronald et al. 2005), and thus act mostly indirect, non-
allele specific and in long ranges. The last property of trans eQTLs was the most attractive to us, 
especially since we were primarily focused on identifying long-range interactions and expected to 
observe many benchmarked trans eQTLs.  
Since the GTEx eQTLs were previously used as the benchmark datasets in FOCS (Hait et al. 2018) 
and JEME (Cao et al. 2017), we used this information to control for our benchmarking procedure. 
Around 170,000 (37%) and 90,000 (38%) of FOCS enhancer-promoter links were reported to be 
supported by ChIA-PET from the CCSI database (Xie et al. 2016) and GTEx eQTLs (GTEx Consortium 
et al. 2017), respectively. However, using the CCSI database we managed to confirm around 
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60,000 FOCS enhancer-promoter links, whereas the GTEx eQTLs confirmed only around 2,500 
FOCS E-P links. After we repeated the benchmarking, but with extended enhancers (+/-500bp) as 
they did in the original publication, we managed to obtain a 10x increase in the number of 
overlaps, and with this, we roughly confirmed the reported percentages, and verified our 
benchmarking procedure.  
In the case of chromatin interactions, we corroborated previous results by FOCS  (Hait et al. 2018) 
and confirmed that ~60% of their EGAs is confirmed by chromatin interactions from the CCSI 
database (although, in their case they only tested ChIA-PET experiments, Xie et al. 2016). 
As a second benchmark dataset, we used two sources of 3C-related experiments: the promoter-
capture HiC (PC-HiC) experiment (Javierre et al. 2016) and the CCSI database (Xie et al. 2016). We 
relied on the notion that the (3C)-derived techniques measure chromatin contact frequencies, 
which correlate well with functional studies of regulatory elements (Pombo and Dillon 2015), and 
thus can be used as a good proxy information of enhancer-mediated gene regulation. The CCSI 
gathers information from all previously conducted 3C, 4C, 5C, ChIA-PET and Hi-C experiments but 
is not an up-to-date database.  On the other hand, as we were specifically interested in the analysis 
of gene expression regulation, we used a genome-wide dataset that is strongly enriched for 
promoter interactions - PC HiC (Javierre et al. 2016).    
 
 
5.3.2. The eQTL studies and chromatin interactions identified by (3C)-derived high-
throughput technologies suffer from low reproducibility 
 
To test the actual benchmarking potential of four benchmarking datasets and whether the two 
eQTLs studies reported more similar results as compared to the chromatin interaction studies (and 
vice-versa if the reported chromatin interactions are more similar to each other than to the eQTL-
eGene associations), we analyzed the characteristics and the performance of benchmark datasets 




Figure 5.3. Heatmap of the benchmarking results for two eQTL-eGene association studies and chromatin interactions 
reported in (Javierre et al., 2016) and the CCSI database (Xie et al., 2016). Overlap percentage was reported for studies 
in columns. For example, 10.4% of the eQTLs from the GTEx database were confirmed by eQTLs reported in Westra 
et al., (2013) 
 
We identified that one third of the PC-HiC chromatin interactions (33.2%) could be benchmarked 
by the CCSI-reported interactions, whereas 16.7% of the CCSI database is supported by the PC-
HiC-identified chromatin interactions from Javierre et al., 2016. Westra eQTLs overlapped 10.4% 
of the GTEx eQTL-eGene associations and vice-versa 7.8% GTEx eQTLs associations was covered 
by the Westra eQTL-gene links. Less than 4% and 7% of PC-HiC interactions were supported by the 
GTEx and Westra eQTL-eGene associations, respectively, as compared to 7% and 11% of CCSI 
covered interactions. The GTEx eQTLs achieved the greatest overlap with the CCSI database (23%), 
but only 10% with another source of chromatin interactions - PC-HiC. On the other hand, 50% of 
the Westra eQTLs overlap with the CCSI chromatin interactions and 25% of PC-HiC interactions. 
Altogether, this indicated that the analyzed benchmarking datasets suffer from poor 
reproducibility. With this in mind, we performed a thorough benchmarking analysis.  
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5.3.3. Different sets of EGAs are diversely covered by eQTL-eGene pairs (eQTLs) and 
chromatin interactions  
 
As expected, EGAs from different datasets were unequally covered by both sources of 
interactions: a total of 7.5%, 9.1%, 11.5% and 18.8% of EnhancerAtlas, FOCS, JEME and 
GeneHancer enhancer-gene associations, respectively, were supported by the GTEx eQTLs (Figure 
5.4., Supplementary Figures 3. and 4.). However, only 1.4% of the inhouseM was confirmed by 
eQTLs but this percentage increased to 7.3% for stringentC models. In the case of Westra et al., 
(2013) eQTLS, we observed an increase in the overlap between EGAs and eQTL-eGenes for each 
defined set of EGAs; 18%, 16%, 23.8% and 25.4% for EnhancerAtlas, FOCS, JEME and GeneHancer, 
respectively. Although only 3.5% of the inhouseM EGAs overlapped Westra eQTLs, this percentage 
increased to 9.5% and 18.2% for flexibleC and stringentC EGAs.  
 
Figure 5.4. Histogram of the percentage of overlap between publication-specific enhancer-gene associations (EGAs) 
and four different benchmark datasets: two eQTL studies (Westra et al., 2013), GTEx database, (GTEx Consortium et 
al., 2017) and two sources of HiC-related experiments (Javierre et al., 2016), CCSI database (Xie et al., 2016). 
Percentage overlap was calculated for each of the seven sets of EGAs. Benchmarked interactions are those in which 
one location (anchor one) of the interaction pair overlaps an enhancer region, and the other location (anchor two) 
overlaps extended gene’s TSS, or vise-versa anchor two overlaps enhancer, whereas anchor one overlaps with 
promoter. On the other hand, if an eQTL-associated gene is equal to the gene associated with the overlapping 
enhancer, such eQTL-eGene was considered to be benchmarked. 
On the other hand, 41%, 55%, 50% and 56% of EnhancerAtlas, FOCS, JEME and GeneHancer 
enhancer-gene associations, respectively, were supported by the CCSI database, whereas 17.6%, 
15%, 20.5% and 32.5% of EGAs were supported by the PC-HiC interactions. In the case of in-house 
models, 14.3% and 9.2% of the inhouseM was confirmed by CCSI and PC-HiC interactions. This 
percentage increased to 36% and 55% for the flexibleC and stringentC models and the CCSI 
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reported interactions; 23.4% stringentC interactions were reported by PC-HiC. Importantly, all 
interactions that do not overlap with interactions reported in the benchmark dataset were filtered 
out prior to this analysis. 
Next, we changed the perspective and analyzed the modelling potential of computational 
methods to predict  eQTLs and chromatin interactions.  
In general, Westra et al., 2013 showed a greater coverage by computational predicted EGAs than 
other benchmark datasets (Figure 5.5., Supplementary Figures 3. and 4.). Consistent with most 
of other benchmark datasets the biggest percentage of overlaps was identified if EnhancerAtlas 
EGAs were used as a benchmark dataset, followed by GeneHancer and JEME.  
 
 
      
Figure 5.5.  Histogram of the percentage of overlap between four different benchmark datasets: two eQTL studies 
(Westra et al., 2013), GTEx database, (GTEx Consortium et al., 2017) and two sources of HiC-related experiments 
(Javierre et al., 2016), CCSI database, (Xie et al., 2016) and publication-specific enhancer-gene associations (EGAs). 
Benchmarked interactions are those in which one location (anchor one) of the interaction pair overlaps an enhancer 
region, and the other location (anchor two) overlaps extended gene’s TSS, or vise-versa anchor two overlaps 
enhancer, whereas anchor one overlaps with promoter. On the other hand, if an eQTL-associated gene is equal to 
the gene associated with the overlapping enhancer, such eQTL-eGene was considered to be benchmarked. On the y-
axis is the percentage of benchmarked eQTLs or chromatin interactions identified by overlapping them with 




Specifically, GTEx eQTLs showed the highest coverage with EnhancerAtlas (14%), but only 2,6% of 
FOCS, and 4% of stringentC supported eQTL-eGene GTEx associations. Compared the GTEx eQTLs, 
Westra et al., 2013 eQTLs showed higher coverage with all other methods to predict EGAs; 30% 
of eQTL-eGene associations were covered with EnhancerAtlas; 25% with GeneHancer and 21% 
with JEME. The most obvious difference in the prediction success was observed for EnhancerAtlas 
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and eQTL studies: twice more Westra et al., 2013 eQTL-eGene pairs was predicted by the 
EnhancerAtlas EGAs than the GTEx eQTLs. Equal discrepancy in predictions was observed for other 
methods as well. 
On the other hand, 17.3% of chromatin interactions reported in the CCSI database was confirmed 
by GeneHancer EGAs, which was followed by 15.7% interactions confirmed by JEME and 15.2% by 
EnhancerAtlas as compared to 6-7% overlap with in-house models. Chromatin interactions 
observed by Javierre et al., 2016 had even lower overlap percentages: 15% of them were 
confirmed by GeneHancer, but only 2.7% by stringentC. 
 
5.3.4. Benchmarking with “in-house” defined set of negative EGAs and results of cellular 
screens revealed that stringentC models have the highest PPV  
 
We next performed the second benchmarking step, in which we used a predefined set of in-house 
EGAs negatives and include cis enhancer-gene interactions from cellular screening as a benchmark 
set (Gasperini et al., 2019). 
We hypothesized that cis enhancer-gene interactions from Gasperini et al. (2019) correspond to 
a set of positive interactions, that if predicted by computational methods, represent true positives 
(TP), and if missed, false negatives (FN). We specifically opted for interactions reported in 
Gasperini et al., 2019, because they managed to capture perturbations of gene expression 
globally. By using single-cell RNA sequencing, and a unique combination of perturbations 
introduced into each individual cells with gRNAs at a high MOI (multiplicity of infection), they 
overcome limitations of the previous methods that either tested a single gene per experiment, or 
had low power due to the low multiplicity of lentivirus infection (Canver et al. 2015; Wakabayashi 
et al. 2016; Diao et al. 2017). We opted for cellular screens since it has been considered that only 
in vivo testing of the reporter or in vivo editing of the enhancer in transgenic animals represent a 
definitive proof of enhancers and their activity (Visel et al. 2007; Catarino and Stark 2018). 
However, until recently (Fulco et al. 2019, Gasperini et al. 2019), only low-throughput assays were 
available to provide a direct functional confirmation or quantitative readout of enhancer activity 
(Arnold et al. 2013, Kvon 2015).  
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However, to be able to fully assess the performance of EGAs methods, we needed to assess other 
two elements of the confusion matrix: false positives (FP) and true negatives (TN) and thus, we 
developed an approach that searched for “negatives'' - enhancer-gene pairs for which we 
expected they would not be statistically associated. To achieve that we proposed an approach 
that is based on data integration of Roadmap epigenomes (Roadmap Epigenomics Consortium et 
al. 2015) and across-cell-type ChromHMM-based chromatin states (Ernst and Kellis 2012). We 
used ChromHMM-predicted chromatin states (Ernst and Kellis 2012, Roadmap Epigenomics 
Consortium et al. 2015) because they were identified by computational modelling and data 
integration of multiple chromatin marks, and thus, they should overcome non-specificity of 
individual chromatin marks and inherent weaknesses of different high-throughput datasets (Yang 
et al. 2010, Ernst et al. 2011). This idea was based on the assumption that  enhancer activity ~ 
gene expression modelling should not be successful for enhancers that were predicted by 
ChromHMM as Polycomb repressed, heterochromatin or quiescent chromatin state across all 127 
cell types and consequently, EGAs for “inactive” enhancers should not be predicted as EGAs.    
In summary, we first screened the 15-states ChromHMM predictions across all 127 Roadmap cell 
types with the location of enhancers and identified whether defined enhancer overlaps with any 
of the three “inactive” ChromHMM-predicted chromatin states: Polycomb-repressed, 
heterochromatin or quiescent. If we identified enhancer that was across all 127 cell types 
“inactive” (100% per base overlap with repressed, heterochromatin or quiescent ChromHMM-
predicted chromatin states, Figure 5.6.), then we considered such enhancer region to be a false 
positive - incorrectly identified as an enhancer. Consequently, we consider each reported 







Figure 5.6. Schematic representation of defining false positive (FP) enhancers in the genome (FPE).  If across all 127 
cell types an enhancer was found to be inactive (100% per base overlap with repressed, heterochromatin or quiescent 
ChromHMM-predicted chromatin states), we considered such enhancer region to be a false positive enhancer (FPE). 
We identified that, out of 321 high-confidence cis enhancer-gene interactions reported in 
Gasperini et al., 2019, 291 indeed overlapped GeneHancer and were considered true positives 
(TPs). A total of 180 (Gasperini et al., 2019) enhancer-gene interactions was benchmarked by 
EnhancerAtlas predictions, out of 210 possible. In addition, 91/114 TP was predicted by FOCS, 
129/169 by JEME. In case of our inhouse models, a total of 45, 61, 67 of stringentC, flexibleC and 
inhouseM EGAs overlapped (Gasperini et al., 2019) defined positives, and thus, were identified as 
TP from this subset (Figure 5.7., Supplementary Table 2).   
  
Figure 5.7. Results of the overlapping procedure for the inhouse sets of expected negative and positive enhancer-
gene associations. Seven sets of computationally predicted EGAs were tested for an overlap. Number of identified 
false positives (FP) is reported on the x-axis, whereas true positives (TP) are reported on the y-axis. TP correspond to 
cis enhancer-gene interactions reported in (Gasperini et al., 2019) that overlapped computationally predicted EGAs. 
FP are computationally predicted EGAs whose enhancers were predicted to be “inactive” by the ChromHMM 
algorithm across all 127 cell types reported in the Roadmap dataset (details in Methods).  
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In the case of negatives, we previously identified that 272 JEME, 274 FOCS, 1121 GeneHancer, and 
13,672 EnhancerAtlas defined enhancers overlap “inactive enhancer” regions present across all 
127 epigenomes (Supplementary Table 1.). Nevertheless, we identified that those enhancers 
participated in 35,618 EnhancerAtlas EGAs or 1,635 GeneHancer EGAs. On the other hand, we 
identified 126 consensusE that were predicted by ChromHMM as repressed, heterochromatin or 
quiescent across all Roadmap cell types. Paired with genes, “inactive” consensusE enhancers built 
3,147 enhancer-gene pairs, each of which was modelled the reg2gene algorithm. However, only 
12 enhancers were reported to have significant association in the inhouseM EGAs, whereas 3 
enhancers had significant EGAs in the flexibleC models. None of the enhancers from the stringentC 
EGAs were identified to be “inactive”. 
Overall, this enabled us to fully assess the performance of computational methods by assessing 
all elements of the confusion matrix: false positives (FP), false negatives (FN), true negatives (TN) 
and true positives (TP). For example, by using defined negatives (expected “inactive” enhancer-
gene pairs) we could assess true negatives (TN) and false positives (FP), whereas cis-interactions 
from Gasperini et al. (2019) allowed us to identify true positives (TP) and false negatives (FN). With 
quantified true and false positives, we could calculate positive predictive value (PPV) as the 
number of true positives (TP) over all positives (PPV=TP/(TP+FP). The highest PPV value was 
observed for stringentC models (100%), followed by flexibleC models (93.4%). On the other hand, 






Multiple computational methods have been developed to map cis-regulatory interactions in the 
human genome. In this chapter, I assessed the potential of our in-house method - reg2gene - and 
several other computational algorithms: JEME (Cao et al. 2017), GeneHancer (Fishilevich et al. 
2017), EnhancerAtlas 2.0 (Gao et al. 2016), FOCS (Hait et al. 2018) to predict eQTLs and chromatin 
interactions, or have their results benchmarked. Since reg2gene provided us with three sets of 
predictions: inhouseM EGAs (enhancer-gene associations that were a direct result of integration 
of twenty different models of gene expression~enhancer activity) and stringentC and flexibleC  
EGAs (two consensus sets of EGAs that were voted based on EGAs from inhouseM, JEME, 
GeneHancer, EnhancerAtlas, and FOCS) we separately benchmarked all three of them.  
As benchmark datasets, we used two sources of eQTLs (Westra et al. 2013, GTEx Consortium et 
al. 2017) and chromatin interactions (Javierre et al. 2016, Xie et al. 2016), results of cellular screens 
(Gasperini et al. 2019) and the ChromHMM-predicted repressed regions in the genome (Ernst and 
Kellis 2012) and performed a total of thirty-five pairwise benchmarking analyses. 
First, we verified the accuracy of our benchmarking protocol by comparing our benchmarking 
results for GTEx eQTLs with the results reported in FOCS (Hait et al. 2018) and JEME (Cao et al. 
2017). Specifically, Hait et al. (2018) reported that FOCS outperforms extant methods in terms of 
concordance with enhancer-promoter interactions identified by ChIA-PET from the CCSI database 
(Xie et al. 2016), HiChIP (Weintraub et al. 2017), and eQTL data (GTEx Consortium et al. 2017). We 
revealed a much lower percentage of overlaps between eQTLs and enhancer-gene associations as 
compared to the reported ones in FOCS, however, after we repeated the benchmarking 
procedure, but with extended enhancer regions (as they did in the original publication), we 
obtained the comparable results, thus verifying our protocol. On the other hand, Cao et al. (2017) 
compared JEME with other state-of-the-art methods for predicting enhancer targets on the basis 
of overlap with eQTLs (Ernst and Kellis 2012, He et al. 2014, Corradin et al. 2014, Roy et al. 2015, 
Whalen et al. 2016) and reported that JEME was the most accurate of all the methods in across-
sample tests, whereas in cross-validation tests, JEME was slightly less accurate than TargetFinder 
(Whalen et al. 2016). However, Cao et al. (2017) reported AUPR, or area under the curve, as a 
performance statistics that requires quantification of all elements of the confusion matrix: true 
positives, false negatives, true negatives and false positives. To count them, they hypothesized 
that eQTLs are the “golden” standard method for assessing enhancer-gene associations and 
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benchmarking. However, this is not necessarily the case (and will be further elaborated later in 
this discussion) especially since eQTL microarrays and RNA-seq technologies suffer from many 
technical limitations (Ellis et al. 2013). In addition, with the second test of our benchmarking 
procedure, e.g. test of assessed and reported concordance between FOCS EGAs and interactions 
reported in the CCSI database (Xie et al. 2016), we corroborated the reported percentage of 
overlaps (although, in their case they only tested a subset of interactions from ChIA-PET 
experiments). 
 
Since we were aware that our analysis suffered from many biases and confounding factors, we 
expect to observe that the final result of multiple benchmarking procedures would look different 
when different high-throughput datasets would be used as a “golden” benchmark. First, eQTLs 
and chromatin interactions are not a direct proof of enhancer-mediated gene expression 
regulation and they suffer from technical and biological limitations (Hariprakash and Ferrari 2019). 
For example, inherent biases in restriction enzyme cutting efficiency, ligation frequency, averaging 
of the chromatin states across the population of cells affect specificity of assessed interactions 
(O’Sullivan et al. 2013). Likewise, since enhancer-promoter loops may be detectable in cell types 
where the target gene is not active (Rao et al. 2014), or their interactions may precede the 
activation of target genes (Stadhouders et al. 2018), the detection of chromatin interactions with 
(3C)-derived methods does not unambiguously prove the presence of an active regulatory 
interaction in a given cell type. Ligation events detected by (3C)-derived technologies could as well 
reflect the higher-order nuclear organization contacts (Gavrilov et al. 2013) or random contacts 
between chromatin (Dekker et al. 2013), which adds to the background noise and imprecise 
detection of chromatin interactions (Pombo and Dillon 2015). In addition, with present 
technologies such as HiC, the appropriate resolution is hardly achievable for the ETG pairing tools; 
for example, in ChIP-seq (and consequently ChIA-PET) the ultimate resolution limit is the 
chromatin fragmentation size, which is usually in the order of a few hundred base pairs (Park 
2009). On the other hand, eQTLs rely on microarray technologies, and as such, they are hindered 
by their specific technical limitations - for example, they do not interrogate the whole genome, 
whereas they focus on specific single nucleotide positions in the genome (Hacia et al. 1999) that 
are not necessarily the causal ones. “Index” SNPs are most likely only “proxy” SNPs which are in 
the linkage disequilibrium (LD) with the causal ones (Schork et al. 2009; Maurano et al. 2012; Tak 
and Farnham 2015). RNA-seq processing itself is not without its own challenges, given that 
mapping bias (Vijay et al. 2013, Panousis et al. 2014), coverage issues, outlier samples, batch 
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effects, and unknown covariates (Leek and Storey 2007) limit data integrity and eQTL 
reproducibility (Ellis et al. 2013).  
Thus, we first cross-compared the benchmarking datasets to get a better overview of the 
underlying confounding factors. In agreement with what was recently reported (Forcato et al. 
2017; Lajoie et al. 2015; Dali and Blanchette 2017), we detected a discordance between two sets 
of chromatin interactions: only one third of PC-HiC interactions was previously reported in the 
CCSI database. This might be a consequence of the analysis that was performed with different 
datasets (originated from different cell types). In other words, enhancers are not being active in 
cell types in which chromatin interactions were identified. However, this discrepancy more likely 
reflected the aforementioned limitations of (3C)-derived technologies - reported chromatin 
interactions do not unambiguously prove the presence of an active regulatory interaction in a 
given cell type (Pombo and Dillon 2015). In addition, the choice of the algorithm used for HiC 
analysis and TAD calling was shown to have a strong impact on the final annotations of TADs, 
especially in terms of TAD numbers and sizes (Zufferey et al. 2018; Wu et al. 2020). This variability 
potentially reflects an underlying hierarchical domain organization that is only partially captured 
by different methods and at different resolutions (Zufferey et al. 2018). More importantly, the 
reproducibility of Hi-C loops was shown to be low at all resolutions; even lower than the 
reproducibility of TAD boundaries (Forcato et al. 2017).  
On the other hand, only 8-10% of eQTLs from one eQTL benchmarking dataset was present in the 
second one (an overlap between GTEx and Westra eQTLS). Small reproducibility of eQTLs between 
samples and tissues has been a long recognized problem (Dimas et al. 2009). However, previous 
studies disagree about the underlying replication rate of eQTLs - for example, Innocenti et al. 
(2011) replicated 67% of the previously identified eQTLs from primary human liver tissue, whereas 
two independent sets of lymphoblastoid cell lines showed ~83% overlap in reported eQTLs (Ding 
et al. 2010). Two sets of eQTLs that are originating from two tissues showed much lower 
reproducibility rate: 8.1% of the eQTLS from the prostate was confirmed by eQTLs identified in 
blood (Larson et al. 2015), 25% of local, and presumably, cis-acting eQTLs were found to be shared 
between blood (PBMCs) and brain (Dimas et al. 2008), and ~30% eQTLs are shared between blood 
and adipose (Dixon et al. 2007). Thus, a discrepancy between two sets of eQTLs can be caused by 
the fact that GTEx eQTLs were tested across 44 tissues, whereas in Westra et al 2013 gene 
expression intensities were measured exclusively in the whole blood samples. However, we did 
not expand our search by including all other SNPs that are in high LD with the index SNP - this 
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could lead to higher reproducibility rate of eQTLs. Nonetheless, such a low reproducibility of 
benchmark datasets opened a question, which, if any, of the aforementioned datasets should be 
used for benchmarking. With that in mind, we benchmarked seven sets of enhancer-gene 
associations, and vice-versa tested which eQTLs and chromatin interactions can be confirmed by 
EGAs. 
 ..... 
As expected (due to their discern properties), EGAs from all seven sets of analyzed EGAs (JEME, 
GeneHancer, EnhancerAtlas, FOCS, inhouseM, stringentC and flexibleC) were diversely covered by 
eQTL-eGene pairs (eQTLs) and chromatin interactions. In general, GeneHancer EGAs showed the 
highest percentage of coverage by both eQTLs and chromatin interactions across all benchmark 
datasets. This did not surprise us because Fishilevich et al. (2017) used eQTLs form the GTEx 
database (GTEx Consortium et al. 2017) and CHiC datasets (Mifsud et al. 2015) as an input data, 
e.g. one of the methods to map cis-regulatory interactions. Likewise, JEME EGAs had the second 
highest overlap percentage with eQTL datasets. Again, Cao et al. 2017 “trained multiple enhancer–
TSS pairs based on ‘gold standard’ answers defined by a set of validation data (ChIA-PET, Hi-C or 
eQTL)”. Thus, since JEME and GeneHancer used eQTLs and chromatin interactions to train their 
models, the result of the benchmarking procedure with those two datasets was likely biased and 
did not reflect the true situation. On the other hand, both eQTLs studies had the highest positive 
predictive values when EnhancerAtlas EGAs were used as a test dataset. Again, EnhanerAtlas 
enhancers were defined using the information about eQTLs, so it was not surprising that eQTLs 
were enriched among EnhancerAtlas data. Nonetheless, the highest percentage of overlaps with 
EnhancerAtlas could be also a result of the size of the benchmark dataset and the length of their 
anchors. For example, EnhancerAtlas anchors were up to 1Mb long and with this resolution it is 
hard to precisely identify interactions between regions that are usually in the order of a few 
hundred base pairs (Park 2009). In addition, both sources of chromatin interactions - the CCSI 
database and PC-HiC - had the highest positive predictive values when GeneHancer EGAs were 
used as a test datasets and as previously mentioned Fishilevich et al. (2017) used  CHiC datasets 
from Mifsud et al. (2015) to predict EGAs. We expect that benchmarking results are biased for 
flexibleC and stringentC models as well, because they represent a consensus of five different sets 
of enhancer-gene associations (EGAs), including the GeneHancer and JEME. Therefore, flexibleC 
and stringentC models indirectly used the GTEx eQTLs and chromatin interactions as an input 
dataset to predict EGAs. This discrepancy was especially obvious when three inhouse datasets 
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were compared together: inhouseM (results of the reg2gene modelling of gene expression ~ 
enhancer activity) had consistently lower percentage of overlaps with tested benchmark datasets 
as compared to stringentC and flexibleC EGAs - sets of EGAs that represent a consensus between 
five different EGAs datasets including reg2gene inhouseM EGAs and which indirectly used eQTLs 
and chromatin interactions for their predictions. The rank of stringentC and flexibleC EGAs 
changed as different benchmark sets were utilized. Thus, it seems that only the result of the 
benchmarking procedure for FOCS EGAs was potentially unbiased in this analysis.  
..... 
Overall, we showed that, due to technical and biological limitations, benchmark datasets used in 
this analysis suffer from poor reproducibility. In addition, results of the benchmarking procedure 
are likely biased since eQTLs and chromatin interactions were initially used in most of the 
computational algorithms to predict enhancer-gene associations (EGAs). To account for this, we 
used 470 high-confidence cis enhancer-gene interactions assessed by cell-based CRISPR/Cas9 
genetic screen from Gasperini et al. (2019) as a set of “positives” and considered predicted cis 
enhancer-gene interactions to represent true positives (TP), and unpredicted - false negatives 
(FN). In addition, we proposed an approach that searches for enhancer-gene “negatives” and 
assesses false positive (FP) and true negative (TN) EGAs. A proposed approach identified enhancer 
regions that were across all 127 cell types from the Roadmap Consortium (Roadmap Epigenomics 
Consortium et al. 2015)  predicted by ChromHMM to be one of the repressed chromatin states 
(Ernst and Kellis 2012) and assumed that all corresponding enhancer-gene pairs should not be 
statistically associated. Overall, this enabled us, for the first time, to fully assess the performance 
of computational methods and assess all the elements of the confusion matrix: false positives (FP), 
false negatives (FN), true negatives (TN) and true positives (TP). Although stringentC had the 
smallest number of true positives (TP=45), it did not predict any FP. On the other hand, ~1,600 
GeneHancer enhancer-gene associations were actually false positives, as well as ~36,000 
EnhancerAtlas FP enhancer-gene associations. Strikingly, across all methods, stringentC and 
flexibleC had PPV over 0.9, but only stringentC reached the highest PPV of 1. Since stringentC and 
flexibleC models are actually ensemble classifiers of five different models of enhancer-gene 
associations (JEME (Cao et al. 2017), GeneHancer (Fishilevich et al. 2017), EnhancerAtlas 2.0 (Gao 
et al. 2016), FOCS (Hait et al. 2018), and reg2gene inhouseM), and we showed that they indeed 
predict more stringent EG associations, we corroborated the previous idea that the an ensemble 
classifier can be used to combine the classification rules of multiple classifiers to narrow down the 
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hypothesis space (Yang et al. 2010). We suspect that with this voting procedure, we “eliminated” 
all publication-specific enhancer-gene associations and retained only the robust ones. In addition, 
a difference in PPV between stringentC and flexibleC models indicated that more stringent voting 
procedure (more votes) predicted more precise results.  
Nonetheless, because of the fact that reg2gene models used Roadmap datasets as an input, 
benchmarking using ChromHMM-predicted “negatives” from the Roadmap datasets could be, 
similar to benchmarking with eQTLs and chromatin interactions, biased. If that would be the case, 
JEME and FOCS, should have much higher PPV since Cao et al. (2017) and Hait et al. (2018) used 
Roadmap datasets as well to train their models. However, that was not the case. Thus, we suggest 
that, based on the currently available data, stringentC models are currently the most stringent set 
of computationally modelled enhancer-gene associations. In the future, when larger sets of 
experimentally validated true positive and true negative E-G pairs will be available, this can be a 
subject of further analysis.  
 
5.5. Conclusions 
A large set of experimentally validated true positive and true negative ETG pairs still lacks in the 
field of genomics. Nonetheless, stringentC is an interesting source dataset whose predictions are 
more precise and stringent than predictions of JEME (Cao et al. 2017), GeneHancer (Fishilevich et 
al. 2017), EnhancerAtlas 2.0 (Gao et al. 2016), FOCS (Hait et al. 2018) and it can be used to, for 
example, annotate non-coding SNPs to genes they regulate. This will be investigated in the last 






Results IV - Application of enhancer-gene 
associations in disease genetics: Stories of the 




In this chapter, I used sets of predicted enhancer-gene associations to link non-coding 
polymorphisms to their putative causal genes. I was intrinsically motivated to perform this 
analysis. 
Abstract 
The assignment of non-coding risk SNPs to their target genes is not straightforward and it has been 
commonly approximated by linking SNPs to their proximal or eQTLs-associated genes. Here, we 
used enhancer-gene associations (EGAs) to annotate risk SNPs to their target genes by simply 
assigning SNPs to the genes associated with SNP-overlapping enhancers. We annotated three sets 
of non-coding SNPS: risk SNPs reported in the GWAS Catalog, colorectal cancer (CRC) associated 
SNPs and the rs10411210 with seven sets of enhancer-gene associations: JEME (Cao et al. 2017), 
GeneHancer (Fishilevich et al. 2017), EnhancerAtlas 2.0 (Gao et al. 2016), FOCS (Hait et al. 2018), 
stringentC, flexibleC and inhouseM.  
We identified that sets of annotated genes varied in their size - for example, using the 
EnhancerAtlas EGAs we associated ~400 genes to 312 colorectal cancer polymorphisms reported 
in the GWAS Catalog.  On the other hand, the stringentC method predicted only 14 CRC genes, 
however, 65% of them were previously identified to be associated with the CRC. Likewise, results 
of downstream and functional analyses differed when SNPs were annotated to genes using 
different sets of EGAs. We analyzed a single SNP - rs10411210 - and identified that it could be 
annotated to 1-8 genes (and 18 EGAs). Likewise, some well-known CRC genes were identified by 
only certain sets of EGAs. Altogether, this suggested that we cannot easily assert one EGAs method 
to be a better source of predictions than others, since each of them can potentially add a piece of 
information needed to improve our understanding of genetic susceptibility.  In addition, we showed 
that EGAs predict genes that were not previously reported for CRC, but were reported for some of 
the CRC-ancestral diseases. In addition, we show that EGAs can be potentially useful to identify 
novel SNP-gene associations, perform functional analysis of the underlying enhancer regions, and 





Thousands of genomic polymorphisms have been statistically associated with human phenotypes 
and diseases through the genome-wide association studies (GWAS; Hindorff et al. 2009). The 
precise molecular mechanisms by which those polymorphisms exert their effects remains mostly 
unknown (Pickrell 2014), especially since the great majority of non-coding SNPs does not directly 
change the gene function or level of its products. Thus, non-coding risk SNPs are considered to 
modulate disease etiology by causing changes in the gene expression of a critical gene 
(Gerasimova et al. 2013).  
The importance of enhancers in disease etiology, especially cancer genomics, was long under-
estimated (Rheinbay et al. 2017; Chen et al. 2018). Putative causal genes were commonly 
annotated to SNPs based on their proximity to genes (Welter et al. 2014) and/or overlap with 
eQTLs (GTEx Consortium et al. 2017). As the role of enhancers in genetic susceptibility to various 
human traits and diseases became more evident (Smith and Shilatifard 2014; Chen et al. 2018), 
SNPs started to be more frequently annotated to their putative causal genes based on the overlap 
with regulatory regions (Styrkarsdottir et al. 2018; Short et al. 2018; Zhang et al. 2018; Schork et 
al. 2019). However, due to an ever-growing number of approaches developed to estimate 
enhancer-gene associations and/or sources of putative EGAs, researchers have been flooded by 
immense amounts of available information. For example, several methods that integrate 
epigenetic and genetic information have been developed: RegulomeDB (Boyle et al. 2012), 
HaploReg (Ward and Kellis 2012), FunciSNP (Coetzee et al. 2012), GWAS3D (Li et al. 2013), 
rSNPBase (Guo et al. 2014); and multiple databases such as EnhancerAtlas (Gao et al. 2016), JEME 
(Cao et al. 2017), GeneHancer (Fishilevich et al. 2017) can be used to annotate SNPs.  
 
Nonetheless, guidelines on how to make choices while running the GWAS downstream analyses 
do not exist now. There are no recommendations that describe which source of data is relevant 
for a specific disease or SNPs context. In addition, a systematic review that compares all sources 
of information in the context of GWAS was never conducted. In this chapter, I set my focus on 
reviewing the performance of various EGAs methods to annotate risk polymorphisms from the 




6.2.1. The intuition behind the hierarchical SNP annotation protocol  
I annotated SNPs to putative genes hierarchically. Each SNP was first tested for the overlap with 
the promoter region. SNP was annotated to the nearest gene if an overlap with promoter region 
(+/-1000bp from the TSS) was identified. The remaining genes were tested for the overlap with 
enhancer regions, and annotated to the enhancer-associated gene. Lastly, genes remaining from 
the second step were assigned to the nearest gene within 1Mb distance. This procedure was 
repeated separately for each set of EGAs (Figure 6.1.). 
 
Figure 6.1. Schematic representation of the hierarchical SNP annotation protocol: in step 1, promoter-overlapping 
SNP is annotated to the nearest gene. Else, in step 2, enhancer-overlapping SNP is annotated to the enhancer-





6.2.2. An overview of used datasets 
As a source of information of disease associated genetic polymorphisms, I selected two databases: 
the GWAS Catalog (Welter et al., 2014) and DisGeNET database (Piñero et al., 2017). 
The GWAS Catalog 
The GWAS Catalog (Welter et al., 2014) is a free online database that compiles unstructured data 
of genome-wide association studies and summarizes it into easily accessible high quality data. 
DisGeNET   
DisGeNET database is one of the largest publicly available collections of genes and variants 
associated with human diseases (Piñero et al., 2017). In July 2019, it contained 310,502 unique 
entries (after I excluded all associations reported in the GWAS Catalog or GWASDB) with 10,012 
genes and 20,607 diseases. 
Benchmarking datasets 
As “CRC benchmark” gene sets, we selected three sets of CRC genes reported in the literature:  
1) 63 CRC genes reported in the most comprehensive review of genetic susceptibility to 
colorectal cancer (Peters et al., 2015), 
2) 1,676 genes reported in the DisGeNET database (Piñero et al., 2017) - one of the largest 
and comprehensive collections of human gene-disease associations - to be associated 
with colorectal cancer, and  
3) 2,096 genes from the DisGeNET database that were associated either with colorectal 
cancer or any ancestral disease to CRC: intestinal cancer, carcinoma, cancer, neoplasm. I 






6.3.1. The GWAS Catalog in numbers 
In February 2019, the GWAS Catalog contained 61,574 unique, non-coding SNP-disease 
associations (corresponding to 17,724 genes and 2,980 traits/diseases). The highest number of 
polymorphisms was reported for blood protein levels (N=2,334). Schizophrenia and breast cancer 
were associated with the highest number of non-coding polymorphisms (N=956 and N=755, 
Figure 6.2.).  
  
Figure 6.2. Histogram of a number of non-coding genetic polymorphisms (SNPs) reported per individual disease in 
the GWAS Catalog. GWAS reported traits (not diseases) were excluded from this figure.   
 
 
We determined the nearest gene for each GWAS SNP and included only those genes that were 
located +/- 1Mb around the SNP position. We obtained a list of 18,003 genes (I did not manage to 
annotate only 47 SNPs). With this procedure we identified that 42.4% of the GWAS genes 
(reported or mapped) corresponds to the nearest gene and 38% of entries do not have reported 
gene associations - SNPs were associated with either “intergenic”/“genic” regions or reported to 
have unknown gene association (NR).  
To analyze putative differences that could result when SNP-gene links would be assessed using 
different sets of EGAs, we performed SNP annotations using seven sets of EGAs: EnhancerAtlas 
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(Gao et al. 2016), JEME (Cao et al. 2017), GeneHancer (Fishilevich et al. 2017), FOCS (Hait et al. 
2018), stringentC, flexibleC and inhouseM. First, we excluded 3,661 GWAS Catalog SNPs that 
overlapped with promoter regions, and thus, were annotated to the promoter-regulating genes. 
This number of associations corresponds to 0.8% of the total SNP-gene associations assessed using 
EnhancerAtlas, or 4% and 4.1% of associations assessed using the stringentC models or FOCS 
(Figure 6.3.).  
  
Figure 6.3. Percentage and number of the GWAS Catalog SNPs annotated to genes. Different colors separate SNPs 
that were annotated to genes based on the overlap with promoter, enhancers or minimal distance to the nearest 
gene. Percentages of overlap in each category can be seen on the x-axis. Reported numbers correspond to the total 
number of GWAS SNPs that were annotated in each of the three categories (reported numbers should be multiplied 
with one thousand to get the true number). For example, a total of 3,661 SNP was annotated based on the overlap 
with promoters (N=3.7), which corresponds to 0.8% of EnhancerAtlas-based SNP annotations. On the other hand, 
388,702 EnhancerAtlas-based SNP annotations (or 89.1%) were done based on overlap with EnhancerAtlas 
enhancers. Seven sets of enhancer-gene associations used to annotate GWAS SNPs are indicated on the y-axis. 
 
6.3.2. Results of the SNP-to-gene annotation analysis differ if distinct enhancer-gene 
associations (EGAs) are used to annotate SNPs - the GWAS Catalog 
In the next step, we exclusively focused on non-coding SNP annotations. More than 89% 
(N=388,702) of SNP-gene associations could be assessed based on the overlap between SNPs and 
EnhancerAtlas enhancer regions. This corresponded to a four-time increase in the number of SNP-
gene(s)-disease associations as compared to the original GWAS Catalog (Figure 6.4., 
Supplementary Table 3.). Likewise, the initial 61,574 GWAS Catalog SNP-gene(s)-disease 




Figure 6.4. Histogram of the general statistics of the GWAS Catalog SNP annotation analysis based on seven enhancer-
gene association (EGA) sets:  JEME (Cao et al., 2017), GeneHancer (Fishilevich et al., 2017), EnhancerAtlas (Gao et al., 
2016), FOCS (Hait et al., 2018), stringentC, flexibleC and inhouseM. Histograms indicate numbers of SNPs, genes and 
EGAs that were assessed in the annotation procedure. Largest EGA datasets consistently annotated largest numbers 
of SNPs, genes and EGAs. For example, using GeneHancer EGAs GWAS Catalog SNPs were associated with ~25K 
enhancers, and ~75K enhancer-gene associations   
However, the number of gene-disease pairs decreased for other annotations: using the flexibleC 
we managed to annotate 14,857 SNPs (15%), whereas using the stringentC EGAs we linked 4,756 
SNPs with genes via overlap with their enhancers (5.2%). Only 3,535 entries from the GWAS 
Catalog overlapped FOCS enhancers.  
For each EGA method, we identified a reduction in the number of enhancers as compared to SNP, 
which implied that multiple SNPs overlapped a single enhancer. For example, 10,487 GeneHancer-
annotated GWAS Catalog SNPs overlapped 8,601 enhancers. However, for EnhancerAtlas we 
observed the opposite trend, SNPs were commonly annotated to more than one enhancer: 27,769 
EnhancerAtlas-annotated GWAS Catalog SNPs overlapped 70,718 enhancers (Supplementary 
table 3.).  
6.3.3. Results of the SNP-to-gene annotation analysis differ if distinct enhancer-gene 
associations (EGAs) are used to annotate SNPs - colorectal cancer and rs10411210 
As we confirmed our expectation that results of the SNP-to-gene annotation analysis differ if 
distinct enhancer-gene associations (EGAs) are used to annotate SNPs from the GWAS Catalog, 
we tested whether that holds true in smaller samples of risk-associated SNPs. First, we annotated 
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colorectal cancer (CRC) associated SNPs with seven sets of EGAs. Importantly, colorectal cancer 
has been a subject of an extensive research in our lab (Ronen et al., 2019). It has a large genetic 
component - heritable factors contribute to around 35% of the variation in risk of developing CRC 
(Jiao et al., 2014), genes and pathways that are important for initiation and progression of 
colorectal cancer were previously identified (Fearon, 2011; Ronen et al., 2019), and some of the 
associated genetic polymorphisms were confirmed experimentally (Goss and Groden, 2000). In 
addition, the majority of genetic variation that conveys the risk of CRC is located in non-coding 






Figure 6.5. Histogram of the number of gene sets that were found to be associated with colorectal cancer SNP. 
Analysis was based on the annotation of 312 CRC SNPs reported in the GWAS Catalog using an overlap between SNPs 
and enhancers from seven enhancer-gene association sets (details of analysis explained above). Number of genes 
associated with the GWAS Catalog was reported as well. 
 
 
We annotated 312 colorectal cancer polymorphisms reported in the GWAS Catalog (Welter et al., 
2014). Although 381 CRC genes were reported in the GWAS Catalog, the largest EGA dataset - 
EnhancerAtlas - identified the largest number of entries: EnhancerAtlas predicted up to 386 CRC 
genes, GeneHancer around 200, whereas the flexibleC identified 48 CRC genes and stringentC 
method predicted only 14 CRC genes (Figure 6.5., Supplementary Table 4).  
We additionally performed the pairwise comparison of CRC annotated gene sets and identified 
that the two largest datasets: EnhancerAtlas and GeneHancer had the largest gene overlap (Figure 
6.6.). On the other hand, as the stringentC method represents a consensus of different EGA 
methods, gene set predicted with this method had the highest percentage overlap with other sets 




Figure 6.6. Heatmap of the pairwise gene overlap between CRC-associated sets of genes. Associations were identified 
based on the overlap between CRC-reported SNPs and enhancers from seven enhancer-gene association sets: 
EnhancerAtlas (N=386, Gao et al. 2016), JEME (N=146, Cao et al. 2017), GeneHancer (N=200, Fishilevich et al. 2017), 
FOCS (N=16, Hait et al. 2018), stringentC, flexibleC and inhouseM. In addition, CRC genes from the GWAS Catalog 
(N=381) and genes nearest to the SNP were reported (N=277).  
A total of 16 genes was confirmed by more than 3 sets of EGAs, but all seven methods agreed 
upon CRC association for only two genes: RHPN2 and SERPINH1. Genes such as RPS3, KLF13 or 
GDPD5 were not associated with CRC only when FOCS EGAs were used as a source of information 




Figure 6.7. Presence of absence of a specific gene in a set of CRC-associated genes as assessed by seven different 
methods (x-axis). Red color marks the presence of a gene, whereas white marks its absence from the  analyzed set.  
Only association of RHPN2 and SERPINH1 genes were corroborated across all sets of EGAs 
 
 
Next, we selected one of the CRC-associated non-coding SNPs - rs10411210 - and annotated it 
with seven sets of EGAs (Figure 6.8.). Three fundamental pieces of information motivated us to 
study rs10411210. First, intronic enhancers were commonly found to be engaged in the long-
range gene interactions with distant genes (Pomerantz et al. 2009; Harismendy et al. 2011; 
Maurano et al. 2012; Smemo et al. 2014). Second, along with cancer-associated genes, clusters of 
aberrantly active gene enhancers that drive dysregulated expression of oncogenes were 
previously identified in many cancer types (Sur and Taipale 2016). Third, its link to a region with 
regulatory potential was previously suggested and enhancer-correlated histone modifications 
were enriched at the 19q13.1 locus (Carvajal-Carmona et al. 2011). However, the previous 
bioinformatics analysis, which systematically searched for enhancer elements at this loci, was 
unable to pinpoint the cancer-causing element (Niittymäki et al. 2011).  
 
Figure 6.8. General statistics describing enhancer and gene annotations identified for the rs10411210 SNP. SNP 
annotations were obtained using seven sources of enhancer-gene association sets: EnhancerAtlas (Gao et al. 2016), 
JEME (Cao et al. 2017), GeneHancer (Fishilevich et al. 2017), FOCS (Hait et al. 2018), stringentC, flexibleC and inhouseM 
by overlapping rs10411210 with enhancer regions. For example, eleven EnhancerAtlas enhancers, five genes and 18 
EG pairs overlapped rs10411210.  
In general, we identified eleven enhancer regions that were associated with rs10411210 when 
annotations were assessed using EnhancerAtlas EGAs. Those enhancers were paired with five 
genes and participated in 18 EnhancerAtlas enhance-gene associations (Figure 6.9., 
Supplementary Table 5). Other methods (except for GeneHancer and JEME) annotated 
rs10411210 to more than one enhancer as well. stringentC annotated one gene to two enhancer 
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regions: one larger - chr19:33531704-33533702 (1999bp) and one shorter 439 bp 
(chr19:33532126-33532564) which we further researched in detail.    
 
Figure 6.9. A visual representation of the results that were obtained by annotating a single SNP - rs10411210 - using 
enhancer-gene association from seven publications/methods and eQTLs from Westra et al. 2013 and the GTEx 
database (GTEx Consortium et al. 2017). From one to eight genes were annotated to this SNP by overlapping it with 
enhancer regions.  Seven sources of enhancer-gene association sets were: EA - EnhancerAtlas (Gao et al. 2016), JEME 
(Cao et al. 2017), GH - GeneHancer (Fishilevich et al. 2017), FOCS (Hait et al. 2018), Str - stringentC, Flex - flexibleC 
and IHM - inhouseM. 
In the previous studies, rs10411210 was directly annotated to the RHPN2 gene due to its location 
in the intronic region of this gene (COGENT Study et al. 2008, Carvajal-Carmona et al. 2011, 
Niittymäki et al. 2011). All seven methods confirmed this association as well (Figure 6.10., 
Supplementary Table 6).  
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However, we linked rs10411210 with 17 (16) other genes: CEP89, ANKRD27, PEPD, NUDT19, 
SLC7A9, GPATCH1, FAAP24, ZNF507, PDCD5, CTD-2085J24.3, CTD-2540B15.9, CEBPG, CTD-
2540B15.12, C19orf40, WDR88, LRP3, SLC7A10. Although FAAP24 and C19orf40 actually represent 
the same gene (rs10411210 was annotated to FAAP24 by GeneHancer, whereas rs10411210 -
C19orf40 link was reported by JEME), this association was missed by the flexibleC EGAs. This 
indicated it as a limitation of our annotation method.  
 
Figure 6.10. Presence of absence of a specific gene in a set of rs10411210-associated genes assessed by seven different 
methods (rows). Red color marks the presence of a gene, whereas white marks its absence from the analyzed set. 
Only association of the RHPN2 gene and rs10411210 is corroborated across gene sets 
 
Other SNP-gene associations were rarely agreed upon. For example, SLC7A9 was confirmed only 
by JEME, inhouseM and flexibleC EGAs, whereas CEP89 was identified by EnhancerAtlas, 
GeneHancer and JEME. If GeneHancer EGAs would not be taken in consideration, we would miss 
association between CRC and PDCD5, whereas GPATCH1-CRC association was missed for 
inhouseM and EnhancerAtlas annotations.  
 
All except for one association (chr19:33529636-33535923-ZNF507 from the GeneHancer 
database) were located within the same TAD region in the bowel cells (Dixon et al., 2012).  
 
  
Since rs10411210 is only an index SNP - SNP assigned with the highest association significance 
with colorectal cancer in the underlying association study - we decided to identify which additional 
genes would be assigned to CRC if all SNPs in a haplotype block ∼chr19:38 168 000–38 364 000 
that contains rs10411210  itself would be analyzed (Carvajal-Carmona et al., 2011). We identified 
21 SNPs that are in R2=0.8 LD with rs10411210 and successfully annotated 16 with all seven 
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sources of EGAs (Supplementary Table 7.). As a result, we expanded the list of potential gene 
targets with six additional genes: KCTD15, CTD-2540B15.7, AC007773.2, CTD-2085J24.4, 
RN7SKP22, DPY19L3. 
 
6.3.4. Results of the enrichment analysis differ if distinct enhancer-gene associations 
(EGAs) are used to annotate SNPs  
Since we showed that results of the SNP-to-gene annotation analysis differ if distinct enhancer-
gene associations (EGAs) are used to annotate risk SNPs, we further analyzed characteristics of 
identified sets of genes.  
We performed the enrichment analysis of seven sets of CRC genes and obtained information for: 
molecular function, cellular component, biological process, human phenotype ontology, OMIM 
reported diseases (Kanehisa, 2002) and gene enrichment in the KEGG (Croft et al., 2011), 
Reactome (Hamosh et al., 2000), and PANTHER (Mi et al., 2013) pathways.  
 




Figure 6.11: Results of enrichment analysis for genes annotated to CRC SNPs. A. Results of the enrichment analysis 
(OMIM database) for 200 CRC genes annotated using GeneHancer EGAs. B. Results of the enrichment analysis 
(PANTHER pathways) for 146 CRC genes annotated using JEME EGAS. ARVD=Arrhythmogenic Right Ventricular 
Dysplasia (ARVD), IBD=inflammatory bowel disease. 
 
 
As expected, gene sets showed enrichment for different pathways, phenotypes and diseases. For 
example, GeneHancer-annotated CRC genes showed the enrichment for colorectal cancer genes 
reported in the OMIM database (Figure 6.11.A) and well-defined CRC signaling pathways, TGFβ 
and Ras in PANTHER pathways (Supplementary Figure 5.). HPO (human phenotype ontology) did 
not indicate any enrichment for CRC, but did for sacral dimple, or abnormality of liposaccharide 
metabolism. Interestingly, JEME-annotated CRC genes were enriched for all previously identified 
CRC pathways (Wnt, PI3K-mTOR, Ras-ERK (MAPK), p53) in the PANTHER pathways database 
(Figure 6.11.B). On the other hand, the same set of genes was enriched in prostate cancer genes 
in OMIM and prostate neoplasm genes in HPO (Supplementary Figure 5.). Analysis of 
EnhancerAtlas-annotated CRC genes identified enrichments for cardiomyopathies (HPO, OMIM), 
phospholipid traits (GO_BP, biological processes) and RNA PolII activity (GO_MF, molecular 
function), whereas, stringentC gene sets showed enrichment for inositol-1,3,4,5-
tetrakisphosphate-5-phosphatase activity, PI3K regulatory subunit binding, etc. (Supplementary 
Figure 5.). 
 
6.3.5. Up to one fifth of the newly annotated CRC genes could be easily benchmarked 
Next, we set off to benchmark results of the SNP-to-gene annotation analysis specifically for 
colorectal cancer associated SNPs. To achieve that we used three “benchmark” datasets: CRC 
genes reported in Peters et al., (2015) and DisGeNET database (Piñero et al., 2017), and genes in 
the DisGeNET database that are associated with CRC, intestinal cancer, carcinoma, cancer and 
neoplasm (DisGeNET_A). 
Importantly, Peters et al. (2015) conducted the most comprehensive review of genetic 
susceptibility to colorectal cancer genes in which all genes previously associated with CRC were 
reported. The intuition behind defining the third benchmark dataset - DisGeNET_A - was to include 
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genes that have not yet been associated with CRC, but could likely be in the future. We 
hypothesized that some of the unknown CRC genes were associated with non-CRC diseases 
through GWASes and the majority of them, if truly associated with CRC, should be associated with 
CRC related-phenotypes such as the intestinal cancer, carcinoma, cancer, neoplasm.  
We identified that EnhancerAtlas annotated CRC genes had the highest overlap with the CRC 
genes reported in the DisGeNET database (N=37/386). We could additionally link 11 genes with 
the CRC related-phenotypes in the DisGeNET database - previously, those 11 genes were not 
directly associated with CRC.  (Figure 6.12., Supplementary Tables 8. and 9.).  
  
Figure 6.12. Histogram of the number of overlaps between three CRC benchmark gene sets and seven CRC gene sets 
that were identified by SNP-to-gene annotation procedure. Benchmark CRC gene sets correspond to: 1) DisGeNET - 
1,676 CRC genes reported in the DisGeNET database, 2) DisGeNET_A - 2,096 genes from the DisGeNET database 
associated with colorectal cancer, intestinal cancer, carcinoma, cancer, neoplasm and 3) Published - 63 CRC genes 
reported in Peters et al. 2015. Seven CRC gene sets were assessed based on SNP-to-gene annotation procedure using 
EGA reported in EnhancerAtlas (Gao et al. 2016), JEME (Cao et al. 2017), GeneHancer (Fishilevich et al. 2017), FOCS 
(Hait et al. 2018), stringentC, flexibleC and inhouseM. Importantly, only novel overlaps between sets of genes were 
reported for DisGeNET_A. For example,  GeneHancer-annotated CRC genes overlapped 21 DisGeNET genes (15 
DisGeNET and 6 DisGeNET_A CRC genes). 
 
 
GeneHancer-annotated CRC genes overlapped 21 DisGeNET genes (15 CRC DisGeNET and 6 
DisGeNET_A CRC genes). A total of 10 JEME genes overlapped DisGeNET genes (8 CRC and 2 
additional DisGeNET_A CRC genes), whereas 3 FOCS genes were identified in DisGeNET, but we 
did not identify any novel gene-CRC association using the DisGeNET_A set of genes (Figure 6.12.). 
From the 14 CRC stringentC-annotated genes two (DUSP10 and DVL1) overlapped CRC genes 
reported in DisGeNET  and two genes (DUSP10 and RHPN2) overlapped previously reported CRC 
genes (Peters et al., 2015). However, none of the identified genes associated with CRC was 
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additionally identified in the DisGeNET_A set of CRC genes (the same holds true for inhouseM and 
flexibleC gene sets). 
 
If percentages were taken into account, a maximum of 19% genes form a given dataset (FOCS 
EGAs) could be confirmed by CRC genes in the DisGeNET database. In the case of the stringentC-
annotated genes that corresponded to 14%, whereas 10% of the EnhancerAtlas CRC genes was 
benchmarked. 
 
6.3.6. 65% of CRC genes annotated using the stringentC EGAs was previously associated 
with the CRC  
 
We further focused on the smallest group of genes that were annotated to CRC SNPS - 14 genes 
identified using stringentC EGAs: DUSP10, MTHFSD, RHPN2, RS3, SERPINH1, GDPD5, KLF13, 
DCBLD1, GOPC, DIDO1, DVL1, FAM83B, PPP2R4, TOR1B.  
Of those, only the RHPN2 gene is a well-described gene associated with CRC and reported in the 
GWAS Catalog (He et al., 2015; Tenesa and Dunlop, 2009). Nonetheless, we identified that seven 
other reported genes were associated with CRC as well: DUSP10 (Png et al., 2016), RPS3 (Tang et 
al., 2019), DVL1 (Kho et al., 2009), GOPC (Terasaki et al., 2002), DCBLD1 (He et al., 2016; Kang et 
al., 2015), GDPD5 (Feng et al., 2018) and KLF. Two genes (DUSP10 and DVL1) were the CRC genes 
reported in the DisGeNET database and two genes (DUSP10 and RHPN2) overlapped CRC genes 
reported in (Peters et al., 2015). Majority of the remaining stringentC-annotated CRC genes were 
previously implicated in cancer: PPP2R4 in posterior fossa group B ependymoma (Xing et al., 
2006), FM83B in breast, lung, ovary, cervical, testis, thyroid, bladder, and lymphoid cancers 
(Cipriano et al., 2014), SERPINH1 in neuroblastoma, breast cancer progression, gastric and 
stomach cancer (Zhang et al., 2010); (Zhu et al., 2015), KLF13 in glioma (Wu et al., 2019), and 
DIDO1 in adenocarcinoma (Liu et al., 2010). MTHFSD was reported in the GWAS Catalog for 
FEV/FEC ratio and TOR1B for dystonia (Welter et al., 2014).  
We studied whether we could discern that some of the above SNP-gene associations could be 
more biologically relevant by analyzing their co-localization in the same TAD region. For this 
analysis, we were inspired by work of Symmons et al., (2014) - they identified that enhancers are 
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generally contained within the same TAD as genes they regulate, thus interacting more likely (with 
higher frequency) than if they are contained in different domains. We hypothesized that the “co-
localization” of SNPs (overlapping enhancers) and genes in the same TAD region could be used as 
the filtering feature to select the true SNP-gene associations: those that do not overlap the same 
TAD region are false positives, and those that are identified in the same TAD are true positives. 
We analyzed TAD regions reported in (Dixon et al., 2012; Nora et al., 2012, cells of the bowel 
tissue) and screened for the [SNP/enhancer]-gene pairs that were located within the same TAD 
region. Thirteen genes indeed were located in the same TAD region as their enhancer. However, 
DIDO1, PPP2R4 and TOR1B were not identified in the same TAD region as their SNP-overlapping 
enhancers (Table 6.1.). 
Table 6.1. Genes found to be annotated to twelve CRC-associated SNPs from the GWAS Catalog. Their association 
with specific phenotypes was indicated, as well as co-localization in the same TADs in the bowel tissue (Dixon et al., 
2012). 
Gene Associated phenotype Within TAD  
DUSP10 Colorectal tumorigenesis (Png et al., 2016) yes 
MTHFSD FEV/FEC ratio (MacNair et al., 2016; Shrine et al., 2019), plasma 
parathyroid hormone levels (Matana et al., 2018), amyotrophic lateral 
sclerosis (MacNair et al., 2016; Shrine et al., 2019) 
yes 
RHPN2 CRC-association report for rs10411210 (He et al., 2015; Tenesa and 
Dunlop, 2009)  
yes 
RPS3 Changes in gene expression in colon adenocarcinomas and 
adenomatous polyps compared to adjacent normal colonic mucosa 
(Tang et al., 2019)  and breast cancer (Ono et al., 2017) 
yes 
DIDO1 Esophageal adenocarcinoma (Ono et al., 2017) No 
PPP2R4 Posterior fossa group B ependymoma (Xing et al., 2006) No 
TOR1B Dystonia, autoimmune No 
FAM83B breast, lung, ovary, cervical, testis, thyroid, bladder, and lymphoid 
cancers (Cipriano et al.,2012; Cipriano et al., 2014; Okabe et al., 2015)  
yes 
DVL1 Wnt signal pathway in colorectal cancer  (Kho et al., 2009) yes 
GOPC prognostic marker in colorectal cancer (Terasaki et al., 2002), lung 
adenocarcinoma, angiosarcoma, etc. in the DisGeNET database 
(Piñero et al., 2017). 
yes 
DCBLD1 colorectal cancer (He et al., 2016; Kang et al., 2015), squamous cell yes 
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carcinoma, bile duct cancer, lung cancer, adenocarcinoma, uterine 
corpus endometrial carcinoma, etc. 
SERPINH1 neuroblastoma, breast cancer progression, gastric and stomach cancer 
(Zhang et al., 2010); (Zhu et al., 2015) 
yes 
KLF13 glioma (Wu et al., 2019), cholesterol biosynthesis and colorectal 
cancer development (Yao, 2019), prostate cancer (Wang et al., 2018) 
yes 






6.3.7. Enhancer-binding TFs and co-factors were previously reported in colorectal cancer   
 
We performed a more detailed analysis of rs10411210-to-gene annotation results to pinpoint the 
underlying biological mechanism of rs10411210 association with colorectal cancer. To achieve 
that we analyzed enhancer locations, transcription factor binding site (TFBS) motifs and CHiP-Seq 
signals for transcription factors. First, we compared locations and size of enhancers across 
methods (Figure 6.13.).  
 
Figure 6.13. A visual representation of results that were obtained by annotating a single SNP - rs10411210 - using nice 
different approaches: enhancer-gene association from seven publications/methods and eQTLs from Westra et al. 
2013 and the GTEx database (GTEx Consortium et al. 2017). From one to eight genes were annotated to this SNP by 
overlapping it with enhancer regions. Seven sources of enhancer-gene association sets were: EA - EnhancerAtlas (Gao 
et al. 2016), JEME (Cao et al. 2017), GH - GeneHancer (Fishilevich et al. 2017), FOCS (Hait et al. 2018), Str - stringentC, 
Flex - flexibleC and IHM - inhouseM. 
The size of enhancers varied from several hundred to several thousand base pairs: a maximum 
length of 8,031 bp was reported for EnhancerAtlas enhancers, whereas JEME and in-house models 
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report 345 and 439 bp enhancers. Thus, we could not precisely identify an enhancer location that 
conveyed the SNP-disease association. However, based on our previous knowledge about defined 
enhancer regions (stringentC enhancers are the most robust definition of enhancer regions), we 
decided to select and analyzed one enhancer region - chr19:33532126-33532564 - which 
corresponded to 439bp “consensus” enhancer region reported in stringentC models. For a given 
enhancer, we identified binding sites for cancer-associated TFs and TF-coactivators associated 
with colorectal cancer such as ATF3, CREB1, EP300 and STAT3 (Supplementary Table 10.). In 
addition, we identified TF binding motifs for CRC-related transcription factors: GATA2, SP1, STAT3, 
JUNB, SOX9, etc.   
Initial bioinformatics analysis failed to pinpoint the cancer-causing element at the 19q13.1 locus 
(Niittymäki et al. 2011), but subsequent efforts found HEY1, RXRA, FOSL2, JunD, P300 and 
BAF155 to bind strongly to the region encompassing rs10411210 (Carvajal-Carmona et al. 
2011). However, the identified CHiP-Seq peaks usually spanned more than 1kb in length as 
compared to the 439-bp regions identified in this research. In addition, it is well known that many 
cancer malignancies require oncogenic and/or tumor suppressor TFs for their survival, 
proliferation, and disease progression (Murakawa et al. 2016) and many oncogenic TFs and co-
factors were identified to be over-activated in colorectal cancer (Peters et al. 2015; Nagaraju and 
Bramhachari 2017).   
 
6.3.8. Path to follow: enhancer pleiotropy detection with SNP-enhancer-gene 
annotations  
By focusing our analysis to a single set of SNP-gene annotations (originated from stringentC 
models), we made few observations that could represent interesting avenues of future research. 
We selected stringentC-based annotations due to the fact that stringentC associations are based 
on the consensus enhancer definition, characterized by the highest positive predictive value and had 
the lowest number of predictions (Chapter 3). 
First, we observed that SNPs from various association studies can commonly overlap the same 
enhancer regions - LOXL1 was one of such genes (Figure 6.14.). LOXL1 was previously associated 
with multiple SNPs and phenotypes in the GWAS Catalog and with multiple enhancers (Welter et 
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al., 2014). Its association was reported for coronary artery disease, aortic root size, waist-hip ratio, 
joint mobility, hand grip strength, height, etc. (Supplementary Figure 6.).  
 
Figure 6.14. Visual representation of stringentC enhancers and GWAS Catalog SNPs that overlap with the LOXL1 gene. 
Three stringentC enhancer regions were found to be located in the intergenic regions of LOXL1 gene: E1 - 
chr15:74222688-74224043, E2 - chr15:74228665-7422857 and E3 - chr15:74233359-74235313. E1 overlaps with three 
GWAS Catalog SNPs associated with three different phenotypes: rs62004866 - hand grip strength, rs150025731 - joint 
mobility, rs28522673 - coronary artery disease. E2 regions overlap rs4886782 SNP associated with various waist 
circumference or BMI phenotypes. E3 enhancer and rs12441130 overlapping SNP is associated with heel bone mineral 
density  
Only five out of twelve LOXL1-associated SNPs reported in the GWAS Catalog overlapped the 
stringentC enhancers, and thus, could be annotated. Three of them (rs62004866, rs150025731, 
rs28522673) overlapped one enhancer region: chr15:74222688-74224043 (E1); whereas 
rs4886782 overlapped chr15:74228665-7422857 enhancer (E2) and rs12441130 chr15:74233359-
74235313 enhancer (E3). E1-overlapping SNPs were identified through three different association 
studies (GWAS): rs62004866 was associated with hand grip strength (Tikkanen et al., 2018),  
rs150025731 with joint mobility (Pickrell et al., 2016), and rs28522673 with coronary artery 
disease (van der Harst and Verweij, 2018), Supplementary Table 11.). Thus, this example 
confirmed that SNPs associated with different phenotypes can overlap a single enhancer region.  
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Second, we identified that annotating SNPs-to-genes via EGAs has the potential to reveal novel 
SNP-gene-(disease) associations. We hypothesized that if we identified one SNP-gene association 
that was missed by GWA studies (but later confirmed), we could identify many others as well. For 
example, using the stringentC enhancer-gene associations (EGAs) we identified gene targets for a 
total of 4,756 GWAS Catalog SNPs, but 1,285 of those entries had no gene association reported 
(in the GWAS Catalog coded as: intergenic, Intergenic or NR - not reported). In addition, a total of 
1,558 or 33% of interactions was confirmed by previously reported SNP-gene associations.  
Specifically, we identified LOXL1 association with rs12441130. This polymorphism was previously 
associated with the heel bone mineral density phenotype and its association with the LOXL1 gene 
was reported in the GWAS Catalog (Kim, 2018). Nonetheless, we additionally identified the 
rs12441130 association with the LOXL1-AS1 gene (Supplementary Figure 7.), which was not 
identified through the GWA studies, but was recently confirmed by Pasutto et al., (2017). This 




Thousands of risk-associated, mostly non-coding, polymorphisms have been identified in the 
human genome (Welter et al. 2014). Only a handful of them have been functionally characterized 
or mechanistically linked to phenotypes (Frazer et al. 2009). Non-coding variants were shown to 
cause common diseases more likely than non-synonymous coding variants (Manolio et al. 2008) 
and they account for the vast majority of heritability (Gusev et al. 2014), however, their precise 
gene targets and the molecular mechanisms by which they exert their effects are mostly unknown 
(Pickrell 2014; Welter et al. 2014). Until today, risk SNPs have been generally annotated to their 
putative causal genes based on their proximity to gene targets (Welter et al. 2014) or by using 
information from the eQTL studies (GTEx Consortium et al. 2017). Consequently, more than 40% 
of genes reported (or mapped) in the GWAS Catalog correspond to genes that are closest to their 
risk SNPs (our in-house analysis).  
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Recently, the role of enhancers in genetic susceptibility to various human traits and diseases 
became more evident (Smith and Shilatifard 2014; Chen et al. 2018) and researchers started to 
annotate non-coding SNPs using information about enhancer-gene associations (EGAs) 
(Styrkarsdottir et al. 2018; Short et al. 2018; Zhang et al. 2018; Schork et al. 2019). Multiple sources 
of EGAs have been reported, however, we do not know if and how different sources of information 
influence results of annotation. To get a better understanding of this topic we annotated three 
sets of risk SNPs using seven sets of enhancer-gene associations: EnhancerAtlas (Gao et al. 2016), 
JEME (Cao et al. 2017), GeneHancer (Fishilevich et al. 2017), FOCS (Hait et al. 2018) and our in-
house models: stringentC, flexibleC and inhouseM. We simply overlapped GWAS SNPs; SNPs 
associated with colorectal cancer and rs10411210 with sets of enhancers and linked them to 
corresponding enhancer-associated gene(s).  
We observed large differences in sets of genes annotated to all three sets of risk SNPs. Ten times 
more SNP-gene annotations would be observed if we used EnhancerAtlas EGAs as an annotation 
tool as compared to FOCS EGAs. This was likely a consequence of multi-gene SNP annotations - 
enhancers often regulate multiple genes (Maurano et al. 2012), and thus, more than one gene 
could be (and was) annotated to the majority of analyzed SNPs and enhancers. In addition, 
multiple EnhancerAtlas enhancers frequently overlapped a single SNP - especially obvious in the 
case of rs10411210 and its eight overlapping enhancers. In case of other methods, the majority of 
risk SNPs was actually located outside of defined enhancer regions.  
We identified more than a ten-fold difference in the number of annotated genes across different 
EGA methods for 312 CRC SNPs and corroborated our previous findings for the GWAS Catalog. The 
largest set of enhancer-gene associations (EnhacerAtlas) identified the largest number of 
associated genes (~400). However, pairwise analysis of CRC-associated sets of genes did not show 
that any two sets of genes had a discernibly better overlap, although we did identify that all seven 
EGA annotations linked CRC SNPs with RHPN2 and SERPINH1. RHPN2 is a well-known gene 
associated with CRC (Tenesa and Dunlop 2009; He et al. 2015), whereas expression of SERPINH1, 
also known as heat shock protein 47 (HSP47), in colorectal cancer tissue was found to be 
significantly higher than in adjacent normal colonic mucosa (Mori et al. 2017).  
Likewise, we identified differences between gene sets annotated to a single SNP - rs10411210. 
The  link between rs10411210 and enhancer region was previously suggested (Carvajal-Carmona 
et al. 2011), but rs10411210 was consistently annotated to the RHPN2 gene (COGENT Study et al. 
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2008, Carvajal-Carmona et al. 2011, Niittymäki et al. 2011). We delineated 16 linked genes linked 
to this SNP, but only RHPN2 was confirmed by all methods. Other genes, such as GPATCH1 and 
CEP89 (identified by JEME), were previously reported for colorectal cancer; whereas PDCD5 and 
CEBPG genes were linked with either colorectal cancer or some other type of carcinoma in 
DISGENET or GWAS Catalog. Cohen et al. (2017) assessed GPATCH1 gene as a putative gene target 
for a recurrently gained variant enhancer loci that overlaps with rs10411210. Murakawa et al. 
(2016) reported that enhancers covering rs10411210 target the CEP89 gene. Likewise, ANKRD27, 
SLC7A10, SLC7A9, WDR88, ZNF507 were identified to be associated with cancer in the COSMIC 
database - the largest and most comprehensive resource for exploring the impact of somatic 
mutations in human cancer (Forbes et al. 2011). Lastly, we identified an association between 
CEBPG, FAAP24 (C19orf40), LRP3, PDCD5 genes and cancer using an on-line text-mining tool - 
DISEASES (Pletscher-Frankild et al. 2015).  
 
Importantly, some known CRC genes were identified by only a certain set of EGAs. This suggested 
that we could not easily assert one EGAs method to be a better source of predictions than others 
could. Especially since each of them can potentially add a piece of information needed to improve 
our understanding of genetic susceptibility. We analyzed whether we can single out some of the 
identified EGAs by analyzing their co-localization within the same TAD. However, we identified 
that only one EG association did not colocalize in TADs from the bowel cells (Dixon et al. 2012). 
Thus, TAD colocalization of enhancers and genes does not seem to be the most discriminative 
approach to differentiate between true and false enhancer-gene associations. However, it would 
be interesting to include additional TADs from other cell types and analyze whether certain EGAs 
are differentially found outside or inside of TAD regions in healthy versus individuals with 
colorectal cancer.  
 
In addition, since rs10411210 is just an index GWAS SNP (COGENT Study et al. 2008, Zhang et al. 
2014) at the 19q13.q locus, we studied the overlapping haplotype block at ∼chr19:38 168 000–38 
364 000 (Carvajal-Carmona et al. 2011) and identified 21 SNPs and six additional genes that are in 
LD (R2=0.8) with this SNP. Two of them: DPY19L3 and KCTD15 are reported in the COSMIC 





We used enrichment analysis to highlight differences across CRC-associated gene sets and 
identified that different gene sets showed enrichment for different pathways, phenotypes or 
diseases. Interestingly, only JEME-annotated CRC genes were enriched for all CRC associated 
pathways: Wnt, PI3K-mTOR, Ras-ERK (MAPK), p53. Since JEME predictions were assessed using 
the eQTL datasets (Cao et al. 2017) and eQTLs are very abundant across many databases including 
frequently used to discover novel pathways (GTEx Consortium 2015), the pathway analysis and 
JEME EGAs were assessed based on the same set of data which likely biased our analysis.  
..... 
By benchmarking sets of CRC-gene association with three sources of CRC-related genes: genes 
reported in Peters et al. 2015, DisGeNET database (Piñero et al. 2017), and genes associated with 
CRC, intestinal cancer, carcinoma, cancer and neoplasm in the  DisGeNET  database, we could 
confirmed up to one fifth of the newly annotated CRC genes (FOCS EGAs). Expectedly, the number 
of benchmarked genes correlated with the size of the EGA datasets. If we expanded the 
benchmark dataset with genes that are associated with diseases with similar etiology such as 
intestinal cancer, carcinoma, cancer and neoplasm with colorectal cancer, we managed to 
additionally benchmark some of the associated genes that were confirmed with targeted 
literature research. For example, although only RHPN2 is a well-described gene associated with 
CRC, the majority of other genes that were associated with colorectal cancer using stringentC EGAs 
could be confirmed as well (Png et al. 2016, Kang et al. 2015, He et al. 2016, Feng et al. 2018, Tang 
et al. 2019). Genes that have never been associated with CRC (DIDO1, PPP2R4 and TOR1B) “broke” 
the TADs boundaries - they were located outside of defined TADs. This indicated the potential of 
the TAD co-localization information to discern putative SNP-gene associations and corroborated 
the observations of Symmons et al. (2014) that the great majority of the genes colocalizes with 
their regulatory regions.  
Using enhancer-gene associations reported in the stringentC models we identified some novel 
SNP-gene associations and opened novel avenues of our research. For example, we confirmed 
associations between rs12441130 and LOXL1 and LOXL1-AS1. The expression levels of LOXL1-E1A, 
LOXL1 and LOXL1-AS1 genes was shown to correlate with genotypes at the rs12441130 position 
and their  alternative splicing is affected in hTCF cell line (Pasutto et al. 2017). However, LOXL1-
AS1 - rs12441130 association represented a novelty (from the perspective of the GWAS Catalog). 
Thus, with this example, we demonstrated that many of the currently unknown annotations could 
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be discovered if the risk SNPs would be systematically analyzed in the light of the stringentC and 
other enhancer-gene associations.   
Lastly, we analyzed the scope of information that can be revealed by performing a functional 
analysis of a single enhancer region chr19:33532126-33532564. This region overlaps CRC-
associated SNP rs12441130. We identified a number of binding sites for cancer-associated TFs and 
TF-coactivators such as ATF3, CREB1, EP300 and STAT3 and the TF binding motifs for GATA2, SP1, 
STAT3, JUNB, SOX9, etc. Many of the aforementioned TF were associated with CRC: for example, 
SP1 is an important transcriptional regulator that plays a significant role in CRC initiation and 
metastasis (Bajpai and Nagaraju 2017). Reduced expression or overexpression of GATA 
transcription factors has been associated with CRC, whereas expression of the SOX9 gene was 
increased in CRC tissues compared with adjacent normal tissues (Lü et al. 2008). In vitro and in 
vivo studies showed that ATF3 promotes growth and metastasis of colon cancer tumors (Hackl et 
al. 2010) and AP-1 TF family members are differentially expressed in neoplastic and nonneoplastic 
colorectal tissues, whereas upregulation of Fra-1 and c-Jun represents an early event in human 
CRC tumorigenesis (Zhang et al. 2005). Nonetheless, additional experimental analyses should be 
performed to identify the underlying mechanism and TFs that mechanistically associate this with 
colorectal cancer. 
We observed that SNPs from various association studies can overlap a single enhancer region. We 
found this information to be very exciting, since it could be used to identify novel examples of 
enhancer-based pleiotropy (Sabarís et al. 2019). In other words, changes in the same enhancer 
region can trigger different phenotypes and cause pleiotropy. For example, we identified locus 
chr15:74222688-74224043  (E1) a single intronic enhancer region within  the LOXL1 gene that was 
associated with multiple SNPs and phenotypes in the GWAS Catalog: hand grip strength,  joint 
mobility and coronary artery disease (Pickrell et al. 2016; Tikkanen et al. 2018; van der Harst and 
Verweij 2018). We speculate that if the link between aforementioned phenotypes really exists, it 
could be rheumatoid arthritis (RA) - a complex multisystem inflammatory disease characterized 
by the loss of immunologic self-tolerance, chronic inflammation, and destruction of the joints 
(McInnes and Schett 2011). Its association with an increased prevalence of coronary heart disease 
and a high cardiovascular (CV) mortality was previously identified (Goodson 2002; Gonzalez-Gay 
et al. 2005).  
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This approach can also be used to increase the number of testable variants associated with CRC 
as well. For example, the E1 enhancer region was found to be associated with two additional 
genes: ISLR and STOML1. For example, LOXL1 catalyzes the polymerization of tropoelastin to form 
the mature elastin polymer, allow efficient elastin core cross-linking and in knockout mice, it 
triggers a phenotype characterized by an abnormal elastic tissues and basement membranes of 
blood vessels (Liu et al. 2004). The STOML1 gene encodes stomatin - an integral membrane protein 
that localizes to the cell membrane of red blood cells and other cell types (Mairhofer et al. 2009). 
ISLR, as a member of the immunoglobulin superfamily, is likely involved in adhesion or binding to 
other proteins in solution or at the cell surface and implicated in immunity (Nagasawa et al. 1999). 
Nevertheless, a more detailed analysis is required to understand the link between the LOXL1 gene 
intronic enhancer and associated phenotypes. For the sake of writing this thesis, I did not dive 
deeper in the analysis of this link.  However, it is a good showcase that demonstrates the potential 
of pooling information across different studies and discovering novel examples of enhancer-based 
pleiotropy. In addition, this could support Corradin et al. (2014) that different SNPs in the same 
LD block could identify enhancers that cooperatively regulate the same gene. 
In this specific analysis, we were limited by the fact that we used only the stringentC enhancer-
gene annotations. Thus, we could easily miss many other (potential or confirmed) gene 
associations. For example, a known association of the MYC gene and colorectal cancer (Peters et 
al. 2015) was confirmed by EnhancerAtlas, GeneHancer, flexibleC, or the inhouseM EGAs, whereas 
the PGC gene reported only in EnhancerAtlas is known to be involved in the PGC-1/ERR signaling 
axis in cancer (Deblois et al. 2013; LeBleu et al. 2014). Thus, researchers should start the SNP 
annotation analysis with the smallest set of enhancer-gene associations (stringentC) and then 
expand it with other available information. Likewise, although we included information from the 
HiC experiments (Dixon et al. 2012), we did not reflect on other possible sources of data that could 
provide us with additional information about SNP-gene-disease interactions such as eQTL studies, 
CRISPR-Cas experiments, etc. We did not include information about SNPs that are in LD with CRC-
associated index SNPs as well.  
6.5. Conclusions 
We showed that many non-coding SNPs can be annotated to their target genes by “borrowing” 
information from enhancer-gene associations (EGAs) - we simply assigned SNPs to the genes 
associated with SNP-overlapping enhancers. Nonetheless, annotated sets of genes do differ when 
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different sets of EGAs are used as a source of information. Many established gene-disease 
associations are not necessarily present across all datasets and one needs to integrate information 



















Complex organisms developed multiple mechanisms to regulate gene expression, but most 
regulation is believed to occur at the level of transcription initiation by cis-regulatory sequences 
that recruit a distinct set of trans factors. Proximal promoters (Lenhard et al. 2012) and distal 
enhancers (Lettice et al. 2003) are among the best-characterized cis-regulatory sequences in the 
human genome (Andersson et al. 2015). Promoters are located nearby the transcription start sites 
of genes and integrate a total regulatory input into the rate of transcriptional initiation (Lenhard 
et al. 2012), whereas enhancers are distal elements that interact with promoters and further 
refine gene expression across cell types and developmental stages (Banerji et al. 1981,  Gerster et 
al. 1986, Blackwood and Kadonaga 1998).  
 
How do enhancers spatially and temporarily modulate gene expression represents one of the 
central questions of genomics (Weber and Schaffner 1985; Gerster et al. 1986; Szutorisz et al. 
2005,Muse et al. 2007; Zeitlinger et al. 2007; Core et al. 2008). Previously, low-throughput 
experiments empowered us to learn certain aspects of enhancer-mediated gene expression 
regulation; however, to fully understand and appreciate its complexity it is necessary to 
systematically identify and characterize all regulatory elements in a genome-wide manner and 
discern their cell-type specific patterns. Up today, multiple approaches have been utilized to study 
enhancer-mediated long-range gene regulation and they can be broadly categorized into four 
categories: predictions using information from the eQTL studies (Rockman and Kruglyak 2006; 
Gaffney et al. 2012; GTEx Consortium et al. 2017) or (3C)-derived technologies (Dekker et al. 2002; 
Simonis et al. 2006; Dostie et al. 2006; Lieberman-Aiden et al. 2009; Fullwood et al. 2009), and 
direct functional confirmation of enhancer activity by reporter assays or cellular screens (Arnold 
et al. 2013; Kwasnieski et al. 2012; Arnold et al. 2013; Kheradpour et al. 2013; Kvon 2015; 
Gasperini et al. 2019). However, they are hindered by technological and biological limitations of 
high-throughput technologies that are reflected in a high number of false positives and negatives 
(Hariprakash and Ferrari 2019). 
 
The fourth approach, computational modelling of gene expression ~ enhancer activity, has been, 
as well, commonly used to map enhancers to their putative genes; and it was the main subject of 
this thesis. Recently, several data integration approaches aimed to predict enhancer-gene 
associations were developed using a large number of tissues, cell types and cell lines: 
172 
 
EnhancerAtlas (Gao et al., 2016),  JEME (Cao et al. 2017), GeneHancer (Fishilevich et al., 2017), 
FOCS (Hait et al. 2018), HANCER (Wang et al. 2019). I reviewed and characterized differences 
between their results and I set off to develop a novel computational approach. I performed a 
thorough benchmarking of seven sets of computationally identified enhancer-gene associations 
and reviewed how different predictions of EGAs can influence the result of functional analysis of 
risk SNPs.  
 
In Chapter 3, I systematically compared computational predictions of enhancer-gene associations 
and identified their differences. I showed that individual sets of predictions differ tremendously; 
especially in the location, number and properties of defined enhancer regions. Thereby, we 
showed (and confirmed) that the key bottleneck in understanding enhancer-promoter 
communication has been the lack of the tools to precisely identify and characterize the functions 
of large numbers of enhancers in the human genome (Hariprakash and Ferrari 2019). In addition, 
the initial choice of epigenomic marks used to map enhancers has a large impact on the final 
number and characteristics of defined enhancers (Zentner and Scacheri 2012). I showed that 
enhancer-gene association methods differed in the algorithmic details, but also in the way 
multiple parameters and information were used to define enhancers and promoters or quantify 
their activities. I further used this information to improve the reg2gene - a novel computational 
method that models gene expression ~ enhancer activity. 
 
In Chapter 4, I explained the process of developing the reg2gene method. In short, reg2gene was 
built upon extensive data modeling and integration of the largest collection of epigenomics or 
transcriptomic data in humans at time - the Roadmap datasets (Roadmap Epigenomics 
Consortium et al. 2015) and its five sub-datasets: H3K4me1, H3K27ac, DNAme, DHS and RNA-Seq. 
reg2gene implements three correlation-based methods: Pearson, Spearman and distance 
correlation and executes the elastic net regression (Zou and Hastie 2005) and random forest 
(Breiman 2001) to account for the fact that multiple enhancers can act on a gene in a cooperative 
fashion (Reuter et al. 2015). Likewise, since an accurate enhancer definition represents a 
cornerstone upon which enhancer-gene models should be built (Hariprakash and Ferrari 2019), I 
performed modelling using a “consensus” enhancer definition. Each enhancer-gene pair 
(enhancers +/-1Mb around each TSS) was modelled a total of twenty times, and models were 
integrated by the majority voting approach and further improved by an ensemble voting with 
previously reported enhancer-gene associations (EGAs). I identified two sets of enhancer-gene 
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associations: a flexible set of ~230K EGAs reported in at least 2 publications and a stringent set of 
~60 EGAs reported in three or more publications. 
In Chapter 5, I analyzed sets of enhancer-gene associations in the light of multiple benchmarking 
datasets. The main idea behind this analysis was to test whether some of the computational 
methods predicted more accurate EGAs than other methods. As a benchmark datasets, I selected 
datasets that have been frequently used to benchmark computationally predicted EGAs (Gao et 
al. 2016, Cao et al. 2017, Hait et al. 2018): eQTLs and chromatin interactions. However, I showed 
that such benchmark datasets suffer from low reproducibility and doubted results of our and 
previous benchmarking procedures. I ran additional benchmarking with high-confidence cis 
enhancer-gene interactions assessed by cell-based CRISPR/Cas9 genetic screen (Gasperini et al. 
2019) and I proposed an approach that searches for enhancer-gene “negative” associations. This 
approach enabled us to, for the first time, fully assess the performance of computational methods 
and assess all the elements of the confusion matrix and demonstrate that stringentC models have 
the highest PPV (positive predictive value) of 1.  
In Chapter 6, I present results of SNP-to-gene annotation analysis performed using different 
sources of enhancer-gene associations. Specifically, I annotated risk polymorphisms from the 
GWAS Catalog, colorectal cancer (CRC) SNPs, rs104111210 and I identified that sets of annotated 
genes varied in their size. I show that, although the stringentC method could predict only 14 CRC 
genes, 65% of them were previously associated with CRC. I demonstrated that some of the well-
known gene-CRC associations were missed by certain EGAs methods and present in other 
annotations, which indicated that each method could potentially add another piece of information 
necessary to improve our understanding of genetic susceptibility. Using benchmark datasets, I 
showed that novel SNP-CRC associations could be detected. Lastly, I identified examples of 
enhancer-based pleiotropy and novel gene-disease association.   
7.2. Conclusions 
The results presented in this thesis show that, even today, when a large number of methodological 
solutions has been proposed to map enhancers to their putative genes, we still do not have a 
systematic assessment of enhancer-gene associations in a genome-wide manner.  
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Data integration and availability of novel epigenomic datasets has been slowly improving our 
predictions of enhancer-gene associations, but we might never be able to identify a single “golden-
standard” approach for discovering and documenting enhancer-gene interactions in a genome-
wide manner.  
Nonetheless, we should continue integrating information from various data sources to improve 
our understanding of gene regulation in health and disease.  
Even in the light of aforementioned limitations, enhancer-gene associations represent an exciting 
resource for annotating risk SNPs to their target genes. 
 
7.3. Future perspectives 
 
The main bottleneck of computational models of enhancer-gene associations is the requirement 
for a large number of available cell types with comparable quality and resolution of data 
(Hariprakash and Ferrari 2019). Since this is an area of extensive scientific efforts - IHEC (The 
International Human Epigenome Consortium, Stunnenberg et al. 2016) and the shared effort of 
its nine members - ENCODE, Roadmap Epigenomics, BLUEPRINT, DEEP, Canadian Epigenetics, 
Environment and Health Research Consortium (CEEHRC; Canada) together with the national 
epigenome projects from Japan, Korea, Singapore and Hong Kong recently set off to produce 1,000 
reference epigenomes - we could soon expect major improvement in the number and quality of 
available datasets. The IHEC project is still ongoing, but  it already represents the largest collection 
of tissues and cell types for which epigenomic profiling has been systematically done (Bae 2013; 
Albrecht et al. 2016). I would expect that reg2gene models would achieve better accuracy and 
precision if they would be trained using the IHEC datasets. In this modelling scenario, we would 
simply increase the number of training examples and reduce the hurdle of "large p, small n" 
problem (high-dimensional data with few examples). I would expect that, if not me, somebody 
will perform such analysis in the future. 
 
I hypothesize that meta-analysis can be very useful in genomic studies as well (similar to its proven 
usefulness in the genome-wide association studies; Cantor et al. 2010). Meta-analysis is a 
statistical method that combines results of different studies, especially those with small sample 
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size or with conflicting results. It was often used to combine information from multiple GWAS and 
can increase the chances of finding true positives among the identified associations. In the case of 
IHEC epigenomes, it can be used to combine results of different consortium datasets to overcome 
their inherent differences and biases.  
 
I believe that, based on current evidence, epigenome editing is the key way to improve our 
knowledge about enhancer-gene targeting. Genetic manipulation approaches can provide 
evidence for the importance of certain regulatory regions, which can be subsequently used to 
train computational algorithms. For example, site-specific epigenomic editing has been done by 
recruiting chromatin-modifying enzymes to specific loci using the CRISPR-Cas system: deactivated 
Cas9 - dCas9 (Jinek et al. 2012) was already used in a combination with a range of chromatin-
modifying enzymes, general transcriptional activator or repressor proteins such as p300 (Hilton et 
al. 2015), LSD1 (Kearns et al. 2015), DNMT3A (Rivenbark et al. 2012; Siddique et al. 2013), KRAB 
(Fulco et al. 2016) to add or remove chromatin marks at the target. Recent experiments (Fulco et 
al. 2019; Gasperini et al. 2019) combine CRISPR-Cas perturbations with single-cell analyses (flow 
cytometry, expression profiling, etc.). Altogether, I hope that larger and more robust sets of 




The immediate application of computational modelling of enhancer-gene associations can be seen 
in human genetics: annotation of the risk-associated polymorphisms with genes they truly 
regulate represents a crucial step in understanding disease etiology of almost all human diseases. 
I presented certain examples of it in this thesis, but there is many more left to be explored.  
 
On the other hand, as a bioinformatician, I spent a lot of my working time visualizing ChIP-Seq 
signals for H3K4me1 and H3K27ac in the IGV Browser (Thorvaldsdóttir et al. 2013). Many of the 
visualized peaks seemed to be (function) enhancer regions. However, I could not discern which 
genes such regions regulate. With a database of EGAs, I can simply screen enhancers and 
potentially identify their targets.  
In addition, reg2gene package can be simply used to support further modelling of similar biological 




Lastly, many questions about EGAs remained unanswered. Which enhancers regulate two genes 





















Supplementary Figure 1. Distribution of anchor sizes for the CCSI database and PC-HiC results form (Javierre et al., 
2016). Since each reported chromatin, interacting pair consists of two anchors (A1 and A2), each of them was 
individually analyzed and distribution of their length was reported on the x-axis. On average, anchor1 (A1) and 






Supplementary Figure 2. Histogram of the number of interactions reported in each benchmark dataset: eQTLs from 
(Westra et al., 2013) and the GTEx database (GTEx Consortium et al., 2017) and PC-HiC experiments from (Javierre 






Supplementary Figure 3. Heatmap of the results of the benchmarking procedure for all analyzed datasets. The 
number of identified overlaps between two datasets was reported as the statistics. Here, we analyzed a total of 12 
datasets: 7 sets of enhancer-gene associations (EnhancerAtlas (Gao et al., 2016), JEME (Cao et al. 2017), GeneHancer 
(Fishilevich et al., 2017), FOCS (Hait et al., 2018), reg2gene inhouseM (in-house m.), stringentC (stringent m.) and 
flexibleC models (flexible m.); two sources of eQTLs from (Westra et al., 2013, Westra eQTL) and the GTEx database 
(GTEx Consortium et al., 2017), GTEx), PC-HiC experiments from (Javierre et al., 2016, PC HiC) and the CCSI database 
(Xie et al., 2016); CCSI), and cis-regulatory interactions reported in (Gasperini et al., 2019). In rows, one can get 
information about the coverage of a given dataset, by other dataset. For example, out of 449 analyzed (Gasperini et 




Supplementary Figure 4. Heatmap of the results of the benchmarking procedure for all analyzed datasets. The 
percentage of pairwise overlap between two datasets was reported as the statistics. We analyzed a total of 12 
datasets: 7 sets of enhancer-gene associations (EnhancerAtlas (Gao et al., 2016), JEME (Cao et al. 2017), GeneHancer 
(Fishilevich et al., 2017), FOCS (Hait et al., 2018), reg2gene inhouseM (in-house m.), stringentC (stringent m.) and 
flexibleC models (flexible m.); two sources of eQTLs from (Westra et al., 2013, Westra eQTL) and the GTEx database 
(GTEx Consortium et al., 2017), GTEx), PC-HiC experiments from (Javierre et al., 2016, PC HiC) and the CCSI database 
(Xie et al., 2016); CCSI), and cis-regulatory interactions reported in (Gasperini et al., 2019). In rows, one can get 
information about the percentage of coverage of a given dataset, by other dataset. For example, out of 18.2% of 
















Supplementary Figure 5. Results of the enrichment analysis for gene sets that were annotated to 312 CRC-associated 
SNPs using an overlap between SNP and enhancer regions from a set of enhancer-gene associations (EGAS). We 
performed gene enrichment analysis for: molecular function, cellular component, biological process, human 
phenotype ontology, OMIM disease, and KEGG, Reactome, and PANTHER pathways using enrichR R package 
(Kuleshov et al., 2016) and plotted TOP10 enrichment results (if applicable). A. Results of the enrichment analysis for 
biological processes for 14 CRC genes that were identified based on the overlap with stringentC EGAs. B. Results of 
the enrichment analysis for Reactome pathways for 14 CRC genes that were identified based on the overlap with 
stringentC EGAs. C. Results of the enrichment analysis for molecular function for 14 CRC genes that were identified 
based on the overlap with stringentC EGAs. D. Results of the enrichment analysis for Panther pathways for CRC genes 
identified using GeneHaner EGAs. E. Results of the enrichment analysis for OMIM diseases for CRC genes identified 





Supplementary Figure 6. A schematic representation of detecting plausible enhancer pleiotropy for the LOXL1 gene 
and its GWAS-associated SNPs. Original information is that rs28522673 is associated with cardiovascular disease via 
LOXL1 gene. Simply, by querying the GWAS Catalog we could supplement that information by identifying all SNPs 
and diseases associated with the LOXL1 gene. Using information about an overlap between rs28522673 and 
chr:7422268-74224043 enhancer regions, allowed us to detect putative enhancer pleiotropy. We identified an 
overlap between chr15:74222668-74224043 enhancer region and SNPs associated with different phenotypes 
(rs150025731 and rs62004866). In addition, we could identify an association of this enhancer region with non-LOXL1 





Supplementary Figure 7. A schematic representation of detecting plausible novel gene targets and extending previous 
knowledge for rs12441130.  Original information was that rs12441130 was associated with heel bone mineral density 
via the LOXL1 gene. Simply by using information from the GWAS Catalog we could identify additional SNPs and 
diseases associated with the LOXL1 gene. On the other hand, we identifying an overlap between rs124411310 and 
chr15:74233359-7423513 enhancer region, thereby associating rs12441130  with novel gene target - the LOXL1-AS1 


















































Supplementary Table 1. Statistics behind four published methods: EnhancerAtlas 
(Gao et al., 2016), JEME (Cao et al. 2017), GeneHancer (Fishilevich et al., 2017), FOCS 
(Hait et al., 2018), and three in-house methods that predict enhancer gene 
associations: reg2gene inhouseM, stringentC and flexibleC models. For each 
method, we report numbers of enhancer and genes that interact in enhancer-gene 
associations. In addition, we calculated an average number of genes per enhancer, 
and enhancer per gene, as well as enhancer length. We report a number of 
enhancers that show full per-base overlap with regions predicted by ChromHMM 
as heterochromatin, repressed Polycomb, weak repressed Polycomb and quies. 
Lastly, we report the expected number of enhancers (number of enhancers 
reported in the individual publication).  
 
Supplementary Table 2. Confusion matrix for enhancer-gene associations. Positives 
correspond to the cis enhancer-gene interactions from (Gasperini et al., 2019), 
whereas negative were defined by an in-house protocol that identified regions in 
the genome that were consistently inactive - across all 127 cell types in the 
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Roadmap dataset. TP correspond to cis enhancer-gene interactions reported in (Gasperini et al., 2019) that 
overlapped computationally predicted EGAs, whereas FN are is enhancer-gene interactions reported in (Gasperini et 
al., 2019) that were not predicted. FP are computationally predicted EGAs whose enhancers were predicted to be 
“inactive” by the ChromHMM algorithm across all 127 cell types reported in the Roadmap dataset (details in Methods 
section). TN are EGAs whose enhancers were predicted to be “inactive” by the ChromHMM algorithm across all 127 
cell types reported in the Roadmap dataset and their association was not identified. TP=true positive, FP= false 
positive, TN= true negative, FN= false negative. 
 
TP [EGA] FN [EGA] FP [EGA] TN [EGA] PPV 
stringentC 45 19 0 3,147 100% 
flexibleC 61 26 4 3,143 93.4% 
InhouseM 67 39 47 3,100 58.8% 
FOCS 91 23 293 NA 23.7% 
JEME 129 40 671 NA 16.1% 
EnhancerAtlas 180 30 35,618 NA 0.5% 
GeneHancer 291 30 1,635 NA 15.1% 
 
Supplementary Table 3. General statistics behind the GWAS Catalog annotated SNPs across all seven EGA methods 
used to annotate SNPs. Number of SNPs annotated to enhancers are reported along with corresponding enhancer-








Supplementary Table 4. A list of genes that were annotated to 312 colorectal cancer SNPs from the GWAS Catalog 
using 7 sources of enhancer-gene associations: EnhancerAtlas (Gao et al., 2016), JEME (Cao et al. 2017), GeneHancer 









Supplementary Table 5. General statistics behind annotation results for rs10411210 SNPs across all seven EGA 
methods used to annotate it. Number of enhancers, genes and enhancer-gene associations (EGAs) annotated to 
rs10411210 are indicated. In this case, results were calculated for benchmark datasets as well: two sources of eQTLs 
from (Westra et al., 2013, Westra eQTL) and the GTEx database (GTEx Consortium et al., 2017), GTEx), PC-HiC 
experiments from (Javierre et al., 2016, PC HiC) and the CCSI database (Xie et al., 2016); CCSI), IHM = inhouseM; 





Supplementary Table 6. Enhancer-gene pairs annotated to rs10411210 using information from nine data sources. 
Described in the figure above. 
   










Supplementary Table 8. Statistics behind an overlap across three CRC benchmark gene sets and CRC-annotated gene 
sets. Benchmark CRC gene sets correspond to: 1) DisGeNET - 1,676 CRC genes reported in the DisGeNET database, 2) 
DisGeNET_A - 2,096 genes from the DisGeNET database associated with colorectal cancer, intestinal cancer, 
carcinoma, cancer, neoplasm and 3) Published - 63 CRC genes reported in Peters et al. 2015. Seven CRC gene sets 
were assessed based on EGA from  EnhancerAtlas (Gao et al. 2016), JEME (Cao et al. 2017), GeneHancer (Fishilevich 
et al. 2017), FOCS (Hait et al. 2018), stringentC, flexibleC and inhouseM. Genes that could not be benchmarked are 
indicated under name RemainG. For example, 37 CRC-genes identified using EnhancerAtlas EGAs were previously 
reported in DisGeNET db  (Piñero et al. 2017), for CRC. Additional 11 CRC-genes identified using EnhancerAtlas EGAs 
were reported for intestinal cancer, carcinoma, cancer or neoplasm in DisGeNET db, and 388 genes were not 







Supplementary Table 9. List of genes that were identified by overlapping three CRC benchmark gene sets and CRC-
annotated gene sets. Benchmark CRC gene sets correspond to: 1) DisGeNET - 1,676 CRC genes reported in the 
DisGeNET database, 2) DisGeNET_A - 2,096 genes from the DisGeNET database associated with colorectal cancer, 
intestinal cancer, carcinoma, cancer, neoplasm and 3) Published - 63 CRC genes reported in Peters et al. 2015. Seven 
CRC gene sets were assessed based on EGA from EnhancerAtlas (Gao et al. 2016), JEME (Cao et al. 2017), GeneHancer 






Supplementary Table 10. A table of TF that bind or have binding site motifs in the region chr19:33532126-33532564. 
TFBS indicates transcription factor binding sites that were identified in given region, whereas CHiP-Seq TFBS indicates 






Supplementary Table 11. List of five SNPs that overlapped stringentC enhancers, and thus, could be annotated to 
enhancer-associated LOXL1 gene. Three SNPs (rs62004866, rs150025731, rs28522673) overlapped one enhancer 
region: chr15:74222688-74224043 (E1); whereas rs4886782 overlapped chr15:74228665-7422857 enhancer (E2) and 
rs12441130 chr15:74233359-74235313 enhancer (E3). Additional information from the GWAS Catalog was reported 
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